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1. INTRO 
 
It is suggested that:  
 the molecule carnosine is a potential candidate to counteract the development of 
diabetes or diabetes-related diseases.  
 
This is based on: 
 plentiful in vitro studies focusing on its biochemical and physiological protective 
characteristics 
 
However, up until now: 
 the behavior of endogenous carnosine in a diabetic setting is barely known 
 little in vivo studies are present about the beneficial effects of carnosine 
supplementation 
 
Therefore, this work contains animal and human data to provide: 
 insight into the carnosine metabolism and how it is possibly altered in a diabetic 
state in rodents and humans 
 in vivo evidence about the protective effects of carnosine supplementation in a 
very mild obese-diabetic rat model  
 
 
At least an interesting topic and worthwhile to investigate! 
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2. CARNOSINE AS THE FOUNDING MEMBER OF HISTIDINE-CONTAINING 
DIPEPTIDES 
The story of the molecule carnosine starts at the beginning of the 20th century, because of 
a man called Vladimir Gulewitch. This young Russian chemist, excellently graduated from 
Moscow State University in 1890, discovered carnosine during his search for unidentified 
nitrogen-containing non-protein compounds in meat extracts. Gulewitch identified two 
new molecules present in rather high amounts and called them carnosine and carnitine 
(from the Latin carnis – meat) (Gulewitch 1900). He concentrated his work on the 
substance with the highest amount, i.e. carnosine, and in 1911, the structure of carnosine 
was established (it was found to be the dipeptide beta-alanine-L-histidine)(Gulewitch 
1911). This was the starting point of the “Russian contribution” in World biochemistry of 
the biological activity of carnosine. 
 
Figure 1: Vladimir Gulewitch at his laboratory desk (1929) 
In the 1920s, German scientists noticed that muscles of most birds do not contain 
carnosine, instead its methylated analogue anserine (β-alanyl-N-π-methylhistidine) was 
identified, whereby the name was derived from the Latin word for goose, i.e. anser. 
(Ackermann 1929; Tolkatschewskaya 1929).  
Thereafter, several other carnosine related compounds were identified (figure 2). From 
the perspective of carnosine, the most common variations include 1) methylation on 
either the π or τ nitrogen in the imidazole ring of histidine to form respectively anserine 
(β-alanyl-N-π-methylhistidine) or ophidine (β-alanyl-N-Ƭ-methylhistidine), 2) substitution 
of beta-alanine by γ-aminobutyric acid (GABA) to form homocarnosine (γ-aminobutyryl-
histidine), or 3) acetylation of the terminal amino group of beta-alanine to  
  
Figure 2
arrows.
form N
2013)
skeletal muscle, whereas the muscles of almost all other 
along with its methylated form anserine. Only the muscles of 
such as whales and dolphins, have carnosine along with the methylated form ophidine
Tissue
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So, c
collectively called the 
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. Chemical structure of carnosine and 
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. Species-
-specific because 
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specific because carnosine is the only 
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γ-aminobutyric acid) and they are predominantly present in excitable tissues, such as 
muscle and nervous tissue (Boldyrev 1990).  
In this work, HCDs will refer to carnosine and anserine, as this work will focus 
predominantly on human and rodent muscles. 
 
3. CARNOSINE – CARNOSINASE METABOLISM IN HUMANS AND RODENTS 
Both in humans and rodents, more than 99% of total body carnosine (and also its 
methylated form anserine for rodents) is present in skeletal muscle. This leads to very 
high carnosine concentrations of around ~20-30 mmol/kg dry muscle in humans and 
around ~5-20 mmol/kg dry muscle in rats. Since rats possess anserine as well in 
concentrations of ~20-40 mmol/kg dry muscle, this leads to a more than double HCD 
content compared to humans. To date, it is not fully understood whether anserine is 
synthesized as a result of direct methylation of carnosine by the carnosine-N-
methyltransferase (Mcmanus 1962; Bauer 1994) or as a result of the condensation 
between beta-alanine and π-methyl-L-histidine (Drozak 2010).  
For many years, it was suspected that carnosine was only present in skeletal muscle (in 
millimolar range), in brain (in micromolar range) and in the myocardium of rodents (Aldini 
2004). Recent papers demonstrated, however, that it is present in other tissues as well, 
such as kidney (Kamal 2009; Riedl 2011), liver (Mong 2011), retina (Pfister 2011), spleen 
(Kamal 2009),…although in very low concentrations. Literature about carnosine content in 
human tissues other than skeletal muscle is currently lacking, but it is suspected to be 
absent (Jackson 1996) or limited to the olfactory system in the brain (Petroff 1998). 
The two main biochemical pathways are its synthesis from and its breakdown (hydrolysis) 
into the two constituent amino acids beta-alanine and L-histidine. L-histidine is a 
proteinogenic and essential α-amino acid. Under normal physiological conditions, the 
histidine concentration in biological tissues is present in sufficient amounts , except when 
histidine-free diets are consumed (Tamaki 1977). Beta-alanine is a rather unusual amino 
acid because it is the only naturally occurring free β-amino acid and it is not used in the 
biosynthesis of proteins. Beta-alanine is endogenously formed in the liver by degradation 
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of uracil and thereafter it is secreted into the serum (Traut 2000) or it can be obtained by 
the ingestion of meat and fish, from the hydrolysis of HCD. Noteworhty, beta-alanine is a 
component of the essential vitamin B5 (pantothenic acid), which itself is a component of 
coenzyme A. However, the degradation (or synthesis) of pantothenic acid into (or from) 
its constituent components (beta-alanine and pantoic acid) does not occur in humans or 
other animals (Gropper 2009).  
In general, carnosine synthesis mainly takes place in skeletal muscles by the enzyme 
carnosine synthase (Gulewitch 1911; Drozak 2010), whereas its breakdown occurs 
predominantly in circulation by serum carnosinase (CN1, encoded by the gene 
CNDP1)(Lenney 1990). However, carnosinase is also present in tissues as non-specific 
dipeptidase or tissue carnosinase (CN2, encoded by another gene, i.e. CNDP2), which has 
been demonstrated in kidney, liver, spleen, small intestine and yes, even muscle (Lenney 
1985). Noteworthy, the catalytical rate of CN2 in tissues is markedly lower than the 
catalytical rate of CN1 in serum (Pandya 2011). Indeed, CN2 has a broader substrate 
specificity then CN1 and the optimum pH for CN2 is 9.5, whereas the pH of tissues do not 
exceed 7.4 (Lenney 1985; Teufel 2003). The presence of carnosine synthase in other 
tissues than skeletal muscle in humans is not yet investigated but Miyaji et al. (2012) has 
detected mRNA levels in brain, liver and kidney in rat tissues, which is not surprising as 
carnosine was also very recently detected in those tissues, although at very low 
concentrations (Kamal 2009; Riedl 2011; Pfister 2011). 
More in detail, five important pathways in the metabolism of carnosine can be 
formulated, which are overviewed in figure 3. A first important step (I) is the absorption 
of carnosine from the diet. Carnosine is partly intactly transported across the intestinal 
cells as carnosine appears in blood when high doses are ingested (Gardner 1991; Everaert 
2012). Indeed, PEPT 1 (member of the proton-coupled oligopeptide transporter (POT)-
family, which are able to transfer di- and tripeptides across biological membranes) is 
expressed in the brush border membrane of enterocytes and is able to transfer the HCDs 
using an inwardly direct proton gradient (Daniel 2004; Geissler 2010). However, it is 
suggested that low doses of carnosine are mainly hydrolyzed in the enterocytes by CN2  
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Figure 3. Schematical representation of the five most important pathways
absorption of carnosine from the diet, II) carnosine is almost immediately hydrolyzed by CN1 in circulation, III) 
constituent amino acids (BA and HIS) are transported into the skeletal muscle, IV) Carnosine synthesis, V) carnosine is 
excreted in urine (only if high doses 
CN1: serum carnosinase, CN2: tissue carnosinase or non
are
 
 consumed). Abbreviations: CAR: carnosine, BA: beta
-specific dipeptidase
 in the metabolism of carnosine
. 
-alanine, HIS: L
 in humans.
The 
l i   -histidine, 
 
 I) 
  PART I: GENERAL INTRODUCTION   
 
17 
and that beta-alanine and (methyl)-histidine are subsequently transported into the blood 
by amino acid transporters (Lenney 1985; Bauchart 2007). 
(II) Second, if carnosine reaches the blood (if not hydrolyzed by the enterocytes), it is 
almost immediately hydrolyzed in the circulation by CN1. Noteworthy, CN1 is very active 
in humans in the circulation, but it is absent in the circulation of rodents (Jackson 1991; 
Aldini 2011). In these animals, the catalytical activity of carnosine mainly takes place in 
the kidneys where CN2 is located (Aldini 2011). So, upon ingestion, plasma carnosine 
levels are elevated for ~2 hours in rodents, whereas in humans carnosine is often not 
detectable upon ingestion, or only when high doses are consumed and only in subjects 
with low activity of serum carnosinase, with a peak around 30 minutes after ingestion 
(Everaert 2012).  
(III) Third, it is clear from above that no or little ingested carnosine is left to be 
transported into the muscles or other organs. The constituent amino acids are then 
transported into the skeletal muscle, with histidine being transported by amino acid 
transporters and beta-alanine mainly by the taurine transporter (TauT) (Harris 2006).  
(IV) Since concentrations of beta-alanine in the muscle are very low (< 10 µmol/kg 
wm)(Harris 2006), compared to histidine (~0.5-1 mmol/kg wm) (Parkhouse 1985), it has 
several times been concluded that beta-alanine, rather than L-histidine, is the rate-
limiting precursor in carnosine synthesis in humans (fourth pathway) (Bakardjiev 1994; 
Dunnett 1999; Harris 2006). Noteworthy, brains are also characterized with relatively high 
concentrations of carnosine(-analogues) and the metabolism is quite similar than the 
skeletal muscle because brain tissues are also equipped with taurine transporters (Fujita 
2006) and relative high carnosine synthase activity (Harding 1976). In addition, Murakami 
et al. (2010) has demonstrated that brain carnosine levels are also enhanced by long-term 
beta-alanine supplementation in mice (Murakami 2010). However, as said previously, the 
most common HCD in mammalian brain is the analogue of carnosine ‘homocarnosine’ 
(Petroff 1998), whereby beta-alanine is replaced by GABA, an important neurotransmitter 
in the brain (Kish 1979).  
PART I : GENERAL INTRODUCTION 
 
18 
(V) Finally, if high doses of carnosine are supplemented and if carnosine is not (yet) 
hydrolyzed by CN2 in enterocyts or by CN1 in circulation, then carnosine can appear in 
urine. However, carnosine is mainly reabsorbed from the filtrate and metabolized in the 
renal cells by CN2.  
Tables 1A and 1B summarize the presence or absence of carnosine/anserine and the most 
important enzymes in the metabolism of carnosine in several tissues in respectively 
humans and rodents. 
Conclusion: HCDs are predominantly and abundantly present in skeletal muscle. The 
carnosine system in rodents and humans is quite similar, however two important 
differences can be put forward. First, rodents are characterized by the absence of serum 
carnosinase. Second, skeletal muscles of rodents also possess the methylated variant 
anserine. This work will study both humans and rodents (rats/mice).  
 
 
 
 
 
 
 
 
 
    
 
 
Table 1A. The presence or absence of carnosine/anserine and the most important enzymes in  the metabolism of carnosine in several tissues of HUMANS. 
 Blood Skeletal muscle Brain/CNS Other organs 
Carnosine 0/+ 
 Not in fasted state (Gardner 1991; Park 2005; 
Suzuki 2006; Yeum 2010) 
 Or nM concentrations (Fonteh 2007; Zhou 2013) 
 Only after supplementation (Everaert 2012) 
+++ 
 (Parkhouse 1985; Harris 1990; Mannion 
1992) 
+ 
 Very little (if any) in olfactory bulb 
(Kish 1979) 
 Homocarnosine is abundantly 
present (Kish 1979; Petroff 1998) 
0/? 
 (Jackson 1996) 
Anserine 0/+ 
 Not in fasted state (Suzuki 2006) 
 Only limited after supplementation (Suzuki 
2006; Kubomura 2009) 
0 
 (Kohen 1988; Mannion 1992) 
0 
 (Jackson 1996) 
0 
 (Jackson 1996) 
Carnosine
synthase 
0 
 
+++ 
 mRNA levels (Baguet 2011b; Everaert 
2013)  
+ 
 Homocarnosine – carnosine synthase 
activity (Kish 1979) 
? 
 
CN1 +++ 
 (Lenney 1982) 
0 
 (Lenney 1982) 
++ 
 (Teufel 2003) 
0/+ 
 Absent (Lenney 1982) <-> mRNA in 
liver, kidney (Teufel 2003; Janssen 
2005) 
CN2 0 
 (Lenney 1982; Lenney 1985) 
+ 
 Barely active (Lenny 1985) 
+ 
 (Lenney 1985; Chen 1994) 
+ 
 Kidney, Liver, Spleen, Lung, small 
intestine, … (Lenny et al. 1985) 
0: Absent, +: little present, ++: moderately present, +++: abundantly present, ?: not investigated, 0/+: conflicting results or present in specific situations, 0/?: believed to be absent, but not 
certain. Abbreviations: CN1: serum carnosinase, CN2: tissue carnosinase, CNS: central nervous system. 
  
 
Table 1B. The presence or absence of carnosine/anserine and the most important enzymes in the metabolism of carnosine in several tissues of RODENTS. 
 Blood Skeletal muscle Brain/CNS Other organs 
Carnosine 0/++ 
 Fasting endogenous carnosine concentration: 
n.d. (Lee 2005) or very low (Aldini 2011) 
 After supplementation (Aldini 2011) or after 
exercise (Nagai 2003) 
+++ 
 (Zapp 1938; Davey CL 1960; Crush 
1970) 
+++ 
 Present in olfactory system (Ferriero 
1975; Margolis 1977) 
 But homocarnosine more prevalent 
(Abraham 1962; Ferriero 1975; del Rio 
1977) 
+ 
 Kidney (Peters, 2012, Riedl 2011, Kamal 
2009), retina (Pfister 2011), Liver (Mong 
2011), Spleen (Kamal 2009) 
Anserine 0/++ 
 After supplementation (Kubomura 2010) 
+++ 
 (Zapp 1938; Davey CL 1960; Crush 
1970) 
0 
 (Bauer 1979; Biffo 1990) 
+ 
 Kidney (Peters, 2012) 
 
Carnosine 
synthase 
0 
 
+++ 
  mRNA expression (Miyaji 2012) 
++ 
 mRNA expression (Miyaji 2012) 
+ 
 mRNA detected in liver and kidney, but 
very low (Miyaji 2012) 
CN1 0 
 (Jackson 1991; Aldini 2011) 
0 
 (Teufel 2003) 
+ 
 (Teufel 2003) 
+ 
 Kidney (Margolis 1984; Teufel 2003; 
Peters 2011a) 
CN2 0 
 (Wood 1957) 
+ 
Barely active (Wood 1957; Kunze 1986) 
+++ 
 (Kunze 1986) 
+ 
 (Wood 1957; Kunze 1986) 
0: Absent, +: little present, ++: moderately present, +++: abundantly present, 0/++: absent or n.d. but clearly present in certain situations, 0/?: believed to be absent, but not certain. CNS: 
central nervous system. Abbreviations: CN1: serum carnosinase, CN2: tissue carnosinase, CNS: central nervous system, n.d.: not detectable. 
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4. (BIO)CHEMICAL AND PHYSIOLOGICAL PROPERTIES OF CARNOSINE  
‘The ability of carnosine to prevent advanced glycoxidation end-products (AGEs) and 
advanced lipoxidation end-products (ALEs) formation, on the one hand, and the 
convincing evidence that these compounds act as pathogenetic factors, on the other hand, 
strongly support carnosine as a promising therapeutic agent for oxidative-based diseases, 
such as diabetes. The mechanisms by which carnosine inhibits AGEs and ALEs is still under 
investigation but an emerging hypothesis is that carnosine acts by deactivating the AGEs 
and ALEs precursors, and in particular the reactive carbonyl species (RCS) generated by 
both lipid and sugar oxidation.’ (Vistoli 2012) 
What are AGEs and ALES? When proteins (and in the case of ALEs it can be other 
macromolecules as well) are irreversibly and non-enzymatically modified by sugars and 
lipids (or their derivatives), then they are respectively called AGEs and ALEs.  
Several studies have indicated that AGEs and ALEs have a pathogenic role in the 
development and progression of different oxidative-based diseases, such as diabetes 
(Baynes 2003; Yamagishi 2012; Yap 2012). Their biological (damaging) activity is related to 
different, and in some cases not yet well-defined, mechanisms. But they can for example 
1) attack extracellular matrix proteins, such as collagen, resulting in crosslinking and a 
decrease of their elastic and mechanical functions (Verzijl 2002; Ciulla 2011), 2) modify 
plasma proteins (such as enzymes) and receptors on cells, resulting in disturbed normal 
function, 3) induce pro-inflammatory effects by activating signaling cascades through for 
example RAGE (receptor for AGEs)(Ramasamy 2005). Whether or not the damaging effect 
of ALEs includes such a receptor-mediated mechanism is not yet established.  
As obvious from the above citation, the role of carnosine in the formation of AGEs and 
ALEs is multifactorial. This is a consequence of AGEs/ALEs being a very complex class of 
compounds that are formed by different mechanisms, by heterogeneous precursors and 
which can be formed both exogenously or endogenously. Although the mechanisms are 
very well studied in vitro, there is a huge gap in translating these studies into in vivo 
findings. Below, these mechanisms will be discussed (4.1. to 4.5) and an overview is 
provided in figure 4. 
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4.1. Anti-oxidant activity 
Since the 80s, Alexander A. Boldyrev has dedicated his ‘professional’ life to study 
carnosine in relation to oxidative stress, leading to a book ‘Carnosine and Oxidative Stress 
in Cells and Tissues’ (Boldyrev 2006). Carnosine is supposed to exert its anti-oxidant 
effects by a direct and indirect mechanism. 
In vitro evidence is provided that carnosine can directly inactivate reactive oxygen species 
(ROS), such as superoxide anion (O2
•-) and hydroxyl radical (OH•) and peroxyl radicals 
(ROO•) at physiological concentrations (Boldyrev 1988; Kohen 1988; Boldyrev 1992; 
Pavlov 1993; Klebanov 1997; Tamba 1998). ROS like O2
•- and OH• are both a cluster of two 
atoms that contain an unpaired electron (free radicals). They are formed as necessary 
intermediates in a variety of normal biochemical reactions, but when generated in excess 
or not appropriately controlled, radicals can damage a broad range of macromolecules. It 
is assumed that the imidazole group is the preferential site for O2
•- and OH•-attack 
(Tamba 1999). 
When ROS are not neutralized, the most reactive hydroxyl radical (OH•) can further create 
peroxyl radicals (ROO•). The hydroxyl radical can easily act on the fatty acid side chains of 
lipids (in the various membranes of the cell, especially mitochondrial membranes), 
forming a lipid peroxyl radical, which can further evolve to reactive carbonyl species such 
as 4-hydroxy-2-nonenal (HNE), malondialdehyde (MDA) and acrolein. Here as well, the L-
histidine moiety is required for the scavenging activity towards peroxyl radicals (Kohen 
1988).  
Caution is warranted, as Decker and coworkers re-evaluated the anti-oxidant activity of 
carnosine in 2000 because of the presence of contaminating hydrazine (ranging from 0.01 
to 0.2%), a powerful reducing agent that can inactivate free radicals, in commercial 
carnosine preparations. They still confirm that purified carnosine was capable of 
scavenging lipid peroxyl radicals, although at a millimolar range (Decker 2000) and 
question the role of carnosine as a free radical scavenger in vivo. Importantly, following 
research indicated that the radical scavenging activity of purified carnosine is not due to 
reducing properties, meaning not acting as an electro-transfer agent (Aldini 2011).
   
 
 
 
Figure 4. Carnosine can inhibit the formation of AGEs and ALEs by several proposed and evidence-based mechanisms: 1) an anti-oxidant mechanism, 2) a hypoglycemic mechanism, 3) a 
transglycating mechanism, 4) quenching of reactive carbonyl species (RCS), 5) quenching of carbonylated proteins. RCS: reactive carbonyl species, AGEs: Advanced glycation end-products, 
ALEs: advanced lipoxidation end-products.   
CARNOSINE
Amino group of
PROTEIN
LIPIDS
Schiff’s Base
Amadori
product
AGEs
Carbonylated  
Proteins
ALEs
RCS
oxidation
oxidation
+ protein
transglycation
oxidation
+
oxidation
GLUCOSE
1 3 2 1 1 4 5 1
PART I: GENERAL INTRODUCTION 
 
24 
 Although the above literature points to no or limited role of carnosine as a direct anti-
oxidant in vivo, carnosine does seem to be meaningful in vivo as an indirect anti-oxidant. 
Lee et al. (2005) were the first in demonstrating that carnosine improves the enzymatic 
anti-oxidant activity in streptozotocin (STZ)-induced diabetic Balb/cA mice. Carnosine 
supplementation (0.5 g/l or 1 g/l in drinking water) could restore decreased levels of 
catalase (CAT) and glutathione (GSH) peroxidase in diabetic liver and kidney (Lee 2005). In 
addition, aged rats receiving a daily dose of 250mg/kg (intraperitoneal) carnosine for one 
month, had less lipid peroxidation (malondialdehyde and diene conjugates) compared to 
aged control rats and depleted levels of blood GSH, superoxide dismutase (SOD) and 
glutathione peroxidase (GPX) were restored (Aydin 2010). This was even confirmed in 
young healthy rats, where supplemented rats had increased activities of enzymatic 
oxidants (SOD and GPX) in liver and skin and decreased lipid oxidation (MDA) compared 
to non-supplemented rats (Kim 2011). It appears that not only enzymatic anti-oxidants 
are ‘spared’ as Aydin et al. (2010) reported that vitamin E was significantly increased in 
carnosine-treated aged rats, pointing towards an non-enzymatic anti-oxidant mechanism 
as well. However, when rats were fed a vitamin E-deficient diet, carnosine 
supplementation could not increase antioxidant status of the rats (Maynard 2001; 
Ibrahim 2008). 
Irrespective of carnosine showing anti-oxidant activities through a direct effect or through 
an indirect effect (enzymatic or non-enzymatic), it is demonstrated that carnosine indeed 
counteracts the formation of lipid peroxidation end-products, both in pathological (cfr 
infra) and exercise-induced conditions (Boldyrev 1988; Dawson, Jr. 2002). For example, 
Dawson et al. (2002) demonstrated that downhill running for 90 minutes increased TBARS 
(thiobarbituric acid reactive substances) levels in the extensor digitorium longus (EDL) 
muscle in rats and this was completely blunted by a supplementation-induced increase in 
muscle HCD.  
Conclusion: The anti-oxidant effect of carnosine is related to a direct and indirect effect. 
The direct effect points to the scavenging of ROS, but although this is extensively 
established in vitro, it has a very limited role in vivo. The indirect effect is related to the 
increase or sparing of enzymatic and/or non-enzymatic anti-oxidants and is confirmed 
in animal models in vivo. 
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4.2. An anti-glycator and hypoglycemic agent 
Alan Hipkiss, the discoverer of carnosine ‘as an anti-glycating agent’, started his work by 
demonstrating that carnosine has the ability to form adducts with reducing sugars like 
glucose (Hipkiss 1994; Hipkiss 1995). In this light, carnosine would be already active in the 
first step of AGE formation, i.e. preventing that the carbonyl group of reducing sugars is 
reacting with the amino group of lysine, by serving as an alternative and competitive 
glycation target (number 2 in figure 4). The anti-glycating property of carnosine has been 
confirmed by several other in vitro studies (Seidler 2000; Yan 2005; Pepper 2010). Of 
course, it can be questioned whether this is relevant in vivo as carnosine (if present in 
circulation) will not be able to quench the huge amount of glucose in the blood in a 
diabetic state. 
In 2005, Szwergold and coworkers documented another mechanism by which carnosine 
and anserine can retard or reverse glycation, i.e. transglycation. The process involves 
decomposition of the very first intermediates of the non-enzymatic glycation cascade 
(aldosamines a.k.a. Schiff bases) by nucleophilic attack of carnosine and/or anserine on 
the preformed aldosamine such as glucosyl-lysine. As consequence, glucosyl-carnosine or 
anserine is formed instead of glucosyl-lysine (Seidler 2004; Szwergold 2005) (pathway 
number 3 in figure 4).  
A completely different mechanism by which carnosine affects blood glucose is by acting 
on plasma insulin (hormone that decreases blood glucose). Nagai and colleagues believe 
that carnosine has hypoglycemic effects through the regulation of the autonomic nervous 
system via the histamine H3 receptor (Yamano 2001; Nagai 2003; Kubomura 2010). In a 
first study, L-carnosine was injected into the intraperitoneal space, the right lateral 
cerebral ventricle (LCV) or the stomach (Yamano 2001). Immediately after L-carnosine 
administration 2-deoxy-D-glucose was injected into the LCV. Nerve filaments were 
isolated from central cut ends of autonomic adrenal, hepatic and pancreatic nerves to 
record efferent activities with a pair of silver electrodes. Central or peripheral 
administration of specific doses of L-carnosine reduced the 2DG-hyperglycemia, inhibited 
neural activities of sympathetic efferent nerves innervating the adrenal gland and liver 
and facilitated the activity of vagal celiac nerve innervating the pancreas. In addition, 
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plasma insulin was increased and plasma glucagon decreased. These results were 
confirmed by two following studies with different protocols, here STZ-induced diabetic 
rats were used and oral doses of carnosine were given (0.1g, 0.01g and 0.001g L-
carnosine was mixed in 100g control diet for 1 week) (Nagai 2003) or anserine was used 
in stead of carnosine (Kubomura 2010). The latter study is of great importance as they 
also supplemented anserine in five healthy humans at the start of an oral glucose 
tolerance test. Anserine ingestion (10 and 100 mg/45 kg body weight) tended to reduce 
blood glucose levels during the tolerance test compared with ingestion of tap water only 
(0.05<p<0.10).  
In line with the aforementioned, Sauerhofer et al. (2007) reported also increased fasting 
serum insulin levels in L-carnosine-supplemented db/db mice compared to non-
supplemented db/db mice. A later and milder manifestation of diabetes was observed in 
the supplemented mice, together with enlarged pancreatic islets containing 
predominantly insulin-producing β-cells. 
Conclusion: Animal studies demonstrate that carnosine has hypo-glycemic effects, 
which is possibly mainly related to the ability to increase plasma insulin. This work will 
study the effect of chronic carnosine supplementation on a glucose tolerance test in 
high-fat diet rats. 
4.3. Quencher of reactive carbonyl species  
Reactive carbonyl species (RCS) are a class of compounds having a carbonyl group ( ) 
and which behave very reactive towards the nucleophilic residues of biomacromolecules 
(protein, DNA and RNA). In literature, RCS refer predominantly towards reactive low-
molecular weight or short chain aldehydes ( ) such as α,β- unsaturated aldehydes 
(e.g. HNE and acrolein), di-aldehydes (e.g. MDA, glyoxal,…) and keto-aldehydes (e.g. 
methylglyoxal), however strictly speaking they also refer to reducing sugars as they 
possess an aldehyde group as well or to the subsequently formed protein carbonyls as a 
carbonyl group is introduced into proteins or to many other carbonyl compounds arising 
from sugars and lipids. Nevertheless, in this work, the term RCS will refer to the first 
mentioned group (as most often used in literature (figure 5) (Aldini 2005; Vistoli 2013). 
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Figure 6. The reaction of carnosine with HNE (4-hydroxy-2-nonenal). The reaction is initiated by the beta-alanine moiety, 
forming the reversible α,β unsaturated imine 1a (Aldini 2002b). 
The biological role of carnosine as a quencher of α,β-unsaturated aldehydes was then 
verified by detecting carnosine-HNE reaction adducts in oxidized rat skeletal muscle 
homogenate. Anserine, the Nπ-methyl derivative of carnosine, showed quenching activity 
similar to carnosine, suggesting that the NƮ-atom of carnosine is probably involved in the 
HNE quenching reaction. In imitation of HNE, a similar reaction was then elucidated for 
acrolein by the same lab (Carini 2003).  
To date, there is only one paper available investigating carnosine-HNE adducts in vivo. 
Aldini et al. (2011) reported higher levels of carnosine-HNE adducts in urine of Zucker 
obese rats compared to the lean control animals, which confirmed HNE overproduction in 
obese animals and the role of carnosine as an endogenous detoxifying agent of RCS.  
Conclusion: Strong in vitro evidence exists that carnosine can act as a scavenger of 
reactive carbonyl species. However, only 1 study has studied and detected carnosine-
HNE adducts in urine of Zucker obese rats. This work will examine the presence of these 
adducts in a high-fat diet rat model in order to assess the scavenging characteristics of 
carnosine in vivo.  
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Nevertheless, in vivo evidence exists that carnosine can decrease the presence of protein 
carbonyls. Nagasawa et al. (2001) demonstrated that muscle carnosine loading in 
Sprague-Dawley rats significantly blunted the increase in muscle protein carbonyl content, 
induced by an intraperitoneal injection of Fe-nitrilotriacetate (Nagasawa 2001). In 
addition, Aldini et al. (2011) showed that increased kidney protein carbonyls in Zucker 
Obese rats (compared to the lean counterparts) were significantly decreased if rats 
received 30mg carnosine/kg body weight in their drinking water for 24 weeks.  
Conclusion: Carnosine can decrease protein carbonyl levels in vivo, however, evidence 
of  the ability of carnosine to directly quench protein carbonyls is currently lacking.  
4.5. Inhibitor of ALEs and AGEs 
‘AGEs (advanced glycation end-products) represent a class of modified proteins, involving 
sugars and their degradation products and are generated by oxidative and non-oxidative 
pathways. The term ALEs (advanced lipoxidation end-products) includes a variety of 
covalent adducts, which are generated by the non-enzymatic reaction of RCS (derived 
from lipids) with the nucleophilic sites of macromolecules such as proteins, DNA and 
aminophospholipids.’ (Vistoli 2013) 
When looking into the formation mechanisms, ALEs and AGEs are not so entirely different 
as it seems from a first point of view. Both classes have non-enzymatic covalently 
modified proteins and oxidative stress is an important player in their formation (although 
not always). Moreover, the name EAGLEs (Either Advanced Glycation or Lipoxidation End 
products) has been created since adducts can be both AGEs and ALEs (Vistoli 2013). For 
example, carboxymethyllysine (CML) is the most dominant AGE, but is an ALE as well. It is 
generated by glyoxal, which can be derived from both lipid and sugar oxidative 
degradation pathways (Fu 1996).  
As consequence of the aforementioned properties of carnosine (chapters 4.1. to 4.5.), 
this dipeptide should have an inhibitory effect on the formation of AGEs and ALEs (figure 
4). Only three recent papers are available studying the effect of carnosine on AGEs/ALEs 
in vivo. Aldini et al. (2011) demonstrated that (3-fold) increased urinary AGEs in Zucker 
obese rats (compared to the lean counterparts) were reduced with 50% if Zucker obese 
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The performance enhancing effect is partly related to the protection against exercise-
induced-acidosis (pH buffering). Carnosine has a pKa value of 6.83 (which is similar for 
anserine and 6.1 for L-histidine), whereas pH level in muscle at rest is 7.05 and can 
decreases up to ~6.4 because of intense exercise. Knowing that the capacity of a 
metabolite to accept protons is maximal when its pKa value equals the pH of the 
surrounding medium, suggests that carnosine is a good candidate to be an important 
intracellular buffer (Bate-Smith 1938; Davey CL 1960). In this light, one of the 2 nitrogens 
of the imidazole ring of carnosine can be protonated in the physiological pH range (Abe 
2000).  
A second proposed ergogenic mechanism of carnosine is improving calcium handling in 
skeletal muscle. Muscle contraction occurs when cross bridges between actin and myosin 
can be formed. It is a complexly regulated chain of events, but one of the first steps is the 
release of Ca2+ from the sarcoplasmic reticulum. Ca2+ will then bind to troponin, which 
will cause a conformational change necessary to allow cross-bridge formation between 
actin and myosin. Carnosine has been suggested to counteract the declined, exercise-
induced, Ca2+ availability by two different mechanisms. First, Russian studies (Batrukova 
1997; Rubtsov 2001) on skinned muscle fibers showed that carnosine increases Ca2+ 
release from the sarcoplasmic reticulum. However, these conclusions were criticized by 
others (Dutka 2004) as non-physiological settings were applied. A second mechanism by 
which carnosine can counteract the decreased Ca2+ availability was proposed by Dutka 
and Lamb (2004). Experiments on rat (Dutka 2004) and human (Dutka 2012) skinned 
fibers showed that for a given concentration of Ca2+ in the sarcoplasm, the produced 
force was higher in the presence of carnosine and this points to increased Ca2+ sensitivity 
instead of an increase in calcium release.  
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5. THE CARNOSINE-CARNOSINASE SYSTEM IN A DIABETIC STATE 
5.1. Diabetes and its insurmountable metabolic changes 
Diabetes Mellitus is a collective term for a condition in which glucose builds up to 
abnormal levels in the bloodstream, causing serious health problems. In general, the 
ability to maintain normal blood glucose levels involves a complex interplay between 
insulin secretion by pancreatic beta-cells and insulin respons in tissues such as liver, 
adipose tissue and skeletal muscle.  
The two most common forms of diabetes are diabetes mellitus type 1 and type 2. 
Diabetes mellitus type 1 (also known as the formerly insulin dependent diabetes or 
juvenile diabetes) is a form of diabetes that results from auto-immune destruction of 
insulin-producing beta-cells of the pancreas and is believed of having a large genetic 
component. On the other hand, diabetes mellitus type 2 (formerly non-insulin dependent 
diabetes mellitus or adult-onset diabetes) has a metabolic component and is often linked 
to obesity and a sedentary lifestyle. It accounts for 90% of all cases of diabetes and it is 
characterized by the combination of decreased insulin secretion and decreased insulin 
sensitivity. However, many other less common/known forms of diabetes exist, such as 
monogenetic forms like MODY ‘Maturity Onset Diabetes of the Young’-variants. 
Although type 1 and type 2 diabetes have long been viewed as two different diseases, 
researchers, however, are currently showing that both types have more in common than 
once believed. For example, both forms are characterized by progressive destruction of 
pancreatic beta-cells via a cytokine-induced apoptosis. In type 2 diabetes mellitus, 
apoptosis is progressively favored mainly by glucotoxicity and lipotoxicity; whereas in 
type 1 diabetes mellitus, apoptosis is rapidly induced by irreversible autoimmune process 
(Cnop 2005; Daneman 2006). 
In addition, both type 1 and type 2 diabetes lead to similar long-term complications and 
metabolic problems. Large prospective clinical studies show a strong relationship 
between glycaemia and diabetic microvascular complications (retino-, nephro- and 
neuropathy) in both type 1 and type 2 diabetes (The Diabetes Control and Complications 
Trial Research Group 1993; UK Prospective Diabetes Study (UKPDS) Group 1998). 
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Furthermore, hyperglycemia and insulin resistance (both independently) seem to have 
important roles in the pathogenesis of macrovascular complications (atherosclerosis and 
cardiovascular disease such as stroke, ischemic disease,…)(Wei 1998; Ebara 2000; 
Ginsberg 2000). 
The last decades, four main metabolic pathways/disturbances have been put forward for 
being responsible for diabetic microvascular and macrovascular complications (figure 8):  
1) increased polyol pathway flux (discovered in 1966):  
This leads to decreases in NADPH, which is an essential cofactor for regenerating 
reduced glutathione (GSH), a critical intracellular anti-oxidant. By decreasing GSH, 
the polyol pathway increases the susceptibility to intracellular oxidative stress. 
Second, increased flux through the polyol pathway increases NADH:NAD+ ratio, 
which inhibits GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) and thus 
increases triose phosphate, leading to elevated levels of AGEs and protein kinase C. 
2) increased hexosamine pathway flux (discovered in late 1990s): 
N-acetyl glucosamine influences transcription factors such as an increase in 
plasminogen activator inhibitor-1 (PAI-1), responsible for vascular inflammation 
and thrombosis. 
3) activation of protein kinase C (PKC) β- and δ-isoforms (discovered in late 1980s):  
induces blood flow abnormalities, vascular permeability, capillary occlusion, pro-
inflammatory gene expression and increases ROS production. 
4) and increased AGE formation (discovered in late 1970s):  
damaging effect is explained in chapter 4.5. 
We will not explore these pathways into further detail, but it is clear that diabetes has 
several insurmountable metabolic changes.  
Until 2001, there was no unifying mechanism linking these four mechanisms. Brownlee M. 
(2001 and 2005) discovered that the overproduction of superoxide by the mitochondrial 
electron transport chain unifies the four well-known pathways (figure 8). This was 
published in an insight review in NATURE (Brownlee 2001) and in The Banting Lecture 
2004 (Brownlee 2005). Briefly, in diabetic cells with high glucose levels (especially non-
insulin dependent cells, such as retinal cells, glomerulus, nerves), there is too much 
glucose being oxidized in the citric acid cycle, ultimately leading to overproduction of 
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lipoproteins (LDL), high-density lipoprotein (HDL), triglycerides, blood pressure, 
smoking,… the insulin–resistant subjects had still a 2-fold increase of cardiovascular 
disease. So, insulin resistance is the major player in macrovascular disease. Coming to our 
point, insulin resistance causes increased free fatty acid (FFA) flux from adipocytes into 
macrovascular (arterial), not in microvascular, endothelial cells, resulting in increased FFA 
oxidation by the mitochondria. This generates on his turn the same electron donors 
(NADH en FADH2) produced by glucose oxidation, resulting in mitochondrial 
overproduction of ROS by exactly the same mechanism as for hyperglycemia. 
This work will focus on diabetes type 2 and the first stage of the disease, namely insulin 
resistance. Insulin resistance (or also called prediabetes type 2) can develop as a result of 
unhealthy lifestyle (overeating and physical inactivity) and genetic predisposition (Shigeta 
2001; Wybranska 2007). It is still under debate which organ (skeletal muscle, liver or 
adipose tissue) is the first target of insulin resistance and which organ can be accounted 
for being the primary defect in the development of type 2 diabetes (Kraegen 1991; Frayn 
2001; DeFronzo 2009), but it cannot be denied that the skeletal muscle plays an 
important role. It comprises ~40% of body mass and mediates over 75% of all insulin-
mediated glucose disposal under normal physiological circumstances, however it 
decreases significantly in insulin resistant individuals (DeFronzo 1985; Stump 2006; Abdul-
Ghani 2010). Several theories about the development of skeletal muscle insulin resistance 
are postulated. First, a body of research proposes that excess delivery of fatty acids to the 
skeletal muscle results in the accumulation of intramyocellular lipid metabolites such as 
diacylglycerol and ceramides, which are both detrimental for the insulin signaling 
pathway (Kraegen 2008; Martins 2012). Second, excess fatty acid oxidation in the 
mitochondria charges the electron transport chain, resulting in an overproduction of ROS 
and subsequently lipid and protein oxidation will occur (Wei 2008; Kewalramani 2010). 
Lipid oxidation products such as HNE can inhibit insulin-induced phosphorylation of 
PKB/Akt (necessary for an adequate insulin signaling) (Pillon 2012). Ingram et al. (2012) 
demonstrated a negative correlation between protein-HNE levels in skeletal muscle and 
glucose disposal rate (by an hyperinsulinemic-euglycemic clamp) in prediabetic and 
diabetes type 2 patients (Ingram 2012). Finally, emerging data indicate that the excessive 
activation of inflammatory pathways may represent a fundamental step in the 
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Briefly, the diabetes-related metabolic problems, possibly influenced by carnosine, are: 
increased reactive carbonyl species (methylglyoxal, HNE), protein carbonylation (as a 
consequence of increased RCS), formation of AGEs, a weakened anti-oxidant defense 
system and increased low-grade inflammation. We can conclude that carnosine possesses 
properties to prevent diabetes-related complications, but more importantly it can be 
expected that carnosine can already act on mechanisms responsible for insulin resistance 
(the initial phase of diabetes type 2). .  
The combination of carnosine being predominantly and abundantly present in the skeletal 
muscle and the skeletal muscle being an important ‘organ’ in the development of insulin 
resistance, rises the hypotheses that increasing muscle carnosine content can be 
protective in the development of insulin resistance. To recapitulate, if carnosine indeed 
acts as a lipid lowering agent (and thus decreasing free fatty acid flux towards skeletal 
muscle), increases the anti-oxidant defense system inside the muscle, quenches reactive 
carbonyl species such as HNE and serves as an anti-inflammatory agent, then the insulin 
signaling pathway will be protected by increasing muscle carnosine stores (as these 
factors are known to directly and indirectly influence the insulin signaling pathway and 
thus glucose uptake in skeletal muscle). Off course, caution is warranted as most 
mechanisms are based on in vitro studies. 
To fully explore the role of carnosine in a diabetic setting two approaches must be 
followed. First, it must be investigated how the carnosine-system behaves in a diabetic 
setting, by looking at carnosine and carnosinase concentrations in respectively tissues and 
circulation. Second, the additional effect of artificially increased plasma or tissue 
carnosine must be explored in a diabetic/insulin resistant setting. 
Concerning the latter, table 2 provides an overview of all in vivo studies done with 
carnosine supplementation in diabetic rodent models focusing on the protective effect of 
carnosine. From this table it is clear that up to now, predominantly severe diabetic 
models are used (i.e. genetically predetermined, STZ-induced diabetes or hyperglycemia 
induced by 2DG-injection of LCV) and no attention has been given to the role of the 
skeletal muscle (the predominant synthesis location of carnosine and an important organ  
  
 
Table 2. An overview of all in vivo studies with carnosine supplementation in diabetic rodent models. 
Study Species Administration protocol Duration Effect 
(Yamano 2001) Wistar rats:  
Hyperglycemia induced by 
LCV-injection of 2DG 
Chicken Essence (containing L-CAR) 
 
IP injection of L-CARN  
(5 µmol to 5 nmol) 
1 week 
 
acute 
 
↓ 2DG-hyperglycemia 
 
↓ blood glucose (0.05 and 0.5 nmol), ↑ plasma insulin, ↓ plasma 
glucagon, ↓sympathetic efferents of adrenal and liver, 
↑parasympathetic efferents of pancreas (0.5 nmol). 
(Nagai 2003) Wistar rats:  
Hyperglycemia induced by 
daily LCV-injection of 2DG  
0.001%, 0.01% and 0.1% (diet)  1 week  ↓ hyperglycemia (0.01% and 0.001%) 
 
(Lee 2005) STZ-induced diabetic 
Balb/cA mice 
L-CAR: 0.5 and 1 g/l (water) 
HIST: 0.5 and 1 g/l (water) 
4 weeks  ↓ hyperglycemia, ↓ hyperlipidemia in heart and liver, ↑enzymatic 
anti-oxidant capacity,↓ inflammation in plasma 
(equal effects for histidine and carnosine) 
[carn] heart and liver: = , [hist] in plasma, heart and liver ↓ vs CON 
(Sauerhofer 2007) db/db mice L-CAR: 4mM (~0.1%,~1g/l water) 17 weeks  ↓ fasting glucose, ↑ fasting insulin, enlarged pancreatic islets (+ 
effect on development of diabetes type 2) 
No effect on diabetic nephropathy 
(Soliman 2007) STZ-induced diabetic 
albino rats 
L-CAR: 100 or 200 mg/kg BW/day  
(IM) 
4 weeks (2 
weeks before 
and 2 weeks 
after STZ) 
↓ hyperglycemia, ↓ hyperlipidemia 
↑liver function and↑ vitamin E status. 
(Yan 2008) STZ-induced diabetic rats L-CAR: 5 or 10 mg/ml in eye drops, 
2x/day 
14 weeks ↓ formahon of AGEs, ↓ progression of lens opacification (only in 
early-stage cataract) 
 
   
 
 
(Kamei 2008) STZ-induced diabetic mice Zinc L-CAR (1:1 at MW): 75-300 mg/kg 
p.o.  
8 weeks ameliorates abnormal sensory perception 
(Mong 2011) C57BL/6 mice receiving 
60% high-fat diet 
L-CAR: 1 g/l (water) 
HIS: 1 g/l (water) 
8 weeks ↓ lipogenic enzymes and transcription factors for fatty acid and 
cholesterol metabolism (SREBPs) 
↓ body weight, epididymal and hepatic fat 
↓ hyperinsulinemia and insulin resistance 
[carn] and [hist] in liver ↓ in HF compared to CON 
(Aldini 2011) Zucker Obese Rats L-CAR: 30mg/kg BW/day (water) 
D-CAR: 30mg/kg BW/day (water) 
24 weeks ↓ hyperlipidemia,  ↓ hypertension,  ↓ renal injury, ↓ protein 
carbonylation, ↓ AGEs and RCS 
[carn]plasma and liver: seems to be ↓(n.s.) in Zucker Obese vs lean 
(Pfister 2011) STZ-induced diabetic rats L-CAR: 1 g/kg BW/day (water) 6 months ↓ development diabetic retinopathy, protects retinal capillary cells 
[carn]retinal cells ↓ in diabetic rats vs healthy rats 
(Riedl 2011) STZ-induced diabetic rats L-CAR: 1 g/kg BW/day (water) 3 months ↓ development diabetic nephropathy (prevents glomerular 
apoptosis and podocyte loss) 
[carn]glomerular cells ↓ in diabetic rats vs healthy rats 
Abbreviations: LCV: lateral cerebral ventricle, 2DG: 2-deoxy-D-glucose, STZ: streptozotocin, L-CAR: L-carnosine, HIS: L-histidine, HF: high-fat, CON: control, AGEs: Advanced glycation end-
products, RCS: reactive carbonyl species, p.o.: per os, IP: intraperitoneal, IM: intramuscular, n.s.: not significant, ↓: decreases/inhibits, ↑: increases/promotes.
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in the development of insulin resistance). In humans, there are no supplementation 
studies in diabetic populations. 
Concerning the first approach (endogenous carnosine system in a diabetic setting), 
Hipkiss and coworkers already speculated a decade ago that carnosine concentrations can 
be possibly decreased in tissues because of its characteristic of being a quencher of
several deleterious species (oxidants, reactive carbonyl species, protein carbonyls….) 
(Brownson 2000; Hipkiss 2000b; Hipkiss 2001; Hipkiss 2002)
fates of carnosinylated proteins is represented in figure 10. However, it must be stressed 
that this hypothesis is based on chemical experiments only, and no evidence for its 
involvement in biological events is availa
Figure 10:
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of STZ-induced diabetic rats (Buse 1980). In humans, only two papers exist and they are 
contradictive. Gualano et al. (2012) reported reduced gastrocnemius carnosine content (-
45%) in type 2 diabetic patients (Glycated hemoglobin ‘HbA1c’: 7.5 ± 0.3%; age: 60 ± 6 
years), but not in soleus muscle, nor in type 1 diabetic patients (Gualano 2012). On the 
other hand, Srikanthan et al. (2012) demonstrated an increase in soleus carnosine in 10 
diabetic type 2 patients (age: 54 ± 13 yrs; HbA1c: 6.0 ± 0.5%; patients on oral and insulin 
therapy were excluded (Srikanthan 2012).  
Conclusion: Carnosine is a likely candidate to counteract the development of diabetes 
and diabetes-related complications because of its properties as an anti-oxidant, an anti-
glycator, an anti-inflammatory and a lipid-lowering agent, a quencher of reactive 
carbonyl species, an inhibitor of protein carbonylation and AGEs/ALEs. There are some 
indications that carnosine content in tissues is possibly decreased in a diabetic state, 
however contradiction exists. In addition, carnosine supplementation studies are 
limited to severe diabetic rodents models and no attention was given to the skeletal 
muscle. Therefore, this work will 1) examine muscle carnosine concentrations in 
rodents and human with various degrees of glucose intolerance and 2) investigate the 
protective effect of carnosine supplementation in a very mild obese-insulin resistant rat 
model. In addition, a distinction will be made between the role of plasma carnosine vs 
muscle carnosine in preventing early-stage metabolic stress. 
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Diabetic patients with two copies of the 5 leucine allele were less susceptible to DN. This 
association was then confirmed by an independent study in 552 diabetic type 2 European 
Americans (Freedman 2007), however other studies did not find an association in type 1 
diabetic patients (Wanic 2008) or found that the association in type 2 diabetic patients is 
sex-specific (only present in women) (Mooyaart 2010). To strengthen their hypothesis, 
Janssen and colleagues showed that the homozygosity for the 5-leucine allele was 
associated with the lowest CN1 activity and vice versa, the more CTG repeats in CNDP1 
(the 6, 7 or 8 leucine allele), the higher the CN1 activity (Janssen 2005). Noteworthy, this 
was only demonstrated in healthy individuals.  
These genetic data in human patients introduced the working mechanism why the 5-5 
CNDP1 genotype decreases the risk in developing DN: the 5-5 CNDP1 genotype is related 
to the lowest carnosinase activity (Janssen 2005; Mooyaart 2010; Everaert 2012), which is 
thought to provide high(er) levels of plasma carnosine (Everaert 2012), and thus 
protecting tissues (such as kidneys) from ROS, RCS, AGEs, ALEs, …(Aldini 2005; Boldyrev 
2006), whereby the risk of diabetes-related complications is decreased (figure 12).  
 
 
 
  
 
 
 
 
Figure 12. Proposed physiological mechanism for the protective effect of the 5-5 genotype on the development of 
diabetic nephropathy. Abbreviations: ROS: reactive oxygen species, RCS: reactive carbonyl species, AGEs: advanced 
glycation end-products, ALEs: advanced lipoxidation end-products, CNDP1: serum carnosinase gene (based on Janssen, 
2005). 
 
5-5 CNDP1 genotype 
Low carnosinase protein content and activity 
High plasma carnosine levels 
Protection against ROS, RCS, AGEs, ALEs, … and 
dyslipidemia 
Decreased risk of developing diabetic nephropathy 
PART I: GENERAL INTRODUCTION 
 
46 
In this light, Sauerhofer et al. (2007) investigated this hypothesis by manipulating serum 
carnosine levels of db/db mice. First, endogenous L-carnosine serum levels were 
artificially lowered by overexpressing the human CN1 enzyme (transgenic mice), second, 
diabetic mice were given L-carnosine in their drinking water. As hypothesized, fasting 
plasma glucose as well as HbA1c levels rose significantly earlier and remained higher in 
transgenic animals. In the opposite approach (carnosine supplementation in db/db mice), 
diabetes manifested later and milder.  
Conclusion: The carnosinase system appears to be important in diabetic patients. 
However, parts of the working mechanism are only confirmed in healthy subjects or in 
animal models. Therefore, this work will look into some pieces of the carnosinase-
diabetes puzzle, by investigating whether low carnosinase activity/content is protective 
for diabetes related complications (with the focus on a  disturbed lipid profile) in 
diabetic type 2 patients. In addition, the behavior of CN1 in diabetic type 2 patients will 
be explored (the determinants of CN1 will be discussed for a healthy population in 
chapter 6.2. of the introduction). 
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Muscle fiber type composition can partly provide an explanation for this age-sex 
difference in muscle carnosine content, because women and elderly are characterized by 
a smaller cross-sectional area (CSA) of predominantly fast-twitch fibers (Simoneau 1989). 
In addition, there are no sex differences in fiber type distribution between boys and girls 
until the age of 8 (Vogler 1985) and this is the only age group with no difference in muscle 
carnosine content. Moreover, Tallon et al. demonstrated that carnosine content is equal 
in muscle fibers of the same kind between men and women (Tallon 2007).  
However, there are some indications that androgens take part as well in explaining the 
age-sex differences in muscle carnosine content, irrespectively of muscle fiber type. 
Penafiel et al. (2004) demonstrated that castrated mice have 40% less muscle carnosine 
compared to the uncastrated animals and testosterone administration in female mice 
increased muscle carnosine content by 268% (Penafiel 2004). This increase can never be 
explained by changing CSA of fiber types as it has been shown that testosterone 
supplementation has limited or no impact on CSA of fiber types (Sinha-Hikim 2006).  
Logically, as beta-alanine is present in meat and fish (under the form of anserine and 
carnosine), it can be suggested that dietary habits (being a vegetarian or eating 
little/much meat) influence muscle carnosine content (the average daily intake of beta-
alanine from an omnivore western diet equals approximately ~330 mg/day (Everaert 
2011). However, data are still controversial. Everaert et al. (2011) has demonstrated that 
12 male long-term (> 8 years) vegetarians had lower muscle carnosine levels compared to 
male omnivores (-20%), whereas switching from an omnivorous diet to a vegetarian diet 
for 5 weeks did not alter muscle carnosine content (Baguet 2011a). Probably the 
intervention period was too short to induce a significant decrease, however, the impact 
of switching to a vegetarian diet is still unclear. 
Conclusion: The main determinants of muscle carnosine content are muscle fiber type, 
sex and age. However, it has to be determined whether diabetes can alter muscle 
carnosine content as well (as suggested from the quenching theory above, cfr. 5.2.). 
Therefore, this work will investigate skeletal muscles of different obese/diabetic rodent 
models.  
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muscle carnosine, this is less than 6%. However, there is no information available about 
long-term urinary beta-alanine excretion.  
When relating muscle carnosine loading to diabetes, we can question whether insulin (a 
key hormone in diabetes) can stimulate beta-alanine uptake in muscle, by triggering the 
sodium dependent beta-alanine transporter Taut. This would be similar to the 
metabolism of creatine, another popular nutritional supplement that enhances 
performance through muscle loading. Here, insulin stimulates the sodium-dependent 
creatine transporter as well (Green 1996; Steenge 1998; Sweeney 1998)(mechanism will 
be schematically represented in part III, figure 2).  
Upon discontinuation of beta-alanine supplementation, muscle carnosine levels will 
gradually return to baseline, pre-supplementation levels in 6-20 weeks (a long wash-out 
period) (Baguet 2009; Stellingwerff 2012). A first attempt to establish a maintenance dose 
(to keep up elevated muscle carnosine levels) was published by Stellingwerff et al. (2012). 
They demonstrated that after an initial loading protocol of 3.2g beta-alanine/day for 4 
weeks, a further ~30% increase in muscle carnosine occurred after 4 weeks of taking 1.6g 
beta-alanine per day. We can conclude that the optimal maintenance dose must be found 
between 0 and 1.6g beta-alanine per day. Finding a maintenance dose is particularly 
important for long-term studies about the effects of chronically elevated muscle 
carnosine levels on sports performance or in clinical situations. Therefore, this work will 
investigate 3 intermediate doses: 0.4g/day, 0.8g/day and 1.2g/day. 
Conclusion: Muscle carnosine loading is accomplished by beta-alanine supplementation, 
however 1) a large variability exists in muscle carnosine loading response and 2) it is 
unknown how much beta-alanine is retained by the body during chronic 
supplementation. Therefore, this work will 1) focus on possible determinants such as 
the effect of insulin, sex, body weight and fat-free mass in the loading phase and 2) 
urinary excretion and muscle accumulation of beta-alanine will be explored during 
chronic supplementation. Finally, this work will propose a maintenance dose to keep up 
elevated muscle carnosine stores.  
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6.2. Determinants serum carnosinase 
Studies investigating the enzyme serum carnosinase are mainly coming from the clinical 
field, as the relevance of CN1, or its gene (CNDP1), is predominantly related to diabetes 
or diabetes-related complications (cfr supra).  
Similar to muscle carnosine content, serum carnosinase describes a considerable 
variation between individuals (Lenney 1982). The stability within individuals throughout 
the day is remarkably stable (Peters 2011b), however, the stability over weeks/months is 
not known. Below, the known or putative determinants are described. Notably, these are 
only applicable for humans, as CN1 is not present in serum of rodents.  
Age and sex. CN1 activity is found in small amounts in newborns (Bando 1984) and raises 
gradually with age until adolescence is reached, with no further change throughout life 
(Lenney 1982), however, CN1 protein content does not differ between children and 
adults, pointing towards different CN1 conformations in the respective age groups (Peters 
2010). Once adolescence is reached, a sexual dimorphism appears, i.e. women have 
higher levels of both CN1 activity and content compared to men (Bando 1984; Peters 
2010; Everaert 2011). 
CTG repeats. This is discussed above (subchapter 5.3.). However, briefly, Janssen et al. 
(2005) reported that a particular genotype is associated to CN1 activity. The five leucine 
allele was associated with the lowest CN1 activity levels (Janssen 2005). Although this 
association appears to be relevant for diabetic patients (as explained above), it is not (yet) 
investigated in this specific population, which represents a big gap in the literature.  
N-glycosylation is recently reported as another determinant and is directly related to 
diabetes. N-glycosylation is a subclass of glycosylation (the most frequent 
posttranslational modifications of macromolecules) and contains the attachment of a 
sugar molecule (glucose3-mannose9-N-acetylglucosamine2, which is called an N-glycan) to 
a nitrogen atom in an amino acid residue of a protein. This type of linkage is important for 
both the structure and function/activity of proteins and takes place in the endoplasmic 
reticulum. CN1 is susceptible for enzymatic N-glycosylation, as it has three putative N-
glycosylation sites (Teufel 2003). Knowing this, Riedl et al. (2010) stepwise deleted the 3 
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putative N-glycosylation sites in transfected cells and in these cells CN1 secretion and 
activity was gradual inhibited. Next, Riedl et al. (2010) suggested that hyperglycemia 
would increase CN1 secretion/activity because of increased N-glycosylation. 
Hyperglycemia triggers the hexosamine pathway, leading to elevated UDP-N-
acetylglucosamine (GlcNAc) concentrations (figure 8) (Brownlee 2001). As Sasai et al. has 
demonstrated that the level of UDP-GlcNAc is a critical factor in the production of N-
glycans, which on his turn increases N-glycosylation (Sasai 2002), these increased levels of 
UDP-GlcNAc will probably enhance CN1 secretion/activity. Indeed, they demonstrated 
that 11 homozygous diabetic (type 1 and type 2) patients for the 5-leucine allele had 
increased CN1 activity levels (~20%) compared to 15 homozygous healthy controls (Riedl 
2010). This may be a disadvantage for diabetic patients, as it is suggested that high CN1 
activity levels counteract the protective circulating dipeptide carnosine (upon dietary 
ingestion). 
Other determinants. CN1 belongs to the family of the M20- metalloproteinases. As the 
name speaks for itself, these proteinases use metal ions for its catalytical activity (Lenney 
1985; Teufel 2003). In addition, there is a competitive inhibition between the substrates 
of carnosinase, being not only carnosine, but also homocarnosine and anserine. However, 
it is uncertain whether this is relevant in vivo (Peters 2010; Peters 2011b).  
Combining the two latter chapters about muscle carnosine content and serum carnosine 
activity, it seems that muscle carnosine content and serum carnosinase activity are 
related. For example, women and elderly have low muscle carnosine levels, but display a 
high activity of CN1. However, Everaert et al. (2011) has shown that there is no inverse 
relationship between carnosine content in muscle and carnosinase activity in circulation 
within subjects. Similarly, the polymorphism of the CNDP1 gene does not predict muscle 
carnosine levels. The authors explain this finding to a different compartimentation 
because carnosine is mainly present in muscle, whereas carnosinase (CN1) is present in 
circulation. 
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Conclusion: Age, sex and CTG repeats are the dominant determinants of serum 
carnosinase, although demonstrated in a healthy population. This work will examine 
whether the determinants age and sex still hold for a diabetic population and whether 
prolonged hyperglycemia (HbA1c) is positively correlated with serum carnosinase in a 
large cohort diabetes type 2 patients. In addition, the effect of an exercise program 
(aiming to attenuate hyperglycemia) on serum carnosine content and activity will be 
examined.  
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7.  EXPERIMENTAL AIMS AND OUTLINE OF THE THESIS 
Carnosine is a dipeptide with several biochemical and physiological properties 
presumably relevant in a diabetic state. The introduction has put forward some 
arguments for an altered carnosine-carnosinase system in a glucose intolerant state. In 
addition, evidence has been given that carnosine administration counteracts the 
development of diabetes or diabetes-related diseases.  
In part II, animal and human studies provided an answer whether or not the carnosine-
carnosinase system is truly affected in a diabetic state. In addition, it was demonstrated 
how carnosine (or beta-alanine) administration can be protective in an early stage of 
metabolic disease. Therefore, five studies were performed (figure 15): 
First, it was investigated how muscle carnosine loading by beta-alanine supplementation 
takes place under normal physiological conditions and whether insulin (one of the key 
hormones in diabetes) plays a role. This was indirectly investigated by comparing long-
term beta-alanine supplementation in between the meals (out-phase) or during the meals 
(in phase) (study 1).  
In line with this, a theoretical explanation was given for net carnosine turnover in 
different situations (baseline, loading, washout and maintenance) and the beta-alanine 
dose was proposed in order to maintain moderately elevated muscle carnosine levels 
(relevant for athletes and presumably relevant in clinical populations) (study 2).  
In a next study (study 3), the effect of carnosine supplementation in a high-fat rat model 
was investigated to elucidate the early metabolic effects of carnosine administration. In 
addition, a critical unanswered question was the site of action of carnosine, being either 
carnosine levels in tissues (with focus on muscle) or in plasma. Therefore, this was 
investigated using oral carnosine versus beta-alanine supplementation, since beta-alanine 
can increase muscle carnosine levels, without a concomitant increase in plasma carnosine. 
The fourth study originated from the uncertainty that muscle carnosine levels are actually 
decreased in a diabetic state, since we did not observe decreased muscle carnosine levels 
in our mild high-fat diet rat model (study 3). Therefore, rodents receiving various degrees 
of high-fat diets, resulting in various degrees of glucose intolerance, were examined for 
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their muscle carnosine content. Ultimately providing an answer whether muscle 
carnosine is actually decreased in a glucose intolerant state.  
Finally, CN1 content and activity was investigated in 243 diabetic type 2 patients, before 
and after a 6-month intervention, being either an exercise program (aerobic, resistance or 
combined exercise) or remaining sedentary (study 5). This design allowed us to explore 
the behavior of baseline CN1 in a diabetic state and whether or not it could be influenced 
by exercise training. In addition, the hypothesis ‘low carnosinase is protective in the 
development of diabetes related metabolic disturbances’ was tested.  
In part III, the main findings of the thesis were summarized and discussed to finally  end 
with a brief conclusion.  
 
 
Figure 15: Schematic representation of the experimental aims and outline of the thesis.
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Study 1. Meal and beta-alanine co-ingestion enhances muscle carnosine loading 
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ABSTRACT 
Introduction. Beta-alanine (BA) is a popular ergogenic supplement as it can induce muscle 
carnosine loading. We hypothesize that, by analogy with creatine supplementation, 1) an 
inverse relationship between urinary excretion and muscle loading is present, and 2) the 
latter is stimulated by carbohydrate-and protein-induced insulin action.  
Methods. In study A, the effect of 5 weeks slow-release BA (SRBA) supplementation 
(4.8g/day) on whole body BA retention was determined in 7 men. We further determined 
whether co-ingestion of carbohydrates and proteins with SRBA would improve retention. 
In study B (34 subjects), we explored the effect of meal-timing on muscle carnosine 
loading (3.2g/day during 6-7 weeks). One group received pure BA (PBA) in between the 
meals, the other received PBA at start of the meals, in order to explore the effect of meal-
induced insulin release. Further, we compared with a third group receiving SRBA at start 
of the meals.  
Results and conclusion. Orally ingested SRBA has a very high whole body retention (97-
98%), that is not declining throughout the 5 weeks supplementation period, nor is it 
influenced by co-ingestion of macronutrients. Thus, a very small portion (1-2%) is lost 
through urinary excretion, and equally only a small portion is incorporated into muscle 
carnosine (~3%), indicating that the majority of ingested BA is metabolized (possibly 
through oxidation). Secondly, in soleus muscles, the efficiency of carnosine loading is 
significantly higher when PBA is co-ingested with a meal (+64%), compared to in between 
the meals (+41%), suggesting that insulin stimulates muscle carnosine loading. Finally, 
chronic supplementation of SRBA versus PBA seem equally effective.  
 
 
 
 
Keywords: beta-alanine retention, ergogenic supplements, carnosine synthase 
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INTRODUCTION 
Human skeletal muscles contain carnosine (β-alanyl-L-histidine), a cytoplasmic dipeptide, 
in relatively high concentrations (~ 5 mmol/kg wet weight) (Harris 1990). Chronic 
supplementation of beta-alanine (BA), the rate-limiting precursor for carnosine synthesis, 
can significantly increase muscle carnosine content by 40 – 80% when ingested in doses 
of ~ 1.6 – 6.4 g/day for ≥ 4 weeks (Harris 2006; Derave 2007; Hill 2007b; Baguet 2009; 
Stellingwerff 2012). BA supplementation has recently become an intensive research topic, 
not only in the exercise and performance-enhancement field, but also in clinical 
populations with chronic glycoxidative and inflammatory damage. An increase in muscle 
carnosine is related to an increase in performance for high-intensity exercise (Hill 2007a; 
Baguet 2010; del Favero 2012). Moreover, low muscle carnosine levels are found in 
certain clinical populations such as diabetes type 2 and elderly (del Favero 2012; Gualano 
2012), which may suggest that carnosine loading could be beneficial. These findings are 
assisted by in vitro and preclinical research suggesting a multitude of physiological roles 
for carnosine, such as a regulator of muscle excitation-contraction coupling via increasing 
calcium sensitivity, proton buffer, antioxidant, an inhibitor of protein glycation, as 
extensively reviewed by Boldyrev (2012) and Derave et al. (2010). 
In order to understand the mechanism of muscle carnosine loading, it is necessary to gain 
insight into the metabolic fate of chronically ingested BA in humans. Decombaz et al. 
(2012) acutely supplemented pure (PBA) and slow-release (SRBA) BA and showed a very 
high whole body retention for both forms, respectively 96.3% and 98.9%. SRBA was 
developed in order to avoid high peak concentrations of BA in the blood, which is 
associated with side-effects such as paresthesia, however its efficiency for muscle 
carnosine loading has never been directly compared with PBA. When calculating the 
percentage of the total ingested BA dose (PBA or SRBA ingested over a prolonged period) 
that is actually incorporated into muscle carnosine, this is less than 6% (Hill 2007b; Baguet 
2009; Stellingwerff 2012). Therefore, we expect that the retention of BA, albeit nearly 
maximal upon a first oral challenge (Decombaz 2012), will decrease during chronic 
supplementation. This would be similar to two other popular nutritional supplements that 
enhance performance through muscle loading, namely creatine and carnitine, which are 
similar small nitrogen-containing molecules with high natural abundance in skeletal 
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muscle. Even though the biochemical mode-of-action with respect to involvement in 
energetic pathways leading to exercise performance enhancement is different between 
creatine, carnitine and carnosine, the mechanism of accumulation in muscle is strikingly 
similar: the muscular loading is mainly limited by the transsarcolemmal transport system 
and the transport is dependent on and driven by sodium ion co-transport. The retention 
of creatine and carnitine is high in a first ingestion, but subsequently decreases during 
chronic supplementation. After 3 days (20 g/day) creatine retention decreases from 53% 
to 41% (Green 1996a) and after 14 days (3 g/day) carnitine retention decreases from 98% 
to 90% (Stephens 2007).  
Interestingly, the urinary loss of creatine and carnitine seems to be inversely related to 
the muscle loading efficiency, or in other words, when the muscle pools get saturated and 
reach maximal levels, the compounds (creatine, carnitine) start to appear more 
abundantly in the urine (Green 1996b; Stephens 2007). According to this rationale, the 
search for new interventions to improve the muscle loading efficiency can start with 
looking at interventions that decrease urinary excretion, as a proxy of muscle 
accumulation. Indeed, when large amounts of carbohydrates are co-ingested with 
creatine or carnitine, its urinary excretion decreases (Green 1996a; Stephens 2007). The 
follow-up research then demonstrated that more creatine and carnitine is accumulated in 
the skeletal muscle under the influence of carbohydrate- and protein-mediated insulin 
release (Green 1996b; Steenge 1998; Wall 2011). Insulin stimulates the sodium-
dependent creatine (CreaT) and carnitine (OCTN2) transporter, secondary to its action of 
increasing sarcolemmal Na+/K+-ATPase pump activity and therefore transmembrane Na+ 
flux (Sweeney 1998; Clausen 2003). Because it has been shown that the most important 
BA transporter (TauT) is strongly dependent on sodium and chloride co-transport 
(Bakardjiev 1994), it is equally expected that muscular BA uptake, and hence carnosine 
loading, is enhanced by insulin action. 
Therefore, this study was designed to investigate the distribution of chronically ingested 
BA, by looking at urinary BA excretion and muscle carnosine loading. Secondly, does co-
ingestion of carbohydrates and proteins has the potential to alter this distribution of BA in 
the body? And finally, is SRBA more efficient concerning muscle carnosine loading 
compared to PBA?  
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MATERIALS AND METHODS 
Subjects 
Forty-five healthy non-vegetarian men and women participated in the present studies 
(study A and B), which were approved by the local ethical committee (Ghent University 
Hospital, Ghent, Belgium). All gave their written informed consent to take part in the 
studies and were aware that they were free to withdraw from the experiment at any 
point.  
Study protocol  
Study A (represented in figure 1). Seven men (age: 22.1 ± 1.3 yr, body weight: 80.7 ± 11.8 
kg) were supplemented for 5 weeks with 4.8g slow release beta-alanine (SRBA) (3x/day 2 
tablets of 800 mg, PowerBar). Retention was measured weekly (by ingestion of 1.6g SRBA 
in fasted state and collection of urine up to 6h post-ingestion) and calculated by the 
amount of BA not excreted in urine. Total urinary volume was determined and urine 
aliquots were collected in EDTA-coated tubes and stored at -20°C for further HPLC 
analysis of BA. During the 6h period, the subjects were withdrawn from food, but had at 
liberty access to water. From week 2, subjects performed the retention twice on 
consecutive days: in the first condition subjects took 1.6 g SRBA in fasted state (= FASTED), 
in the second condition subjects took 1.6g SRBA together with the intake of 2 energy 
carbohydrate-rich bars of PowerBar (=CHO) (PowerBar Europe GmbH). To sustain 
elevated levels of plasma insulin, the first carbohydrate-rich bar (Energize C2 max: 39.1g 
CHO + 5.8g protein) was taken 10min after BA intake and the second protein rich bar 
(Protein Plus: 22.2g CHO + 16.6g protein) 55min after BA intake. According to Steenge et 
al. (2000) , we can assume that the ingestion of 61.3 g CHO + 22.4 g protein would elevate 
plasma insulin above 70 mU/L. 
Study B (represented in figure 1). In order to determine the effect of meal-induced insulin 
release on muscle carnosine loading, we first aimed to design a protocol in which the area 
under the curve (AUC) for plasma insulin and BA would either overlap with each other or 
would be completely separated from each other. For this purpose we subjected four 
participants to a small acute pretest (age: 22.5 yr, body weight: 76.6 kg, 2 males and 2 
females). 
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Figure 1: Schematic representation of study design A and B   
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Over a period of 8 hours, subjects ingested 2 meals, starting with a breakfast at 8 am (850 
kcal: 74% CHO, 14% P, 12% F) and a lunch at 12 pm (950 kcal: 66% CHO, 13% P, 21% F). 
Both meals were standardized and contained no meat. Breakfast consisted of 4 slices of 
white bread with chocolate-hazelnut paste, 200ml semi-skimmed milk, 1 banana and 
125gr fruit yogurt. Lunch contained a 150gr baguette topped 40gr young cheese, 30gr 
mayonaise and vegetables with a 33cl orange juice. Subjects all drank 1,5L water during 
the 8 hours. Two subjects (1 male, 1 female) ingested PBA (2 x 800 mg) interspersed in 
between meals (at 10.30 am and 2.30 pm: ‘PBA’) and two other subjects ingested PBA at 
the start of the meals (8 and 12 am: ‘PBA+meal’). Every 30 to 45 minutes venous blood 
samples (EDTA coated tubes and serum tubes for respectively BA and insulin 
determination) were taken from a catheter, placed in an antecubital vein. We defined the 
AUC where elevated plasma BA values (> 30 µM) coexisted with moments of elevated 
plasma insulin levels (> 25 µU/ml) induced by meals.  
We subsequently adopted this protocol of the pretest, i.e. comparison of ingesting PBA 
either during or interspersed between meals, into a full study lasting 46 days. In addition, 
a third experiment group was included that chronically ingested SRBA in the same dose. 
Thirty-four subjects (age: 19.4 ± 1.0 yr, body weight: 66.6 ± 9.9 kg), both males (n = 16) 
and females (n = 18) were randomized into three sex-balanced groups. All groups 
received 3.2g BA daily, divided over 4 intakes of 800 mg each, with at least 3h between 
intakes. The first group, ‘PBA’, received PBA between the meals/snacks (CarnoSyn beta-
alanine powder in 400 mg gellules, Natural Alternatives International (NAI), San Marcos, 
USA). Subjects were not allowed to eat 150 minutes before and 90 minutes after each 
intake (4 daily) of BA, throughout the 46 days. The second group, ‘PBA+meal’, received 
PBA at the start of each meal (3x/day) and a fourth pill had to be taken with a 
carbohydrate-rich snack. The last group, ‘SRBA+meal’, took SRBA (CarnoSyn SR tablets, 
NAI) 30 minutes before a meal or snack. Before and after the supplementation period 
muscle carnosine content was measured and during supplementation subjects had to fill 
in a diary for the registration of every BA and meal/snack consumption. Finally, all 
subjects completed a questionnaire of their meat and fish consumption during the first 2 
weeks of the study in order to quantify daily dietary BA ingestion, as described by Baguet 
et al. (2009). 
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Determinations in plasma and urine samples 
The concentration of BA in plasma and urine was determined by high-performance liquid 
chromatography (HPLC). One hundred microliters of EDTA-containing plasma and urine 
was taken and added with 11.1 µl S-sulfosalicylic acid to deproteinize the samples. These 
deproteinized samples were dried under vacuum (40°C) for 45 minutes. Dried residues 
were resolved with 40 µl of coupling reagent: methanol-triethylamine-H2O-
phenylisothiocyanate (7:1:1:1) and allowed to react for 20 min at room temperature. 
Samples were dried again and resolved in 100 µl sodium acetate buffer (10 mM, pH 6.7). 
The same method was applied for the standard solutions of BA (Sigma, dissolved in 
deionized distilled water). Derivatized samples (20 µl) were chromatographed on a 
Waters HPLC system with a Spherisorb C18/ODS2 column (4.6 x 150 mm, 5 µm), ODS2 
guard column (80Å, 5 µm, 4.6 mm X 10 mm) and UV detector (wavelength: 210 nm). The 
columns were equilibrated with buffer A (10 mM sodium acetate adjusted to pH 6.8 with 
6% acetic acid), buffer B (60% acetonitrile-40% buffer A) and buffer C (100% acetonitrile) 
at a flow rate of 0.8 ml/min at 25°C. The limit of quantification was 7 µM. Plasma insulin 
was determined by electrochemiluminescent assay on a Cobas E411 (Roche Diagnostics, 
Mannheim Germany). 
Determination of muscle carnosine content  
Carnosine content of all the subjects was measured by proton magnetic resonance 
spectroscopy (1H-MRS) in soleus and gastrocnemius medialis muscles, as described by 
Baguet et al. (2010). The subjects were lying in supine position on their back and the 
lower leg was fixed in a holder with the angle of the ankle at 20° plantar flexion. All the 
MRS measurements were performed on a 3-T whole body MRI scanner (Siemens Trio, 
Erlangen) equipped with a spherical knee-coil. Single voxel point-resolved spectroscopy 
(PRESS) sequence with the following parameters was used; repetition time (TR) of 2.000 
ms, echo time (TE) of 30 ms, number of excitations is 128, 1.024 data points, spectral 
bandwidth of 1.200 Hz, and a total acquisition time of 4.24 min. The average voxel size for 
the soleus and gastrocnemius muscle was respectively 40 mm x 10 mm x 28 mm and 40 
mm x 11 mm x 30 mm. The line width of the water signal for the soleus and 
gastrocnemius muscle was on average respectively 24.6 Hz and 27.6 Hz, following 
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shimming procedures. The absolute carnosine content (in millimolar; mM) was calculated 
as described before by Baguet et al. (2010). 
Statistics 
A general linear model repeated measures ANOVA was used to evaluate a decrease in BA 
retention over time. To look for differences between PLA and CHO a paired sample t-test 
was performed at each time point. To examine the absolute and relative difference in 
muscle carnosine between ‘PBA’ and ‘PBA+meal’, a 2x2 general linear model repeated-
measures ANOVA was performed, with absolute/relative increase in muscle carnosine as 
the dependent variable and muscle group and intervention group as the between-
subjects factors. A posthoc independent two sample T-test was performed to study the 
difference for each muscle separately. To investigate the efficiency of PBA+meal versus 
SRBA+meal, the same statistics were performed as above. All analyses were done with 
SPSS statistical software (SPSS 20, Chicago, IL) and statistical significance was set at p < 
0.05. 
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RESULTS 
Whole body beta-alanine retention (Study A).  
Urinary BA excretion was found to be very low and unaltered throughout the study in all 
subjects. Of the ingested 1600 mg SRBA, only ~26 mg (range 1 - 75 mg) was excreted in 
the urine. Whole body BA retention was 97.98% during a first oral challenge with SRBA. 
Long-term supplementation did not affect the retention (week 1 – 5: 97.98 ± 1.45%, 98.45 
± 1.20%, 98.05 ± 0.85%, 98.53 ± 0.66 %, 98.79 ± 0.59%, respectively, p > 0.05). Logically, 
co-ingestion of SRBA with carbohydrates and proteins did not enhance BA retention 
(week 2: 98.37 ± 0.92%, week 3: 98.71 ± 0.83%, week 4: 98.54 ± 0.98%, week 5: 97.56 ± 
1.74%, p > 0.05) (figure 2).  
Figure 2: Study A: BA retention during a 5-week supplementation period of 4.8g SRBA/day with (CHO) or without 
(FASTED) co-ingestion of CHO and proteins. * p<0.05 versus CHO. 
Plasma insulin and beta-alanine (Study B).  
Figure 3 represents the profile of plasma insulin and BA during 8 hours when PBA 
ingestion is interspersed in between (A) or coincides (B) with meals. In figure 3A, the 
moments of insulinemia (>25 µU/ml) and beta-alaninemia (> 30 µM) are clearly separated, 
whereas in 3B the elevations in plasma insulin and BA clearly overlap. This is represented 
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by respectively 0% and 82% of the total AUC of plasma BA showing elevated BA levels at 
the moment of hyperinsulinemia.  
 
Figure 3: Study B: Blood profile of plasma insulin and beta-alanine (BA) during 8 hours. 3A. average of 2 subjects taking 
PBA in between the meals (PBA). 3B. average of 2 subjects taking PBA at the start of the meals (PBA+meal). 
 
Muscle carnosine content (Study B).  
There were no differences between the groups concerning age, height, weight and total 
dietary BA intake (table 1) nor concerning baseline carnosine concentration in soleus and 
gastrocnemius (table 2). Baseline soleus carnosine concentration (3.47 ± 0.87 mM) was 
lower compared to gastrocnemius muscle (4.51 ± 1.36 mM; p< 0.001). In soleus, the 
absolute (1.98 ± 0.96 mM) and relative (63.6 ± 41.6 %) increase in carnosine was higher 
3A. 
3B. 
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when PBA (4 x 800 mg) was taken at the start of each meal/snack (‘PBA+meal’), compared 
to the group that ingested PBA in between the meals (‘PBA’, respectively 1.40 ± 0.44 mM 
and 40.7 ± 14.2 %, table 2 and figure 4) (main effect ‘group’: p=0,08 ; independent two 
sample t-test for soleus separately: p=0,049). In gastrocnemius muscle, the effect of meal 
timing was not present (independent two sample t-test for gastrocnemius separately: 
p=0.531). The muscle carnosine loading in the group ‘SRBA+meal’ was not statistically 
different from ‘PBA+meal’.  
 PBA PBA+meal SRBA+meal 
Number of subjects (M/F) 10 (4/6) 12 (6/6) 12 (6/6) 
Age (yr) 19,3 (± 0,9) 19,3 (± 1,1) 19,6 (± 0,9) 
Height (cm) 173,0 (± 7,0) 171,7 (± 11,2) 174,3 (± 10,4) 
Weight (kg) 68,2 (± 10,1) 66,7 (± 8,8) 65,3 (± 11,3) 
Dietary BA intake (mg/day)  213 (± 146) 250 (± 82) 245 (± 93) 
 
Table 1: Baseline values of the three groups of study B. There are no significant differences between the groups. Data 
are means ± SD. 
 
 
M. SOLEUS [Carnosine] Pre 
(mM) 
[Carnosine] Post  
(mM) 
Delta 
(mM) 
PBA 3.54 (± 0.86) 4.94 (± 1.13 )* 1.40 (± 0.44) 
PBA+meal 3.46 (± 0.93) 5.44 (± 1.02)* 1.98 (± 0.96) † 
SRBA+meal 3.43 (± 0.89) 5.14 (± 1.06)* 1.71 (± 0.62) 
M. GASTROCNEMIUS [Carnosine] Pre 
(mM) 
[Carnosine] Post 
 (mM) 
Delta 
(mM) 
PBA 4.59 (± 1.66) 6.09 (± 1.73 )* 1.50 (± 0.83) 
PBA+meal 4.26 (± 0.93) 5.98 (± 0.91)* 1.72 (± 0.61) 
SRBA+meal 4.70 (± 1.53) 6.48 (± 1.67)* 1.78 (± 0.99) 
 
Table 2: Muscle carnosine concentrations before and after a 46-days loading protocol (study B) in the three 
intervenhon groups. Data are means ± SD. * p<0.05 versus pre. † p< 0.05 versus PBA.  
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Figure 4: Relative increase in muscle carnosine concentrations before and after a 46-days loading protocol (study B) 
between the groups ‘PBA’ and ‘PBA+meal’ (figure 4A) and ‘PBA+meal’ and ‘SRBA+meal’ (fugure 4B). * p < 0.05: vs PBA. 
Data are means ± SD. 
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DISCUSSION 
Whole body beta-alanine retention.  
The main finding of study A is that of the total amount of chronically ingested SRBA (168 
gr over 5 week period) only very little (~2.7 g or 1.6%) is excreted in the urine (figure 2). 
This is surprising because it could be calculated from previous studies (Harris 2006; 
Baguet 2009; Stellingwerff 2012) that muscular uptake and the incorporation efficiency of 
exogenous BA into carnosine are very low as well. In the present study, the amount of BA 
converted into muscle carnosine was calculated to be ~4.1g (2.8%), when assuming that 
40% of body mass is muscle mass. Thus, it seems that the vast majority (~160g or 95-96%) 
of the ingested BA is neither going into muscle carnosine nor into the urine. Therefore, 
the alternative metabolic fate is currently unknown and merits further investigation. 
These new findings for BA are in sharp contrast with creatine, another popular ergogenic 
nutritional supplement. As for BA, it is a small nitrogen-containing, non-proteinogenic 
molecule with high abundance in skeletal muscle and a similar transsarcolemmal 
transport system. It has been repeatedly demonstrated, already upon the first publication 
in 1992 by Harris et al. (1992), that the major portion of the ingested creatine is either 
excreted in the urine or accumulated in the muscle, with a reciprocal relationship 
between the two options (Green 1996a; Green 1996b; Steenge 1998; Steenge 2000). It is 
clear that for BA, urinary excretion cannot be used to make an indirect estimation of 
muscular accumulation of carnosine.  
This finding brings to mind an important question: where does all the BA go? One 
possibility is oxidation and energy provision. The contribution of alpha-amino acids to 
energy delivery in muscle and other tissues is usually quite low, as compared to 
carbohydrates and fat. However, when certain amino acids are available in excess, e.g. 
branched chain α-amino acid supplementation, then they will be oxidized and their 
contribution to total energy delivery can amount to up to 10% (Jeukendrup A. 2010). 
Indications exist that not only α-amino acids, but beta-amino acids as well can serve as an 
energy source when available in excess, which would certainly be the case with the 
ingestion of BA in such high daily doses (3.2 to 6.4 g/day; (Harris 2006; Hill 2007b; Baguet 
2009; Stellingwerff 2012)). In order to enter the citric acid cycle the amino group of BA 
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has to be removed through a transamination reaction, catalyzed by BA transaminase 
(EC:2.6.1.19; also known as GABA transaminase (Griffith 1986; De Biase 1995)). 
Interestingly, we recently demonstrated its expression in rodent skeletal muscle and 
showed that its transcription is upregulated upon BA supplementation (Everaert 2013). 
Therefore, we suggest that BA oxidation could be an important metabolic fate of 
chronically ingested BA, possibly in skeletal muscle, but likely in other organs such as liver, 
kidney and brain (De Biase 1995; Ito 2001). However, it is not excluded that other 
metabolic pathways are involved as well. Yet, it seems unlikely that the conversion of BA 
into carnosine in other (non-muscle) tissues is of any quantitative significance, because 
presence of carnosine (Flancbaum 1990; Jackson 1996) and carnosine synthase (Harding 
1976) in non-muscle tissues is several orders of magnitude lower than in muscle. 
The effect of macronutrients on beta-alanine retention.  
We observed that co-ingestion of carbohydrates and proteins (61 g CHO + 22 g P) with 
SRBA did not alter urinary BA excretion and hence BA retention (figure 2). However, as 
mentioned above, urinary BA excretion is not a good inverse estimate of muscle 
carnosine accumulation. Thus, this observation does not exclude a shift towards more 
muscle carnosine loading, if this depends on the insulin sensitivity of the sodium-
dependent BA transporter. In order to resolve this question, we needed to look at muscle 
carnosine loading in a long-term protocol in which BA was ingested either in the presence 
or absence of hyperinsulinemia.  
The effect of meal-timing on muscle carnosine loading.  
In study B, we could confirm in a one-day pre-test that subjects taking PBA in between 
the meals and subjects taking PBA at start of the meals had different (respectively out-of-
phase versus in-phase) blood profiles concerning plasma insulin and BA (figure 3). 
Respectively 82% and 0% of the total AUC of plasma BA showed elevated BA levels (> 30 
µM) at the moment of insulinemia (> 25µU/ml). In the follow-up chronic supplementation 
study, we were able to demonstrate that carnosine loading in the insulin-sensitive soleus 
muscle increased by 64% when PBA (4 x 800 mg) is taken at the start of each meal/snack 
compared to 41% when PBA was ingested in between the meals (figure 4). This finding 
may have practical applications, i.e. regarding the advice on how and when to ingest BA 
MEAL AND BETA-ALANINE CO-INGESTION 
 
75 
for optimal muscle carnosine loading results. Yet, it may also provide further insight into 
the physiological mechanism and limitations to muscle BA uptake and carnosine synthesis. 
Most researchers postulate that very high physiological insulin levels (approaching ~ 100 
µU/ml) are necessary to stimulate the equally sodium dependent transporters of creatine 
(CreaT) and carnitine (OCTN2) and hence to alter their retention and muscle 
concentration (Green 1996a; Green 1996b; Steenge 1998; Steenge 2000; Stephens 
2007b). However, Greenwood et al. (2003) suggested that creatine retention can be 
increased even with relatively small amounts (18 g) of simultaneous carbohydrate 
ingestion. We could demonstrate that meal-timing alone can beneficially influence 
muscle carnosine loading. In figure 3, average meal-induced insulin plasma peaks are 
shown, but individual peaks vary between 53 and 102 µU/ml. Clausen et al. (2003) 
showed that Na+/K+ pumps in skeletal muscle are stimulated by insulin over a range of 
concentrations down to low physiological levels. Therefore, it is possible that meal-
induced elevations in serum insulin are capable of triggering the sodium-dependent 
transporter TauT. In our study, a meal-induced effect could only be confirmed in soleus 
muscle. Considering the fact that this is a more insulin-sensitive muscle (James 1985), it is 
not unlikely that the soleus responds better on insulin induced BA uptake. In addition 
Lavoie et al. (1996) demonstrated that insulin-induced translocation of Na+/K+ ATPase 
subunits to the plasma membrane, one of the two possibilities to increase Na+/K+ ATPase 
activity, is restricted to oxidative fiber-type skeletal muscles which are predominantly 
present in soleus. However, caution remains warranted as other postprandial changes 
than an increase in serum insulin might be at play.  In addition, one could argue that the 
the difference in dietary beta-alanine intake (PBA: 213 mg/day vs PBA+meal: 250 mg/day) 
is responsible for the difference in soleus carnosine loading (PBA: 41% and PBA+meal: 
64%). However, dietary habits do not seem to influence muscle carnosine, as our lab 
(Baguet et al., unpublished results) could recently demonstrate that switching from an 
omnivorous diet to a vegetarian diet for 6 months does not after baseline muscle 
carnosine concentration.  
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Slow release versus pure beta-alanine supplementation.  
To our knowledge, this is the first study that directly compares the loading efficiency of a 
similar dose of PBA and SRBA in a chronic supplementation study. It was initially 
hypothesized that SRBA would be more efficient than PBA because of a better BA 
retention (resp. 98.9% and 96.3%) upon acute ingestion (Decombaz 2012). We now know 
that whole BA retention is not a good indicator of muscle carnosine loading efficiency. In 
the current study, we could show that there was no significant difference between long-
term supplementation of SRBA (SRBA+meal) compared to PBA (PBA+meal) (figure 4B). If 
we believe that the percentage of the AUC of plasma BA, that occurs during 
hyperinsulinemia, is of importance for enhancing BA uptake in skeletal muscle, we may 
expect that ‘SRBA+meal’ is more responsive than ‘PBA’, but less than ‘PBA+meal’. This 
expected order is observed in the soleus, but not in the gastrocnemius. Possibly, this is 
merely an epiphenomenon and also other aspects of the kinetics, such as the peak 
plasma BA concentration and the total AUC for BA may play a role in the effectiveness of 
BA on muscle carnosine loading.  
Conclusion 
In this article we show that despite only a small portion of chronically ingested BA is 
incorporated into muscle carnosine, there is equally only a very small portion lost through 
urinary excretion. We therefore hypothesize that the majority of ingested BA is 
metabolized. Secondly, we show that BA supplementation is more effective when co-
ingested with a meal, suggesting that insulin could play a role in muscle carnosine loading. 
Finally, we conclude that SRBA is equally effective as PBA in muscle carnosine loading. 
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ABSTRACT  
Introduction. Chronic beta-alanine (BA) supplementation is an increasingly popular 
nutritional strategy, because it can elevate muscle carnosine content and thereby 
enhance high-intensity exercise performance. The current study investigates 1) whether 
sex and body mass are determinants of BA induced muscle carnosine loading, and 2) the 
optimal maintenance dose for ensuring constantly elevated muscle carnosine stores.  
Methods. During the loading phase, 34 participants (men and women) were 
supplemented with 3.2g (4x800 mg) BA/day for 46 days (slightly different loading 
strategies were applied concerning the effect of meal-timing and supplementation form 
(Stegen et al. 2013)). Thereafter, 19 participants (men and women) continued taking free-
powder BA for 6 more weeks (maintenance phase). The participants were matched and 
re-divided into three groups respectively receiving 0.4g BA/day, 0.8g BA/day and 1.2g 
BA/day. Muscle carnosine content was measured in m. soleus and m. gastrocnemius 
using 1H-MRS. 
Results. Body mass and sex had only minimal effect on the absolute increase in muscle 
carnosine. Given the lower baseline values of women, the relative increase for women 
was higher, indicating that women require less BA for the same relative increase. In 
addition, a significant negative correlation was observed between body mass and the 
relative increase in muscle carnosine (r=-0.45, p=0.007). A maintenance dose of ~1.2 g 
BA/day, was most effective to keep muscle carnosine content elevated at post-
supplementation level. 
Conclusion. Sex and body mass do not markedly affect the absolute increase during 
muscle carnosine loading, although they are determinants for the relative increase. 
Additionally, we established for the first time an effective maintenance dose of ~1.2g 
BA/day to keep muscle carnosine content elevated at 30-50% above baseline for a 
prolonged period. 
Keywords: nutritional supplements, histidine-containing dipeptides, buffering capacity, 
exercise performance, carnosine, beta-alanine  
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INTRODUCTION  
Beta-alanine is an increasingly popular nutritional supplement. It is the rate-limiting 
precursor for carnosine synthesis, a cytoplasmic dipeptide (β-alanyl-L-histidine) in human 
skeletal muscle (Harris 2006). Increasing muscle carnosine is associated with performance 
enhancement in high-intensity exercise (Derave 2007; Hill 2007a; Baguet 2010; del Favero 
2012). The ergogenic mechanism of carnosine presumably relates to its characteristics as 
a calcium sensitizer (Dutka 2012; Everaert 2012) and proton buffer (Parkhouse 1985; 
Baguet 2011). However, various other research fields have investigated this molecule for 
other biological qualities such as scavenger of reactive oxygen species, reactive nitrogen 
species and deleterious aldehydes (malondialdehyde, methylglyoxal, hydroxynonenal, …), 
chelator of zinc and copper ions, and antiglycating and anticross-linking activities (Aldini 
2005; Boldyrev 2012; Boldyrev 2013). These properties suggest a therapeutic potential of 
muscle carnosine loading in clinical populations, a research topic beginning to emerge 
(del Favero 2012; Gualano 2012; Sale 2013). 
An efficient regimen to augment human muscle carnosine content was initially 
established by Harris and colleagues (Harris 2006). The latter and subsequent studies 
have shown that chronic oral supplementation of 1.6 to 6.4g/day of beta-alanine will 
generally lead to increases in muscle carnosine content of ~15-85% in 4 to 12 weeks (Hill 
2007b; Baguet 2009; del Favero 2012; Stellingwerff 2012). Even though we may not yet 
have attained the true maximal or optimal loading protocol, supplementation strategies 
aiming for moderately elevated muscle carnosine levels are frequently used in sports and 
have proven ergogenic effects (Derave 2007; Hill 2007b; Baguet 2010). In contrast, not a 
single study has so far established a suitable maintenance dose. This gap hampers long-
term studies on effects of more chronically elevated carnosine levels, which is more 
relevant in clinical situations and aging. The current study focuses on establishing a 
suitable maintenance dose, although for a specific loading protocol (46 d of 
supplementation with 3.2 g/d of beta-alanine). 
It is known that upon discontinuation, muscle carnosine levels will gradually return to 
baseline (pre-supplementation) levels in 6-20 weeks (Baguet 2009; Stellingwerff 2012). A 
first attempt to establish such maintenance dose for beta-alanine supplementation was 
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published by Stellingwerff et al. (2012). They demonstrated that after an initial increase 
achieved by a 4 week loading protocol of 3.2g BA/day, a further ~30% increase in muscle 
carnosine occurred after 4 weeks of taking 1.6g beta-alanine/day. We can conclude that 
the optimal dose for maintaining elevated muscle carnosine stores must be found 
between 0 and 1.6g BA/day. Therefore, we will investigate 3 intermediate doses: 
0.4g/day, 0.8g/day and 1.2g/day. 
Little is known about the influence of gender, body mass and fat-free mass (FFM) on 
muscle carnosine loading via BA supplementation in the current literature. Previously 
published reports on the effects of beta-alanine supplementation on human muscle 
carnosine content included exclusively male participants (Harris 2006; Derave 2007; Hill 
2007b; Baguet 2009; Baguet 2010; Stellingwerff 2012; del Favero 2012). Only one study 
(del Favero 2012) included both elderly men and women, but they didn’t diversify 
between sexes. Some studies have reported positive effects of beta-alanine 
supplementation on exercise performance in women (Stout 2007; Stout 2008), yet 
without measurement of muscle carnosine content. In addition, it has been shown that 
carnosine metabolism becomes gender-specific in humans upon sexual maturation 
(Everaert 2010; Baguet 2012), with muscle carnosine content being lower and serum 
carnosinase activity being higher in adult women versus men. Several reasons for this 
sexual dimorphism have been postulated, such as muscle fiber type distribution or diet, 
but animal experiments have shown that testosterone is certainly involved (Penafiel 2004; 
Everaert 2013). Up until now, it was not clear whether the factors inducing differences in 
baseline muscle carnosine content would also result in differences in carnosine loading 
between men and women. Therefore, we now aim to establish whether women respond 
equally well, better or worse to BA supplementation.  
Since women are in general lighter and have less FFM, we could assume a larger muscle 
carnosine loading because they receive a higher dose per kilogram body mass or FFM. In 
comparison with other nutritional supplements having ergogenic effects during high 
intensity exercise, the recommended dosing protocol is either a fixed amount irrespective 
of body mass (creatine (Harris 1992; Hultman 1996)) or body mass corrected (sodium 
bicarbonate and sodium citrate (Van Montfoort 2004)). However, it remains to be 
established whether BA should be dosed in relation to body mass.  
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In summary, this study was designed in order to define the optimal maintenance dose for 
ensuring constantly elevated muscle carnosine stores of 30-50% above baseline, secondly 
to clarify whether sex and body mass are influencing factors during muscle carnosine 
loading and finally to provide an explanatory model of loading, maintenance and washout 
of elevated muscle carnosine stores.  
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METHODOLOGY 
Participants 
Thirty-four participants (men and women) volunteered to participate in this study. All 
participants were healthy, non-vegetarian and physically active, but not involved in 
regular training. The study (loading and maintenance phase) was approved by the local 
ethical committee (Ghent University Hospital, Ghent, Belgium), all participants gave their 
written informed consent to take part in the study and were aware that they were free to 
withdraw from the experiment at any point.  
Study design 
During the loading phase, 34 participants (16 men: age: 19.4 ± 1.1 yr, body mass: 73.9 ± 
8.2 and 18 women: age: 19.3 ± 0.9, body mass: 60.2 ± 6.0) were supplemented with 3.2 g 
(4x800 mg) of beta-alanine per day for 6 weeks (46 days). These data were collected from 
a previous study with another research question (Stegen 2013), where all participants 
were randomized into three gender- and body mass-balanced groups (group 1 received 
free-powder beta-alanine between the meals, group 2 received free-powder beta-alanine 
in between the meals and group 3 received slow-release beta-alanine). Although the 
three groups were slightly different loaded, it allowed us to use this dataset to study the 
effect of body mass (BW) , fat-free mass (FFM) and gender on muscle carnosine loading, 
since participants with different body mass and gender were equally dispersed among the 
three groups (group 1: BW: 55-84kg, FFM: 43-72kg; group 2: BW: 54-85kg, FFM: 45-81 
and group 3: BW: 49-88, FFM: 37-61). Group 1 and 2 received CarnoSynTM powder in 
capsules and group 3 CarnoSynTM slow-release (SR) tablets, both delivered by Natural 
Alternatives International (NAI) and analysed using documented HFL screening method by 
HFL sport science. Muscle carnosine content was measured before and after the loading 
phase. Therefore, the percentage of ingested beta-alanine accumulated in skeletal 
muscles could be calculated (vide infra). Anthropometrical variables (length, body mass, 
fat-free mass) and dietary beta-alanine ingestion were also assessed at the start of the 
supplementation period. 
During the maintenance phase, 19 participants volunteered to continue taking free-
powder beta-alanine for 6 weeks in order to determine a maintenance dose. The 
PART II : Study 2 
 
88 
participants (12 men: age: 19.8 ± 1.1 yr, body mass: 74.5 ± 8.1 kg and 7 women: age: 19.7 
± 1.0, body mass: 60.1 ± 4.3 kg) were re-divided into three groups respectively receiving 
0.4g /day, 0.8g /day and 1.2g /day of free-powder BA (CarnoSynTM powder, respectively 1, 
2 or 3 capsules dispersed among the day (before the meal)). Following loading, and 
because of the high drop-out, the participants were re-stratified for 1) loading history 
(carnosine content post-loading, absolute and relative increase in muscle carnosine 
during the loading phase), 2) body mass and 3) gender in order to obtain three new and 
matched groups for the maintenance phase. Muscle carnosine was measured again on 
the end of the 6-week maintenance dose. 
Determination of muscle carnosine content 
Carnosine content of all the participants was measured by proton magnetic resonance 
spectroscopy (1H-MRS) in soleus and gastrocnemius medialis muscles, as described by 
Baguet et al. (2010). When both muscles respond similarly, the average of the two 
muscles is taken and referred to as ‘muscle carnosine’. Otherwise, the soleus or the 
gastrocnemius muscle is mentioned separately. The participants were lying in supine 
position on their back and the lower leg was fixed in a holder with the angle of the ankle 
at 20° plantar flexion. All the MRS measurements were performed on a 3-T whole body 
MRI scanner (Siemens Trio, Erlangen) equipped with a spherical knee-coil. Single voxel 
point-resolved spectroscopy (PRESS) sequence with the following parameters was used; 
repetition time (TR) of 2.000 ms, echo time (TE) of 30 ms, number of excitations is 128, 
1.024 data points, spectral bandwidth of 1.200 Hz, and a total acquisition time of 4.24 
min. The average voxel size for the soleus and gastrocnemius muscle was respectively 40 
mm x 10 mm x 28 mm and 40 mm x 11 mm x 30 mm. The line width of the water signal 
for the soleus and gastrocnemius muscle was on average respectively 24.6 Hz and 27.6 Hz, 
following shimming procedures. The absolute carnosine content (in millimolar; mM) was 
calculated as described before by Baguet et al. (2010) and they reported a relatively low 
coefficient of variation of 9.8% in soleus and 14.2% in gastrocnemius (Baguet 2009).  
  
LOADING PHASE AND MAINTENANCE DOSE 
 
89 
Daily dietary BA intake and % BA accumulated in skeletal muscles 
An estimation of the daily dietary beta-alanine ingestion was achieved by a 2- week 
record of their meat and fish consumption, as described by Baguet et al. (2009). During 
the loading phase the percentage of the total ingested amount of beta-alanine (147 g) 
that is accumulated into the skeletal muscles is estimated for every subject separately by 
assuming that 46% of body mass is muscle mass for 19-years-old men and 33% for 19-
years-old women (Janssen 2000) and by taking into account their personal average 
increase in muscle carnosine. 
Anthropometry 
Height and body mass were determined using a digital balance scale and a stadiometer. 
Fat-free mass (FFM) was assessed by bio-impedance (Bodystat 1500 MDD; Bodystat Ltd., 
Douglas, Isle of Man, UK). For the latter, only a subgroup (n= 23; group 1: 2/3; group 2: 
4/4; group 3: 3/5; men/women) was measured because the equipment (Bodystat 
1500MDD) was not always available. Patients were in supine position for at least 5 min. 
Surface electrodes were attached to the right hand (red lead: behind the knuckle of the 
middle finger; black lead: on the wrist to the ulnar head) and foot (red lead: behind the 
second toe next to the big toe; black lead: on the ankle at the level of and between the 
medial and lateral malleoli). FFM was derived from the impedance and the deducted total 
body water. The intraclass correlation coefficient (ICC) for FFM-measurements with the 
Bodystat 1500 MDD, is 0.987 (Steiner 2002).  
Statistics 
All correlations were evaluated by Pearson correlations. An independent two-sample t-
test was used to study gender differences during loading. To examine whether our three 
maintenance dose groups evolved differently in time, we performed a repeated measures 
analysis of variance (general linear model) with ‘group’ (0.4g/day, 0.8g/day and 1.2g/day) 
as between-participants factor and ‘time’ (post-loading and post-maintenance) as a 
within-participants factor. In case of significant interaction and to determine whether a 
specific maintenance dose results in a decrease/increase compared to post-loading a 
paired sample t-test was performed for each group separately. All analyses were done 
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with SPSS statistical software (SPSS 20, Chicago, IL) and statistical significance was set at p 
< 0.05. 
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RESULTS  
Effects of sex , body mass and fat-free mass on the loading phase.  
The absolute increase in muscle carnosine, after taking 3.2g BA/day for 6 weeks, was 
approximately 1.5-2 mM and was equal irrespective of the muscle type and gender (figure 
1A). Logically, since we confirm that the soleus muscle has lower baseline values 
compared to the gastrocnemius (SOL: 3.47 ± 0.87mM , GAS: 4.51 ± 1.36mM, p<0.05), the 
relative increase in soleus is higher (SOL: + 53.4 ± 30.1%, GAS: + 41.8 ± 26.8%). Similarly, 
women have lower baseline carnosine values compared to men (women: 3.28 ± 0.58 mM , 
men: 4.79 ± 0.85 mM , p<0.05), therefore the relative increase in women is significantly 
higher in gastrocnemius compared to men (women: + 50.8 ± 30.7%, men: +31.6 ± 17.5 %) 
however, not for soleus (figure 1B). The percentage of the ingested beta-alanine that is 
accumulated in the skeletal muscles is higher in men (3.6 ± 1.1%) compared to women 
(1.9 ± 0.8%; p<0.001), however this is explained by the higher body mass and muscle 
mass in men compared to women (body mass: men: 73.9 ± 8.2kg; women: 60.2 ± 6.0kg, 
p<0.001; muscle mass: men: 34.0 ± 3.7 kg; women: 19.6 ± 2.0 kg, p<0.001). 
 
    
Figure 1: Loading phase: Comparison between sexes for absolute (1A) and relative (1B) increase in muscle carnosine 
after a supplementation period of 3.2 g BA/day during 46 days . Data are means ± SD. * significant for p < 0.05 (women 
vs men).  
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In order to assess the effects of body mass and fat-free mass (FFM) on muscle carnosine 
loading, correlations were made with the absolute and relative increase in muscle 
carnosine, separately for gender and muscle type (figure 2). Heavier men have a lower 
absolute increase in soleus carnosine compared to lighter men (r=-0.51, p=0.044, figure 
2A). Nevertheless, this finding could not be confirmed for women and gastrocnemius 
muscle (figure 2A and 2B). In addition, correlations between body mass and the absolute 
increase in muscle carnosine are not stronger when taking FFM into account. For the 
relative increase in muscle carnosine, a stronger relationship with body mass is present 
(r=-0.45, p=0.007 for muscles and sexes pooled), which remains predominantly present 
for men (SOL: r=-0.53, p=0.036; GAS: r=-0.47, p=0.065), and not for women (SOL: r=-0.10, 
p=0.699; GAS: r=-0.44, p=0.069) (figures 2C and 2D). 
   
 
Figure 2: Loading phase: Correlation between body mass and the absolute (2A: soleus, 2B: gastrocnemius) and relative 
(2C: soleus and 2D: gastrocnemius) increase in muscle carnosine for a supplementation protocol of 3.2g BA/day for 46 
days. White and black circles represent respectively women and men. Dashed and solid lines represent significant 
correlations for respectively men only and the entire group. Correlations are significant when p<0.05. 
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Finally, baseline carnosine content did not influence the absolute increase in muscle 
carnosine (men: r=-0.23, p=0.222; women: r=-0.28, p=0.264). As a consequence, men and 
women with higher baseline values have a lower relative increase compared to those 
with lower baseline values (men: r=-0.74, p=0.001; women: r=-0.56, p=0.015).  
Maintenance dose  
No significant differences were present between groups prior to the start of the 
maintenance phase concerning subject characteristics and loading history of muscle 
carnosine (table 1). The group that took 1.2g BA/day remained at the post-loaded level, 
while the other two groups (0.4g BA/day and 0.8g BA/day) showed a decrease relative to 
the initial increase in muscle carnosine with respectively -46% and -32% (figure 3). In 
addition, a strong linear relationship is present (r=0.71; p=0.001) between the 
maintenance dose, corrected for body mass (mg/kg BW per day), and the maintenance in 
muscle carnosine (with 100% indicating perfect maintenance and 0% indicating complete 
return to baseline). From this relationship, optimal maintenance dose is calculated at ~18 
mg/kg BW/day.  
 
Figure 3 : Maintenance phase: Five different maintenance doses on a time scale are shown: before loading (0%), after 6 
weeks loading with 3.2g BA/day (100%) and after 6 weeks receiving a maintenance dose: 1.2g/day (n=7), 0.8g/day (n=6), 
0.4g/day (n=6). The post-maintenance doses are relative to the initial increase during loading. Data of 0 and 1.6g/day 
are derived from Baguet et al. (Baguet 2009) and Stellingwerff et al. (Stellingwerff 2012) respectively. * p < 0.05 
different from post-loading. 
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 0.4 g/day 0.8 g/day 1.2 g/day 
Participants characteristics 
Participants (n, M/F) 7 (4/3) 6 (4/2) 6 (4/2) 
Age (yr) 19.6 (± 1.0) 20.3 (± 1.0) 19.3 (± 0.8) 
Body mass (kg) 67.0 (± 11.4) 68.7 (± 8.6) 72.3 (± 10.1) 
Dietary beta-alanine intake (mg/day) 267 (± 81) 318 (± 194) 243 (± 66) 
Loading history 
Muscle carnosine concentration                    
pre-loading (mM)                                           
SOL 
GAS 
3.63 (± 0.57) 
4.64 (± 1.28) 
3.73 (± 0.75) 
4.92 (± 1.64) 
3.79 (± 1.16) 
5.14 (± 1.35) 
Muscle carnosine concentration                     
post-loading (mM)                                         
SOL 
GAS 
5.31 (± 0.68) a 
6.72 (± 1.69) a 
5.14 (± 1.01) a 
6.43 (± 1.18) a 
5.78 (± 1.14) a 
6.66 (± 0.81) a 
Absolute increase in muscle carnosine           
during loading (mM)                                     
SOL 
GAS 
1.68 (± 0.79) 
2.07 (± 0.92) 
1.41 (± 0.58) 
1.52 (± 0.95) 
1.99 (± 0.55) 
1.52 (± 0.59) 
Post-maintenance carnosine concentration 
Muscle carnosine concentration                   
post-maintenance (mM)                               
SOL 
GAS 
4.50 (± 0.68) a, b 
6.00 (± 1.38) a, b 
4.71 (± 1.27) a, b* 
6.19 (± 1.48) a 
5.71 (± 0.69) a 
6.83 (± 0.71) a 
 
Table 1: Maintenance phase: subject characteristics, muscle carnosine loading history and post-maintenance carnosine 
concentration for the three groups (0.4g BA/day, 0.8g BA/day and 1.2g BA/day as maintenance dose). SOL and GAS are 
respectively soleus and gastrocnemius.  a p<0.05 vs preloading, b p< 0.05 vs postloading, b* p<0.1 vs postloading. Data 
are means ± SD. 
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DISCUSSION 
The current study further examined possible determinants of beta-alanine induced 
muscle carnosine loading and newly established an efficient maintenance dose, following 
a 46-day supplementation protocol of 3.2g beta-alanine per day.  
This study shows that sex and body mass have only minimal effect on the absolute 
increase during muscle carnosine loading. It has already been shown that soleus and 
gastrocnemius muscle respond equally well to beta-alanine supplementation in men, 
irrespective the higher absolute carnosine baseline value of the gastrocnemius. This study 
confirms similar absolute increases of carnosine in the gastrocnemius and soleus muscles 
in females, suggesting that there are no muscle type or sex differences in the response to 
beta-alanine supplementation. However, it remains a subject of debate whether the 
higher relative increases in women (figure 1B) or lighter people (figures 2C and 2D) are 
relevant from a practical point of view. It has already been reported that there is a 
correlation between the relative change in carnosine and performance enhancement (Hill 
2007b; del Favero 2012). In addition, Baguet et al. (2010) (data from our own lab), 
published the correlation between the absolute increase in muscle carnosine and the 
absolute improvement on a 2000m rowing test in highly trained rowers. The manuscript 
only reported the absolute values, but the correlation remained present when values 
were expressed relatively (data not published: p=0.024, r=-0.543). Nevertheless, it 
remains questionable whether this is an argument for establishing a model where gain in 
performance is primarily related to the relative change in carnosine. In figure 4, we have 
graphically demonstrated the relevance of body mass and sex for increasing muscle 
carnosine content with 50%. Although this increase in muscle carnosine is probably not 
the most optimal increase for the most optimal improvement in performance, it is 
considered effective for ergogenic and function-enhancing purposes. 
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Figure 4: Loading phase: The relationship between the daily BA dose (3.2g/day for the entire group) and the relative 
increase in muscle carnosine for lighter (< 60 kg) and heavier (> 60 kg) women (diamonds), and for lighter (< 75 kg) and 
heavier (> 75 kg) men (circles). Dashed lines are the extrapolations to reach a 50% increase in muscle carnosine. 
 
A nicely performed meta-analysis (Hobson 2012), covering 18 studies, about the effect of 
beta-alanine supplementation on exercise performance clearly demonstrated an 
ergogenic effect in exercise lasting 60-240s. However, there are only 4 studies that 
measured muscle carnosine as well. These studies reported increases in muscle carnosine 
with +37% (Baguet 2010), +42% (Derave 2007), +59% (Hill 2007b), +85% (del Favero 2012), 
averaging ~50%. So, in figure 4, we have extrapolated (or intrapolated) the daily dose that 
would be required to achieve a 50% increase over a 6 week loading phase in the men and 
women, each divided in a lighter and heavier half, with a cut-off value of 60 kg for the 
women and 75 kg for the men. This post-hoc calculation indicates that the female 
participants weighing less than 60 kg, with an average of 56 kg, should ingest 2.5 g/day, 
whereas heavier women (~ 64 kg) and lighter men (~ 69 kg) should ingest respectively 3.4 
g/day and 3.6 g/day and heavier men (~ 84 kg) 5.5 g/day (figure 4). If faster loading is 
aimed, BA dose can be increased up to 6.4 g per day with serving doses of 800mg per 
intake (or 1600 mg in case of slow-release beta-alanine). Higher doses may not be advised 
at present because the effectiveness or side-effects have not been studied beyond this 
dose.  
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The present study aimed at determining effective maintenance dose. Previous studies 
(Baguet 2009; Stellingwerff 2012) have shown that following muscle carnosine loading, a 
slow wash-out takes place ultimately leading to return to baseline values. This indicates 
there is some kind of elimination process. However, the nature of the elimination process 
is still unclear at the moment: it could be either 1) an active release through outward-
directed transarcolemmal transporters (e.g. through PHT1 or PHT2 (Everaert 2013a)), 2) a 
passive loss of carnosine through sarcolemmal disrupture (Dunnett 2002), 3) an 
enzymatic degradation (hydrolysis into beta-alanine and L-histidine) through carnosinase 
(CN2, (Everaert 2013)), 4) a combination of these. The carnosine elimination rate is most 
likely positively related to the muscle carnosine content itself, namely the more you have, 
the more you can lose or degrade. Net muscle carnosine turnover is a balance between 
the carnosine synthesis and elimination rate and an effective maintenance dose would be 
one where the synthesis equals the elimination. The carnosine synthesis rate in muscle is 
mainly determined by the sarcoplasmic beta-alanine availability, as beta-alanine is the 
rate-limiting precursor. Sarcoplasmic beta-alanine availability is largely determined by 
dietary beta-alanine intake (Harris 2006) and the enzymatic synthesis and degradation 
pathways of beta-alanine.  
In figure 5, we have graphically displayed a hypothesis for the alterations in net carnosine 
turnover rate in different situations (baseline, loading, washout and maintenance) as a 
result of changes in carnosine synthesis and/or elimination rate. At baseline, there is no 
net change in muscle carnosine as synthesis and elimination are in equilibrium and both 
at a low level. During beta-alanine supplementation (loading), carnosine synthesis will 
markedly increase because of increased precursor availability and net turnover will be 
strongly positive. As supplementation continues, with long duration and high doses, the 
elimination rate will gradually increase as muscle carnosine content and thus elimination 
becomes higher. As a result, the net positive turnover rate will become smaller, as has 
been demonstrated by Hill et al. (2007b), where carnosine loading efficiency was much 
smaller in the second half (+20%) compared to the first half (+60%) of supplementation. 
Upon discontinuation of supplementation, elimination rate is still elevated, whereas 
synthesis rate falls back to baseline values, resulting in a net negative balance, causing 
wash-out (Baguet 2009; Stellingwerff 2012). Finally, keeping muscle carnosine at a 
PART II : Study 2 
 
98 
constant elevated level (maintenance) requires that carnosine synthesis rate is increased 
by a low dose of beta-alanine supplementation, in order to compensate for the increased 
carnosine degradation rate in carnosine-loaded muscles. 
 
Figure 5: Graphical representation of a hypothesis on muscle carnosine turnover, which could explain the currently 
observed effects of the different phases of beta-alanine supplementation on muscle carnosine content. 
We now determined that an average dose of 1.2 g/day is considered optimal to keep 
muscle carnosine content elevated at 30-50% above baseline. Similar with the loading 
phase, it seems that heavier participants need a higher maintenance dose to keep muscle 
carnosine levels at 100% loaded, compared to more lighter participants, since there is a 
strong relationship between maintenance dose, corrected for body mass, and 
maintenance in muscle carnosine. Therefore, we suggest taking ~18 mg/kg BW/day to 
keep up elevated muscle carnosine levels. However, as the carnosine degradation rate is 
positively related to the muscle carnosine content, it can be hypothesized that the 
required maintenance dose may be higher to keep muscle carnosine elevated at supra-
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maximal levels (>100% or even higher above baseline). Future studies will have to 
investigate this issue. 
In conclusion, sex and body mass are not major determinants for the absolute increase in 
muscle carnosine during loading, although they can partly explain the variability in the 
individual response in muscle carnosine loading when expressed as percentual increase 
versus baseline. Furthermore, the establishment of a suitable maintenance dose (~1.2g 
BA/day), following a supplementation period of 3.2g BA/day, will now allow for studying 
the effects of chronically elevated muscle carnosine stores in situations where this is 
required, such as prolonged sports competition period or sustained improvement of 
muscle functionality at old age (del Favero 2012). 
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ABSTRACT  
Introduction. There is growing in vivo evidence that the dipeptide carnosine has 
protective effects in diabetes and diabetes-related diseases. A critical unanswered 
question is its site of action, being either carnosine levels in tissues or plasma. This will be 
investigated using oral carnosine versus beta-alanine supplementation in a very mild 
high-fat diet rat model.  
Methods. Thirty-six male Sprague-Dawley rats received either a control diet (CON), a 60% 
high-fat diet (HF), a HF-diet with 1.8 % carnosine (HFcar), or a HF-diet with 1% beta-
alanine (HFba), as beta-alanine can increase muscle carnosine without an increase in 
plasma carnosine. Insulin sensitivity, inflammatory-signaling and lipidoxidative stress was 
determined in skeletal muscles and blood. In a pilot study, urine was collected.  
Results. The three HF-groups were significantly heavier compared to CON. HFcar and 
HFba equally increased muscle carnosine concentrations and only HFcar reported 
elevated plasma carnosine levels and carnosine-HNE adducts. Elevated plasma and urine 
CML in HF was reduced by ~50% in HFcar, but not in HFba. Likewise, muscle iNOS mRNA is 
decreased by 47% (p<0.05) in HFcar, but not in HFba.  
Conclusions. We can conclude that plasma carnosine, and not muscle carnosine, is 
involved in preventing early-stage lipidoxidation in circulation and muscle inflammatory 
signaling. 
 
 
 
 
 
Keywords: Quenching ability carnosine, advanced lipidoxidation end-products, advanced 
glycation end-products, inflammatory signaling. 
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INTRODUCTION 
All forms of diabetes are characterized by chronic hyperglycemia and are associated with 
(glyc)oxidative and low-grade inflammatory stress (Brownlee 2001; Stehouwer 2002; 
Mangge 2004; Brownlee 2005; Wellen 2005). The molecule carnosine, an endogenous 
histidine-containing dipeptide (β-alanine-L-histidine), is a potential candidate to 
counteract the development of diabetes and diabetes-related diseases. Beneficial effects 
of carnosine administration have been shown in both type 1 and type 2 diabetic rodent 
models (Lee 2005; Soliman 2007; Sauerhofer 2007). Additionally, carnosine was also 
found to be effective in reducing diabetes-related diseases, such as nephropathy and 
retinopathy in diabetic animal models (Pfister 2011; Riedl 2011; Aldini 2011). Current 
evidence in humans is still very scarce, but genetic studies in type-II diabetics suggest that 
polymorphisms leading to high carnosinase (CN1) expression, which impedes high 
circulating carnosine levels (Everaert 2012), are associated with increased risk of diabetic 
nephropathy (Janssen 2005; Mooyaart 2010). 
The protective effect of carnosine could be related to a broad range of (bio)chemical 
properties, which is recently reviewed by Boldyrev et al. (2013). First, it may be related to 
a hypoglycemic effect (Yamano 2001; Nagai 2003; Lee 2005; Sauerhofer 2007; Soliman 
2007), possibly by increasing plasma insulin, which in turn is evoked by the ability of 
carnosine to regulate the autonomic nervous system via the histamine H3 receptor 
(Yamano 2001; Nagai 2003), as well as to preserve or increase β-cells mass of the 
pancreas (Sauerhofer 2007). Second, carnosine has antioxidant activity in physiological 
conditions and induces sparing of (non)-enzymatic antioxidants (Lee 2005; Aydin 2010; 
Kim 2011). This is demonstrated by Lee et al. (2005), who found that decreased levels of 
catalase and glutathione peroxidase in liver and kidney of STZ-induced diabetic Balb/cA 
mice are increased by carnosine administration. Third, carnosine can scavenge reactive 
carbonyl species and reduce formation of advanced lipoxidation end-products (ALEs) and 
advanced glycoxidation end-products (AGEs). A study of Aldini et al. (2011) with Zucker 
obese rats demonstrated a protective/suppressive effect of carnosine on elevated protein 
carbonyls in kidney and elevated total AGEs and 4-hydroxy-2-nonenal-carnosine Michael 
adducts (CAR-HNE) in urine of the rats, which confirms the quenching ability of carnosine 
in vivo. Finally, carnosine appears to have anti-inflammatory characteristics, 
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demonstrated by its ability to decrease the expression of tumor necrosis factor alpha 
(TNFα) and inducible nitric oxide synthase (iNOS) in striatum (Tsai 2010) and plasma (Lee 
2005; Liu 2008) in mice.  
A critical unanswered question regarding the potential therapeutic benefit of carnosine in 
metabolic disorders, is its site of action, being either the tissues or the plasma. The first 
possibility suggests that carnosine supplementation may be effective in correcting 
decreased levels of endogenous tissue carnosine, which have been demonstrated in 
diabetic kidney (Riedl 2011), retina (Pfister 2011) and skeletal muscle (Gualano 2012). 
Over 99% of total body carnosine is located in skeletal muscle (Boldyrev 2006; Derave 
2007) and skeletal muscle is particularly important in the development of the insulin-
resistant state (DeFronzo 2009; Abdul-Ghani 2010). If carnosine would perform its 
beneficial function in skeletal muscle, restoring or boosting endogenous muscle carnosine 
levels via carnosine administration could antagonize oxidation- and glycation-induced 
carbonylation and low-grade inflammation, which are characteristic of the insulin-
resistant skeletal muscle (Oh-Ishi 2003; Bonnard 2008; Kewalramani 2010).The second 
possibility is that the reported positive effects of carnosine administration result from its 
action in the plasma (Aldini 2011) where it can scavenge cytotoxic compounds, such as 
reactive carbonyl species, and hence indirectly protect tissues. In order to distinguish 
between both possible mechanisms, beta-alanine, the rate-limiting precursor for 
carnosine synthesis (Bakardjiev 1994; Harris 2006), can be supplemented. It has been 
shown that beta-alanine supplementation increases muscle carnosine, with no 
concomitant increase in plasma carnosine (Harris 2006). Therefore, if the beneficial 
effects of carnosine administration can be replicated by beta-alanine administration, it 
means that the protective mechanism mainly related to restoring/elevating tissue 
carnosine levels. In vitro experiments have demonstrated that the biochemical properties 
of carnosine are predominantly related to the amino acid L-histidine (Kohen 1988; Egorov 
1997; Decker 2000) or the imidazole moiety of L-histidine (Fontana 2002), or by the 
combination of the amino group of beta-alanine and the imidazolic ring of L-histidine 
(Aldini 2002; Liu 2003), but not by the amino-acid beta-alanine alone. 
Clarifying the site of action of carnosine is particularly important for the translation of 
animal findings to patients. Raising tissue (muscle) carnosine concentrations in humans 
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has been found to be relatively easy by means of chronic oral beta-alanine administration 
(Harris 2006), whereas raising plasma carnosine levels seems very difficult in humans due 
to the high and human-specific serum carnosinase activity (Everaert 2012). 
In the current study, we will investigate whether carnosine and/or beta-alanine 
supplementation can prevent high-fat diet-induced inflammatory signaling in skeletal 
muscle (local effect) and markers of (glyc)oxidation in plasma (systemic effect), and 
whether this prevents disturbed glucose transport in skeletal muscle and whole body 
glucose tolerance. In order to capture the early signs of possible protective effects of 
carnosine, our hypothesis will be tested in a very mild and initial stage of the metabolic 
disease development (high-fat diet induced rat model), in contrast to previous studies on 
severe diabetic models (Lee 2005; Sauerhofer 2007; Soliman 2007; Aldini 2011). 
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MATERIALS AND METHODS 
Animals and diet 
45% fat study: Three-week-old male Wistar rats (n= 24) were obtained from KU Leuven 
animal breeding center. Rats were housed per two in cages at 22°C in a 12 h light/dark 
cycle and were given ad libitum access to standard chow and water. After 1 week of 
acclimation, the rats were randomly assigned to three experimental groups receiving a 
specific diet for 14 weeks. Group 1 (CON) served as a control group and received a normal 
diet (Harlan Tecklad diet; 06416; 10% kJ fat, 20% kJ protein, 70% kJ carbohydrates), while 
the other two groups received a high-fat (HF) diet (Harlan Tecklad diet; 06415; 45% kJ fat, 
19% kJ protein, 36% kJ carbohydrates). The second group (HF) had access to the high-fat 
diet and tap water and the third group (HFcar) additionally received 1.8% carnosine 
(Flamma) in their drinking water (80 mM). This concentration (1.8%) was chosen, as 
Everaert et al. (2013) has shown that this concentration results in a significant increase in 
carnosine (+ 57%) and anserine (+30%) in m. extensor digitorum longus in mice. 
60% fat study: Three-week-old male Sprague-Dawley rats (n=36) were housed as 
described above. The rats were randomly assigned to four experimental groups receiving 
a specific diet for 8 successive weeks. Group 1 (CON) served as a control group and 
received a normal diet (Charles River: D01060501: 10% kJ fat), while the other three 
groups received a high-fat (HF) diet with 60% of energy in the form of fat (Charles River: 
D12492). Group 2 (HF) had access to pure water, group 3 (HFcar) additionally received 1.8% 
carnosine in their drinking water (Flamma, 80 mM) and the last group (HFba) 1% beta-
alanine in their drinking water (Sigma, 112mM). A dose of 1% beta-alanine was chosen as 
Everaert et al. (2013) has shown that 1.2% beta-alanine results in a sign increase in 
carnosine (+156%) and anserine (+46%) in m. extensor digitorum longus in mice. Both 
diets (CON and HF diet) were similar concerning the protein (20% kJ, lactic casein), 
vitamin and mineral content, but differed for carbohydrates (CON: 70% kJ carbohydrates: 
55gr corn starch and 12gr maltodextrin/100gr diet; HF: 20% kJ carbohydrates: 16gr 
maltodextrin and 9gr sucrose/100gr diet) and fats (CON: 1,9 gr lard and 2,4 gr soybean oil; 
HF: 31.5 gr lard and 3.2 gr soybean oil/100gr diet). Up to now, no data exist about a 
possible effect of carbohydrates on muscle carnosine baseline concentration.  
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This study (45% and 60% fat study) was approved by the animal Ethics Committee of KU 
Leuven and the housing conditions were as specified by the Belgian Law of November 14, 
1993 on the protection of laboratory animals (agreement no. LA 1220548). 
Experimental design 
The aim of the initial 45% fat study was to 1) examine whether muscle carnosine 
increases after carnosine supplementation (80 mM of the drinking water) and 2) induce 
overweighed rats with concomitantly metabolic problems. We found only minimal effects 
on body weight with 45% HF feeding, therefore we did a follow-up study using a more 
dramatic high-fat diet (60% fat instead of 45% fat) and a fourth group (HFba) was added 
to test the role of plasma versus muscle carnosine as beta-alanine supplementation can 
increase muscle carnosine without an increase in plasma carnosine. In the 45% fat study, 
we collected 24h-urine in metabolic cages. However, since this negatively impacted the 
food intake and weight gain, we did not repeat the urine collection in the 60% study. 
45% fat study: During the 14-week dietary intervention body weight, food and water 
(with or without BA) intake were recorded. At the end of the intervention, rats were 
individually housed in metabolic cages with their specific diet for 24 hours in order to 
collect a 24h urine sample. Thereafter, rats were terminally anaesthetized by an overdose 
of pentobarbital sodium (Nembutal; Brussels; Belgium) through an intra-peritoneal 
injection and two muscle types (white gastrocnemius and soleus) were dissected.  
60% fat study: During the 8-week dietary intervention body weight, food and water (pure 
water, with BA or CAR) intake were recorded. At the end of the intervention, rats were 
surgically prepared for an intravenous glucose tolerance test (IVGTT) and blood was taken 
during the surgery. After an overnight fast, the IVGTT was performed. The rats were then 
allowed to recover from the IVGTT and received their specific experimental diet for 5 
more days. Following an overnight fast, hindlimb perfusions were performed to assess 
glucose transport and three muscle types (red gastrocnemius, white gastrocnemius and 
soleus) were dissected. 
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Intravenous glucose tolerance tests 
Rats were anaesthetized and surgically prepared for the IVGTT, as described by Vaisy et al. 
(2011).After an overnight fast (16-18 h) conscious rats were injected with 0.8 g 
glucose.kg-1 body weight using a 30%(w.v-1) glucose solution in (w.v-1) saline. Blood 
glucose and plasma insulin concentrations were measured at regular time points until 120 
min after glucose injection (according to Vaisy et al. (2011)). The homeostatic model 
assessment of insulin resistance (HOMA-IR) was calculated from the paired ratio between 
plasma glucose and plasma insulin (Aldini 2011). Total area under the curve (AUC) for 
glucose, insulin and HOMA-IR was calculated using the trapezoidal rule. 
Rat hindlimb perfusions and glucose transport 
Following an overnight fast, rats were anesthetized by an intraperitoneal injection of 
pentobarbital sodium (5 mg/100 g body wt). Hindlimb perfusion was performed as 
described by Wojtaszewski et al. (38) and slightly adjusted by Brandt et al. (2010), and 
was performed in three phases. Following surgical preparation, the hindlimbs were 
allowed to recover for 12 min (phase 1) with a cell-free perfusate recirculation at a flow of 
20 ml/min (medium A). During phase 2, the right hindlimb is tied off and muscles are 
dissected. The left hindlimb was allowed to recover for 10 min with a one-way flow of 
12,5ml/min with medium B, which was identical to medium A (basal glucose transport) or 
with 1000 µU/ml insulin (insulin stimulated glucose transport). Thereafter (phase 3), the 
glucose-free recovery perfusate was exchanged for medium C, an isotopic glucose-rich 
perfusate, for 12 min. At the end, the muscles of the left hindlimbs were dissected, frozen 
in liquid nitrogen and stored at -80°C. This sample was used for the determination of 
muscle glucose transport as previously described in detail (Wojtaszewski 1996). 
Radioactivity was measured in a liquid scintillation counter (1600 TR Liquid Scintillator 
Analyzer; Packard). 
Muscle sampling 
The muscle sampling included the white gastrocnemius (GW, a medial superficial part of 
the gastrocnemius consisiting mainly of fast-glycolytic fibers), the red gastrocnemius (GR, 
a deep proximal and medial portion of m. gastrocnemius, consisting mainly of fast-
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oxidative fibers) and the m. soleus (SOL, consisting mainly of slow-oxidative fibers) (Delp 
1996) from the right and left hindlimb.  
Analyses on muscle 
Quantification of histidine-containing dipeptides by means of HPLC (high-performance 
liquid chromatography). Skeletal muscles were freeze-dried (dw) and dissolved in 
phosphate buffer (1mg dw muscle/100µL PBS) for homogenization. Muscle homogenates 
were deproteinized using 35% sulfosalicylic acid (SSA) and centrifuged (5min, 14000g). 
100µL of deproteinized supernatant was dried under vacuum (40°C). Dried residues were 
resolved with 40µL of coupling reagent:  
Methanol/triethylamine/H2O/phenylisothiocyanate (PITC) (7/1/1/1) and allowed to react 
for 20 minutes at room temperature. The samples were dried again and resolved in 100µL 
of sodium acetate buffer (10mM, pH 6.4). The same method was applied to the combined 
standard solutions of carnosine (Flamma) and anserine (Sigma). The derivatized samples 
(20 μL) were chromatographed on a Waters HPLC system with a Spherisorb C18/ODS2 
column (4.6 x 150 mm, 5 µm), ODS2 guard column (80Å, 5 µm, 4.6 mm X 10 mm) and UV 
detector (wavelength: 210 nm). The columns were equilibrated with buffer A (10 mM 
sodium acetate adjusted to pH 6.4 with 6% acetic acid) and buffer B (60% acetonitrile-40% 
buffer A) at a flow rate of 0.8 ml/min at 25°C. The limit of quantification was 7 µM.  
RT-qPCR for quantification of TNFα and iNOS mRNA levels. Total RNA from rat soleus 
muscle was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA). Briefly, skeletal 
muscle tissue was homogenized in Trizol Reagent using a tissue homogenizer. Total RNA 
was isolated from these homogenates according to the manufacturer's instructions. 
Concentration and purity of RNA samples was determined using a ND-1000 
spectrophotometer (NanoDrop, Wilmington, USA). Reverse transcription was performed 
on 0.5 µg of total mRNA using the Takara Prime Script cDNA Synthesis kit (Takara Bio 
Europe, Saint-Germain-en-Laye, France) according to the manufacturer's instructions.  
For real time cDNA amplification we used SYBR Green Mastermix (Roche Applied Science, 
Penzberg, Germany) and the following primers: rat TNF-α: acaaggctgccccgactatgtgctc (fw), 
gatggcggagaggaggctgactttc (rev); rat iNOS: cccagagtctctagacctcaaca (fw), 
catggtgaacacgttcttgg (rev); rat HPRT: ctcatggactgattatggacaggac (fw), 
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gcaggtcagcaaagaacttatagcc (rev) ; rat RPL19: caatgccaactctcgtcaacag (fw), 
catccaggtcaccttctcgg (rev). 
 The samples were analyzed using the Light Cycler 480 (Roche Applied Science, Penzberg, 
Germany). To control the specificity of amplification, data melting curves were inspected. 
Normalization of gene expression values and selection of reference genes (GeNorm) was 
performed using the QbasePLUS software package (Biogazelle, Ghent, Belgium). 
According to GeNorm analysis, normalization to two reference genes (HPRT and RPL19) 
was optimal for our dataset.  
Blood and urine biochemistry 
Whole blood glucose and plasma insulin concentrations were determined using 
respectively a glucose analyzer (glucocard X-meter) and a sensitive rat insulin RIA kit 
(Linco Research). The enzymatic-colorimetric kits from Sentinel Diagnostic (Milan, Italy) 
were used for the analysis of total cholesterol (#17644) and albumin (#17600). 
Advanced oxidation protein products (AOPP) were quantified according to the method 
previously described by Witko-Sarsat et al. (1998). Briefly, plasma samples were diluted in 
PBS and 200 µl aliquots pipped into each well of a 96-well microtitre plate and acidified 
by adding 20 µl of acetic acid to each well. Standards were prepared by adding 10 µl of 
1.16 M potassium iodide (Sigma, Milan, Italy) to 200 µl of chloramine-T solution (0 to 100 
µmol/l) (Sigma, Milan, Italy) and then spiked with 20 µl of acetic acid. The absorbance of 
the reaction mixture was read after 2 minutes at 340 nm on a Wallac Victor 2 Wallac 1420 
workstation microplate reader. AOPP concentrations are expressed as µM of chloramine-
T equivalents. 
AGEs and ALEs analyses. The plasma and urine content of Nε-(carboxymethyl) lysine (CML) 
protein adduct was measured by the use of a commercially available ELISA kit (OxiSelect™ 
Nε-(carboxymethyl) lysine (CML)ELISA Kit, Cell Biolabs Inc). Plasma and urine were diluted 
and tested in duplicate. Measurement of 4-hydroxy-2-nonenal (HNE) protein adducts in 
plasma was performed using OxiSelect™ HNE Adduct ELISA Kit, (Cell Biolabs Inc. Valter 
Occhiena S.R.L., Torino, Italy). The ELISA assayes were performed according to the 
manufacturer's instructions and the absorbance read on a Wallac Victor 2 Wallac 1420 
workstation microplate reader. Plasma and urinary fulorescent AGEs were determined by 
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using a spectrofluorimeter (Perkin Elmer LS50B) setting the excitation wavelenth at 370 
nm and emission at 440 nm. AGE values were expressed as fluorescence units (FU)/ml for 
plasma samples and in 24 hour for urines. 
Carnosine and Carnosine HNE adduct (CAR-HNE) by HPLC-ESI-MS/MS analysis. Plasma and 
urinary content of carnosine and of the corresponding HNE-Michael adduct (CAR-HNE) 
was determined by LC-ESI-MS/MS in multiple reaction monitoring mode (MRM) mode as 
already reported (Orioli 2007). Briefly, to each sample, 10 µL of a H-Tyr-His-OH solution 
(500 µM solution in 1 mM PBS, pH 7.4) was added as an internal standard and the 
samples were then deproteinized by adding 110 µL of 700 mM perchloric acid solution. 
After 15 min at 4 °C, the samples were centrifuged (26 000g, 10 min), and the 
supernatants were diluted (1:1 v/v) with the mobile phase A 
(water:acetonitrile:heptafluorobutyric acid ; 90:10:0.1, v/v/v), filtered and analysed by LC-
MS/MS. LC-ESI-MS analyses were carried out by using a TSQ Quantum triple-quadrupole 
mass spectrometer (ThermoFinnigan Italia, Milan, Italy) with electrospray ionization (ESI) 
source connected to a HPLC ThermoFinnigan Surveyor LC system equipped with a 
quaternary pump, a Surveyor autosampler, a vacuum degasser. Mass spectrometric 
analyses were performed in positive ion mode. Chromatographic separations were done 
by reverse phase elution with a Phenomenex Sinergy polar-RP column (150 mm 9 2 mm 
i.d.; particle size 4 lm) (Chemtek Analytica, Anzola Emilia, Italy) protected by a polar-RP 
guard column (4 mm 9 2 mm i.d.; 4 lm) kept at 25° C. Separations were done by gradient 
elution from 100% phase A to 80% phase B (CH3CN) in 12 min at a flow rate of 0.2 ml min
-
1 (injection volume 10 µl); the composition of the eluent was then restored to 100% A 
within 1 min, and the system was re-equilibrated for 6 min. The samples rack was 
maintained at 4 °C. ESI interface parameters were set as follows: middle position; 
capillary temperature 270 °C; spray voltage 4.0 kV. Nitrogen was used as nebulizing gas at 
the following pressure: sheath gas 30 psi; auxiliary gas 5 a.u. Mass spectrometric analyses 
were performed in positive ion mode and in MRM mode using the following parent ion -> 
product ions transitions were used for quantitative analysis:  
carnosine: 227. 1 m/z -> 110.1 m/z + 156.6 m/z (collision energy, 38 eV); 
CAR-HNE: 383.1 m/z -> 110.1 m/z + 266.2 m/z (collision energy 40 eV); 
H-Tyr-His-OH : 319.2 m/z -> 156.6 m/z + 301.1 m/z (collision energy, 25 eV). 
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Statistics 
A general linear model repeated measures ANOVA was used to evaluate body weight 
over time. The effects of the different supplementation protocols on delta body weight, 
the weight of the epididymal fat pads, average energy intake, drinking behavior, urine 
and blood parameters, carnosine and anserine concentration in skeletal muscle, glucose 
transport and mRNA expression in skeletal muscle were analyzed with a one-way analysis 
of variance (ANOVA). When a significant group effect was shown, post hoc LSD tests were 
performed. All analyses were done with SPSS statistical software (SPSS 20, Chicago, IL) 
and statistical significance was set at p < 0.05.  
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RESULTS 
Body and fat mass 
45% fat study. Although epididymal fat pads were significantly bigger in HF (HF: 18.7 ± 
6.4g; HFcar: 17.0 ± 5.5g) compared to CON (13.1 ± 3.8g; p< 0.05), we were not able to 
report significant effects of the high-fat diet on body weight (CON: 430 ± 34g; HF: 480 ± 
69g; HFcar: 445 ± 71g; p = 0.254). Carnosine supplementation did not influence these 
parameters.  
In the 60% fat study, body weight and the epididymal fat pads of the HF groups were 
increased compared to the CON group by respectively +12% and +77% (table 1, p < 0.05), 
only the weight of the epididymal fat pads of the HF group was not significantly increased. 
Carnosine (HFcar) and beta-alanine (HFba) supplementation did not significantly change 
the effect of the high-fat diet on body and fat mass. 
 CON HF HFcar HFba 
Start Body Weight (g) 153 (± 16 ) 155 (±8) 157 (± 10) 155 (± 11) 
End Body Weight (g) 486 (± 57) 545 (± 47)* 572 (± 47)* 584 (± 60)* 
Delta Body Weight (g) 334 (± 48) 390 (± 44)* 415 (± 44)* 429 (± 53)* 
Weight Epididymal Fat pads (g) 8.9 (± 2.9) 13.8 (± 6.2) 16.9 (± 6.3)* 16.5 (± 5.9)* 
Average Energy Intake (kJ/day/cage) 761 (± 158) 882 (± 87)$ 942 (± 50)*  996 (± 102)* 
 
Table 1. 60% fat study: Body weight, epididymal fat and average energy intake over 8 weeks for CON, HF and HF treated 
groups (HFcar, HFba). Values are expressed as mean ± SD. * p<0.05 vs CON, $ p<0.1 vs CON. 
Dietary intake 
45% fat study. All rats had a similar energy intake (CON: 620 ± 59, HF: 643 ± 69, HFcar: 
613 ± 95 kJ/day/cage), although it appeared that HFcar drank more (~15%) than the non-
supplemented groups (HF and CON), but this was only significant for weeks 5, 11 and 14. 
Taking into account their average body weight for a period of 14 weeks, the rats from the 
HFcar group ingested 1468 (± 196) mg carnosine/kg BW per day. 
60%fat study. The HF groups (HF, HFcar and HFba) had a significantly higher energy intake 
(+24%) compared to the CON group (p < 0.05, table 1). Both HFcar and HFba had a similar 
drinking behavior and averaged ~37 ml/day during the 8-week intervention, which 
PLASMA CARNOSINE PREVENTS METABOLIC STRESS 
 
117 
resulted in a carnosine intake of 1697 (± 175) mg /kg BW per day and a beta-alanine 
intake of 933 (± 58) mg /kg BW per day, respectively.  
Histidine-containing dipeptides in plasma, urine and muscles.  
45% fat study. In the carnosine-supplemented group (HFcar) urinary carnosine 
concentrations reached levels of 342.1 ± 419.7 nmol/ml, whereas no carnosine was 
detected in urine in the non-supplemented groups (CON and HF) (table 2). Carnosine 
supplementation increased muscle carnosine (SOL: +4.8 mmol/kg DW, GW: +6.5 mmol/kg 
DW) and muscle anserine in SOL (+2.8 mmol/kg DW), but not in GW (-0.4 mmol/kg DW) 
compared to HF (data not shown). HF diet alone did not decrease muscle carnosine nor 
anserine.  
60% fat study. The plasma carnosine concentration of the CON, HF and HFba ranged from 
below limit of quantification (BLQ) (n=3/24) to 1.72 nmol/ml (table 3). However, when 
carnosine was supplemented (HFcar), plasma concentrations reached levels of 15.1 ± 18.5 
nmol/ml. As in the 45% fat study, HF diet alone did not change muscle carnosine nor 
anserine levels. Muscle carnosine content was increased by both carnosine (HFcar) and 
beta-alanine (HFba) supplementation, with no significant differences between those two 
supplemented groups and no significant difference between the three muscle types 
(HFcar: SOL: +5.5, GR: +3.7, GW: +3.5 ; HFba: SOL: +6.6, GR: +5.2, GW: +5.2, all expressed 
as mmol/kg DW) (figure 1). As SOL and GR have lower baseline values, the relative 
increase is markedly higher for muscles with a high percentage of type I fibers (SOL: +123% 
and GR: +75%) compared to muscles with a high percentage of type II fibers (GW: +34%) 
(figure 1A). A similar pattern was observed for muscle anserine, the methylated form of 
carnosine (figure 1B). The average absolute increase of muscle anserine in HFcar and 
HFba compared to HF was ~10.0 mmol/kg DW, with relative increases of +87% for SOL, 
+58% for GR and +22% for GW (figure 1B). The sum of muscle carnosine and muscle 
anserine is designated as histidine-containing dipeptides (HCD). The absolute increase of 
HCD was similar for the three muscle types, but tended to be higher in the HFba group 
compared to HFcar, with respectively +18.6 mmol/kg DW and +11.3 mmol/kg DW 
(p=0.07).  
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Figure 1. 60% fat study
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Inflammatory and glycoxidative markers in plasma, urine and skeletal muscle. 
45% fat study. Metabolic urine profile of the rats is given in table 2. HF diet induced 
marked elevation of urinary carboxymethyl-lysine (CML) concentration (p < 0.05), which 
was prevented by almost 50% through carnosine administration. No differences were 
present for total AGEs. Albumin excretion in the urine increased, although not 
significantly, in HF and reduced to a great extend in HFcar compared to HF. Carnosine-
HNE, a measure for the quenching ability of carnosine towards HNE, was detected in 
urine for 3 out of 8 rats in HFcar only.  
URINE PROFILE PER 24 H CON HF HFcar 
Urine volume (ml/24h) 23.7 (± 7.9) 22.6 (± 4.2) 21.0 (± 10.9) 
CML (µg/24h) 9.8 (± 4.5) 35.5 (± 15.0)** 18.4 (± 15.9)* 
Total AGEs (U.F./24h) 99723 (± 31135) 82799 (± 23919) 92583 (± 43668) 
Albumin (mg/24h) 296 (± 320) 535 (± 461) 129 (± 196)* 
Carnosine (nmol/24h) / / 7729 (± 14901) 
Carnosine-HNE (nmol/24h) / / 0.145 (± 0.084) 
 
Table 2. 45% fat study: 24-h urine profile of CON, HF and HFcar groups. Rats had access to their specific diet. Values are 
expressed as mean ± SD. * p<0.05 vs HF, ** p<0.05 vs CON and HFcar.  
In plasma (60% fat study), a similar pattern was found (table 3). Carnosine 
supplementation decreased plasma CML with more than 50% compared to the HF group 
(HF: 1.80 ± 0.95 nmol/ml, HFcar: 0.78 ± 0.92 nmol/ml, p < 0.05), whereas beta-alanine 
supplementation had no effect (1.65 ± 1.29 nmol/ml). Carnosine-HNE was detected in 
plasma for 2 out of 9 rats in HFcar only. The other metabolic markers (total cholesterol, 
AOPP, HNE protein adducts and total AGEs) were not significantly changed by HF diet, nor 
by supplementation (HFcar and HFba). In figure 2, two mediators of chronic inflammation 
(TNFα and iNOS) in skeletal muscle are shown. Carnosine, but not beta-alanine, 
supplementation decreased the mRNA expression of iNOS in m. soleus by 46.9% 
compared to HF (p < 0.05) and tended to decrease soleus TNFα mRNA by 25.7% 
compared to HFba (p= 0.072). 
 
 
PART II: Study 3 
 
120 
 
PLASMA PROFILE CON HF HFcar HFba 
CML (nmoles/ml) 1.06 (± 1.12) 1.80 (± 0.95)    0.78 (± 0.92)  * 1.65 (± 1.29) 
Total AGEs (U.F./ml) 500.2 (± 162.8) 424.0 (± 79.7) 363.1 (± 80.8) 363.7 (± 75.7) 
Total Cholesterol (mg/dl) 52.2 (± 9.3)     62.5 (± 10.9)  $ 57.4 (± 11.6) 60.8 (± 15.3) 
AOPP (µM eq.Cl.T) 290.2 (± 168.0) 279.3 (± 58.9) 314.6 (± 110.5) 312.4 (± 175.0) 
HNE (nmoles/ml) 1.59 (± 1.20) 1.09 (± 1.10) 1.36 (± 1.12) 0.91 (± 1.16) 
Carnosine (nmol/ml) 0.6 (± 0.4) 0.6 (± 0.5)       15.1 (± 18.5) ** 0.5 (± 0.4) 
Carnosine -HNE (nmol/ml) / / 0.010 ± 0.000 (2/9)  / 
 
Table 3. 60% fat study: Metabolic markers, plasma carnosine and carnosine adducts in plasma of the rats (fasted for 4 
hours). Values are expressed as mean ± SD. ** p<0.05 vs CON, HF and HFba, * p<0.05 vs HF and $ p<0.1 vs CON. 
 
  
Figure 2. 60% fat study: Relative mRNA expression of TNFα and iNOS in m. soleus in CON, HF and the two intervention 
groups (HFcar and HFba). Values are expressed as mean ± SD. * p<0.05 vs HF and HFba, $ p<0.1 vs HFba. 
 
In vivo whole body glucose tolerance (IVGTT) and skeletal muscle glucose transport 
60% fat study. Fasting plasma glucose and the area under the curve (AUC) of plasma 
glucose during the IVGTT were not significantly altered through HF diet, nor by 
supplementation (HFcar and HFba) (figure 3A and 3C). On the other hand, fasting plasma 
insulin was decreased by 45% by carnosine supplementation, but not by BA 
supplementation compared to HF (p < 0.05, figure 3B). The AUC of plasma insulin was 
more than doubled in the HFba group compared to the CON group (p < 0.05, figure 3D). 
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The AUC of HOMA-IR was higher in the three HF groups (HF, HFcar and HFba) compared 
to the CON group (p < 0.05, figure 3E). 
         
       
 
Figure 3. 60% fat study: Intravenous glucose tolerance test (IVGTT). Fig 3A and 3B represent fasting plasma glucose and 
insulin, respectively. Fig 3C, 3D and 3E represent the area under the curve (AUC) for plasma glucose, insulin and HOMA-
IR during the IVGTT. Values are expressed as mean ± SD. * p<0.05 vs CON and ** p<0.05 vs HF. 
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Insulin stimulated glucose transport in skeletal muscle was increased by 3- to 4-fold 
compared to basal glucose transport in every experimental group (CON, HF, HFcar and 
HFba) (p < 0.05), however, no effects of high-fat diet and supplementation (HFcar and 
HFba) were detected (table 4 ). 
Basal  
glucose transport 
(µmol/g/h) 
Insulin stimulated 
glucose transport 
(µmol/g/h) 
Delta 
(µmol/g/h) 
CON 2.0 (± 0.4) 7.9 (± 1.9) * 5.9 (± 1.9) 
HF 3.0 (± 0.7) 7.8 (± 3.7) * 4.9 (± 3.7) 
HFcar 3.2 (± 0.1) 7.6 (± 4.5) * 4.4 (± 4.5) 
HFba 1.5 (± 0.9) 8.9 (± 2.9) * 7.4 (± 2.9) 
 
Table 4. 60% fat study: Basal (± 3 rats per group) and insulin (± 6 rats per group) stimulated glucose transport in m. 
plantaris. Values are expressed as mean ± SD. *p<0.05 vs basal glucose transport. 
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DISCUSSION 
The first pathophysiological signs of HF feeding and the prevention by carnosine 
Potential therapeutic effects of carnosine have so far only been investigated on severe 
and advanced models of diabetes and diabetic complications (Yamano 2001; Nagai 2003; 
Lee 2005; Sauerhofer 2007). Given the multitude of biochemical properties of carnosine 
(Boldyrev 2013), possibly involved in the protective effects, and the multitude of 
physiological and biochemical abnormalities in these severe diabetic models, it is difficult 
to determine what is directly and what is indirectly affected by carnosine administration. 
We have aimed to look at the effects of carnosine in the initial stage of metabolic 
disturbance. In the 45% HF model, despite not yet attaining significant overweight, the 
first signs of the protective effects of carnosine were already observed, mainly by 
reducing urinary CML by 50% and by decreasing microalbuminuria with 75% compared to 
HF, but also by reporting CARN-HNE adducts in urine of some HFcar rats. Similar findings 
(concerning reduction of CML and CARN-HNE adducts) are found in the plasma of our 
overweight 60% HF model. A very recent and prominent paper of Baba et al. (2013) 
confirmed the presence of CAR-HNE adducts in mice and humans and reported the 
discovery of a metabolic pathway leading to the removal of these conjugates. The enzyme 
aldose reductase (AR) catalyzes the reduction of carnosine-aldehyde conjugates 
(carnosine-propanals) into carnosine-propanols in lysates of heart, skeletal muscle and 
brain tissue from wild-type, but not AR-null mice. Concerning the suppressive effect of 
carnosine supplementation on microalbuminuria (induced by chronic HFdiet), it does not 
only point towards a protective effect on kidney damage, but the retention of albumin in 
the circulation could increase whole body anti-oxidant capacity as albumin plays an 
important role in scavenging free radicals (Caraceni 1994).   
In our study, total AGEs were not (yet) altered by HF feeding, which can be explained by 
the fact that CML can derive from glyoxal, which is a by-product of either glycoxidation or 
lipid-oxidation (Vistoli 2013). On the other hand, total AGEs determined by fluorescence 
mainly come from glycoxidation. So, it seems that there are no oxidation products from 
glycoxidation in the plasma of these rats, but more from lipidoxidation and this is in 
agreement with the fat-rich animal diet and with the fact that the animals were 
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euglycemic. Taken together, these data on oxidative damage well indicate that the model 
we used is characterized by a very initial stage of oxidative stress since the AOPP levels 
did not change significantly as well as the protein HNE adducts as determined by ELISA. 
Only CAR-HNE metabolites determined by using the high specific and selective LC-ESI-MS 
methods were determined in some animals. Unlike Aldini et al. (2011), who saw marked 
effects of carnosine on dyslipidemia in Zucker obese rats, we could not confirm it at the 
level of plasma total cholesterol, although this could be explained by the fact that total 
cholesterol was also not (yet) markedly altered by our 60% HF diet (p=0.08). Interestingly, 
metabolic improvements induced by carnosine were not secondary to the prevention of 
overeating/obesity, which was a confounding factor in the study of Aldini et al. (2011). 
We can therefore conclude that carnosine has direct metabolic effects. 
Muscle Carnosine or Plasma Carnosine approach?  
A second aim of the current study was to identify whether beneficial effects are 
secondary to elevated plasma or elevated tissue carnosine concentrations. Our study 
design and results allowed to investigate this, as the HFcar had both elevated plasma and 
tissue (muscle) carnosine content, whereas HFba had only elevated muscle carnosine, 
without elevated plasma carnosine content. Here, we demonstrated for the first time that 
plasma carnosine (HFcar), and not muscle carnosine (HFba), is protective against HF diet-
induced lipidoxidation in plasma and urine (systemic effects) and for inflammatory 
signaling in muscle (target organ). Sustained increased inflammatory signalling in skeletal 
muscle has been shown to induce muscle insulin resistance (Pillon 2012). The fact that 
only HFcar and not HFba protected skeletal muscle from overweight-induced 
inflammatory signalling (although both groups equally increased muscle carnosine above 
normal levels), clearly points to a systemic effect with skeletal muscle as a target organ. 
This would suggest that skeletal muscle cannot be protected from metabolic stress by 
further raising its carnosine content. Muscle carnosine levels were not reduced by HF 
feeding in the present study, suggesting that there is no need to ‘restore’ normal levels, 
which is in contrast with previous reports in the literature (Buse 1980; Gualano 2012). 
One possible and likely mechanism by which systemic changes (like plasma CML) can 
influence inflammatory signaling in muscle/tissues is through the AGE-RAGE axis. CML is 
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an important ligand for RAGE and this AGE-RAGE interaction triggers intracellular events 
increasing nuclear transcription factors such as nuclear factor-kappa B (NF-κB), resulting 
in increased transcription of e.g. TNFα (Yan 1994; Kislinger 1999; Haslbeck 2005) and 
concomitantly increased iNOS expression (Ramasamy 2005). The finding that carnosine 
has a systemic effect, rather than a local effect, creates an obstacle in the road to 
developing a carnosine-related treatment for diabetic patients, as the highly active 
enzyme serum carnosinase (CN1) almost immediately hydrolyses carnosine in plasma into 
its two constituent amino acids beta-alanine and L-histidine upon oral administration 
(Everaert 2012). Further research must, however, first point out whether beta-alanine 
supplementation induces carnosine synthesis in other organs, such as retina and kidney, 
and whether or not this protects the respective organs. 
Glycemic Control  
Up to now, studies on the effect of carnosine on glycemic control have been mainly 
performed in diabetes type 1 models, such as streptozotocin-treated rats (Yamano 2001; 
Nagai 2003; Soliman 2007) and Balb/cA mice (Lee 2005). All studies reported that 
carnosine supplementation increased plasma insulin in the fasted state or during a 
glucose tolerance test, concomitant with decreased levels of glucose. The study of 
Sauerhofer et al. (2007) is the only one using a type 2 diabetic model (db/db mice) and 
they report similar effects as in type 1 models. In this light, our study is novel as it 
demonstrates another mechanism in a HF diet rat model. Fasting plasma glucose was not 
(yet) affected by high-fat diet, nor by HFcar or HFba, but fasting plasma insulin was 
reduced by ~45% in the carnosine supplemented HF group compared to HF, suggesting a 
better basal whole body insulin sensitivity. This study did not induce clear effects on 
glucose tolerance during the IVGTT and on glucose transport in skeletal muscle, therefore 
we cannot assess the effect of carnosine and beta-alanine supplementation. Additionally, 
it is noteworthy that chronic beta-alanine supplementation induced a markedly enhanced 
insulin response during the IVGTT. Possibly, this could be related to the fact that some 
amino acids can acutely and chronically regulate insulin secretion from pancreatic β-cells 
(Newsholme 2006), but the specific role of beta-amino acids, such as beta-alanine, has 
not yet been investigated. 
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Conclusions 
We designed for the first time a study that allows us to distinguish between the effects of 
elevated plasma and tissue carnosine or elevated tissue carnosine alone, by 
supplementing respectively carnosine or beta-alanine. From this study we can conclude 
that plasma carnosine and not muscle (tissue) carnosine is involved in preventing lipid-
oxidation in plasma and inflammatory signaling in skeletal muscle upon HF feeding. 
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ABSTRACT 
Introduction. Muscle carnosine and its methylated form anserine are histidine-containing 
dipeptides (HCDs). Both dipeptides have the ability to quench reactive carbonyl species 
and it is suggested that tissue levels are decreased in pathological circumstances, such as 
diabetes. Yet, some reports found conflicting findings in this regard. 
Methods. Rodent study: Skeletal muscles of rats and mice were collected from 4 different 
diet-intervention studies, aiming to induce various degrees of glucose intolerance: 45% 
high-fat (HF) feeding (rats), 60%HF feeding (rats), cafeteria feeding (rats) and 70%HF 
feeding (mice). The 70%HF intervention enclosed a third group, HF70%+ex, exercising 
5x1h/week for 6 weeks. Body weight (BW), glucose-tolerance and muscle HCDs were 
assessed. Human study: Muscles biopsies are taken from the Vastus Lateralis in 35 non-
vegetarian males (9 lean, 8 obese, 9 prediabetic patients (preT2D), 9 diabetic type 2 (T2D) 
patients) and muscle carnosine was measured.  
Results. Rodent study: Muscle HCDs changed (increased) only in the more drastic diet-
interventions inducing clear increases in body weight and glucose-intolerance (cafeteria 
and 70%HF feeding). Human study: Muscle carnosine of the obese, preT2D and T2D 
increased with 21% (p>0.1), 30% (p<0.05) and 39% (p<0.05), respectively, compared to 
the lean. 
Conclusion. Muscle HCDs increase with progressive glucose intolerance, both in rodents 
(interventional) and humans (cross-sectional). This implicates that the quenching ability 
of HCDs is of minor importance in determining its content in skeletal muscle. Therefore, 
this paper provides several diabetes-related factors possibly influencing muscle carnosine 
content in a diabetic state. 
 
 
 
Keywords: quenching ability, advanced lipoxidation and glycation endproducts, 
carnosinylated proteins.  
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INTRODUCTION 
Histidine-containing dipeptides (HCDs) are peptides consisting of a histidine (or a 
methylated form of histidine) and the atypical amino acid beta-alanine (Boldyrev 1990). 
HCDs are predominantly and abundantly present in skeletal muscle (Zapp 1938; Boldyrev 
1990; Boldyrev 2012), but they are also measurable in other tissues, although in 
concentrations 10- to 1000-fold lower (Boldyrev 2006; Kamal 2009; Peters 2011; Boldyrev 
2013). Human skeletal muscles only possess the HCD carnosine (beta-alanyl-L-histidine), 
whereas rodents have carnosine along with its methylated variant anserine (beta-alanyl-
N-π-methylhistidine) (Davey CL 1960; Crush 1970; Tamaki 1977).  
Carnosine supplementation has recently been associated with a later and milder 
evolution of diabetes in type 1 and 2 diabetic rodent models (Sauerhofer 2007; Soliman 
2007; Pfister 2011; Riedl 2011). The mechanism has been attributed to carnosine’s 
physiological characteristic to increase insulin secretion (Yamano 2001; Nagai 2003; 
Sauerhofer 2007), but also to its biochemical property to quench and scavenge damaging 
species such as reactive oxygen species (Decker 2000), metal-ions (Dobbie H 1955; Mineo 
2002), protein carbonyls (Hipkiss 2002) and reactive carbonyl species (RCS) by forming 
adducts with 4-hydroxy-2-nonenal (HNE) (Carini 2003) and acrolein (Orioli 2005). Until 
recently, these properties of carnosine were only confirmed in vitro. Aldini et al. (2011) 
was the first to report that Zucker Obese rats have higher levels of carnosine-HNE adducts 
in urine compared to their lean counterparts, which points to HNE overproduction in the 
obese animals and confirms the role of carnosine as an endogenous detoxifying agent of 
RCS such as HNE. In addition, Baba et al. (2013) confirmed the presence of carnosine-RCS 
conjugates (HNE and acrolein) in urine from normal, healthy, non-smoking adults and 
demonstrated its existence in skeletal muscle of C57BL/6 mice. Interestingly, anserine has 
similar characteristics as carnosine (Kohen 1988; Egorov 1997; Fontana 2002; Orioli 2005; 
Szwergold 2005), although less intensively investigated.  
As consequence of these scavenging characteristics, it is suggested that carnosine levels 
in diabetic tissues are decreased, as it has been shown that diabetic tissues have high 
production of reactive oxygen and carbonyl species (Brownlee 2001; Brownlee 2005; 
Samjoo 2013). Indeed, decreased carnosine and anserine levels are demonstrated in 
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retina, kidney and liver of obese and diabetic (type 1 and 2) rodents (Pfister 2011; Riedl 
2011; Peters 2011; Mong 2011). However, for skeletal muscle, contradiction exists. In 
rodents, there is only one paper available which shows decreased carnosine levels in 
diaphragm muscle of STZ-induced diabetic rats (Buse 1980). In humans, Gualano et al. 
(2012) reported reduced gastrocnemius carnosine content (-45%) in 14 type 2 diabetic 
patients (but not in soleus muscle nor in type 1 diabetic patients) compared to 14 control 
subjects matched for age, BMI, gender and diet. However, no consensus is reached, as 
another study (Srikanthan 2012) demonstrated an increase in soleus carnosine in 10 
diabetic type 2 patients (patients on oral and insulin therapy were excluded) compared to 
non-diabetic controls. 
Although evidence is scarce, a new research topic about elevating tissue/muscle 
carnosine in clinical populations is emerging because of its physiological and scavenging 
properties. Not only by supplementing carnosine in clinical circumstances, but also by 
proposing beta-alanine as a good alternative (Gualano 2012; Del Favero S 2012; Sale 
2013), because it is the rate-limiting precursor for carnosine synthesis in muscle (Harris 
2006). Therefore, this study is designed to elucidate whether skeletal muscle HCDs are 
affected by diet-induced obesity and glucose intolerance. Moreover, as it is known that 
exercise can reverse metabolic stress in skeletal muscle (Kiens 2006; Pedersen 2012), the 
additional effect of daily endurance training will be studied. 
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METHODS 
Study Design 
Rodent study (intervention study). Skeletal muscles of rats and mice were collected from 4 
different diet-intervention studies, aiming to induce various degrees of glucose 
intolerance. The specifications of the animals and the diets are presented in table 1.  
     Energy content of the diet  
(% total kJ) 
Study Species Strain Gender Intervention 
period 
Macro- 
nutrients 
CON HF/CAF 
  Rat studies  
HF 45% Rats Wistar M 14 weeks Total CHO 
Total fat 
Total protein 
70 
10 
20 
36 
45 (mainly lard) 
19 
HF 60%  Rats Sprague-
Dawley 
M 8 weeks Total CHO 
Total fat 
Total protein 
70 
10 
20 
20 
60 (mainly lard) 
20 
CAF Rats Wistar M 12 weeks Total CHO 
Total fat 
Total protein 
63 
12 
25 
69 (mainly sugar) 
16 
15 
Mouse study 
HF 70% Mice C57BL/6J  F 6 weeks Total CHO 
Total fat 
Total protein 
standard  
chow 
<1 
72 (lard + corn oil) 
28 
 
Table 1: Rodent study: Specifications of the animals and diets for the rat and mouse studies. Abbreviations: M: male, F: 
female, CHO: carbohydrates 
Shortly, in the HF 45% study, 15 male Wistar rats received either a 45% high-fat diet (HF 
45%, n=8) or a control diet (CON, n=7) during 14 weeks. The high fat diet contained 45% 
fat of total kJ, mainly coming from lard (Harlan Tecklad diets, CON:06416, HF:06415). In 
the HF 60% study, 18 male Sprague-dawley rats received either a 60% high-fat diet (HF 
60%, n=9) or a control diet (CON, n=9). Here as well, the fat from the diet was mainly 
coming from lard, but the % of total kJ increased up to 60% (Charles River diets, CON: 
D01060501, HF: D12492). In the CAF study, 22 male Wistar rats received either a cafeteria 
diet (CAF, n=11) or a control diet (CON, n=11) during 12 weeks. The cafeteria diet is 
another type of the obesity-inducing diets, because of its high amount of simple sugars 
(48% of total kJ) and was prepared from powdered rodent pellets (Muracon-G, Carfil 
Quality, Oud-Turnhout, Belgium; 330 g/kg), full fat sweetened condensed milk (Nestlé, 
Vevey, Switzerland; 330 g/kg), sucrose (70 g/kg), and water (270 g/kg) (Vaisy 2011). In the 
HF 70% study, 22 female C57BL/6J mice received either a control diet (CON, n=8), a 70% 
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high-fat diet (HF 70%, n=8) or a HF 70% diet in combination with endurance training (12 
m/min for 60 min per day, 5 days a week) (HF 70%+ex, n=6), during 6 weeks. Seventy-
two % of total kJ was fat and mainly derived from lard (Deldicque 2013). All rodents were 
housed at 22°C in a 12 h light/dark cycle and were given ad libitum access to their water 
and specific diet. 
In all rodent studies, body weight was recorded during the intervention study and glucose 
intolerance was measured at the end of the intervention (cfr infra for the description of 
the glucose tolerance tests). Thereafter, all animals were sacrificed by an intra-peritoneal 
injection of sodium pentobarbital solution and muscles were dissected for the 
determination of muscle HCDs (carnosine and anserine). In the rat studies, the muscle 
sampling included the white gastrocnemius (GW, a medial superficial part of the 
gastrocnemius consisting mainly of fast-glycolytic fibers) and the red gastrocnemius (GR, 
a deep proximal and medial portion of m. gastrocnemius, consisting mainly of fast-
oxidative fibers) (Delp 1996). In the mouse study, the gastrocnemius was taken as a whole 
(GAS), because it is difficult to make a visual distinction between the GR and GW in mice. 
The muscle samples were immediately frozen in liquid nitrogen and stored at -80°C until 
HCD content analysis. All rodent studies were approved by the local animal Ethical 
Committee (the rat studies by KU Leuven, the mouse study by Université catholique de 
Louvain).  
Human study (cross-sectional study). Muscle biopsies were taken from the Vastus 
Lateralis in 35 non-vegetarian males with different degrees in body weight and glucose 
intolerance: 9 lean, 8 obese, 9 prediabetic patients (preT2D), 9 diabetic type 2 patients 
(T2D: diet treated only). Glucose tolerance was classified as defined by the American 
Diabetes Association 2006 (blood glucose at 2 hours OGTT for lean and obese: < 140 
mg/dl; preT2D: > 140mg/dl and < 200mg/dl; T2D: > 200mg/dl). Subjects were age-
matched across the groups, with a mean age of 45 ± 7 yrs. The muscle samples were 
immediately frozen in liquid nitrogen and stored at -80°C until carnosine content analysis. 
Subjects gave their informed consent and the study was approved by the local Ethical 
Committee. 
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Glucose tolerance tests 
Rodent study. The intravenous glucose tolerance tests (IVGTT) in the rat studies (the HF 
45%, HF 60% and CAF-study) were performed according to Vaisy et al. (2011). Briefly, rats 
were anaesthetized and surgically prepared for the IVGTT, which involved catheter 
insertion into the left jugular vein. After an overnight fast (16-18 h) a glucose solution (1g 
glucose.kg-1 body weight using a 30% w.v.-1 glucose solution in w.v-1 saline) was injected 
into the catheter of the conscious rats and blood glucose and plasma insulin 
concentrations were measured at regular intervals. In the HF 45% and the HF 60% study, 
blood glucose was determined at time points 0, 5, 10, 15, 30,60, 90, and 120 min after 
glucose injection and plasma insulin at 0, 10, 30, and 90 min after glucose injection. In the 
CAF study, blood was taken at 0, 10, 30 and 90 min for glucose and insulin determination. 
Total AUCglucose and AUCinsulin were calculated using the trapezoidal rule. 
The oral glucose tolerance tests (OGTT) from the mouse study is described in Deldicque et 
al. (2013). Plasma glucose was determined on time points: 30 min before and 0, 15, 30, 60, 
90 and 120 min following oral glucose gavage, plasma insulin was only determined 30 min 
before and 15min after glucose gavage. Total AUC for glucose (AUCglucose) was calculated 
using the trapezoidal rule. 
Quantification of muscle carnosine, anserine and total HCDs 
HCDs (carnosine and anserine) were quantified by means of reversed-phase HPLC (high-
performance liquid chromatography). Skeletal muscles were dissolved in phosphate 
buffer (rat studies: 1mg dw muscle/100µL PBS; mouse study: 10mg ww muscle/100 µLPBS; 
human study: 1mg ww muscle/15 µL PBS) for homogenization. Muscle homogenates 
were deproteinized using 35% sulfosalicylic acid (SSA) and centrifuged (5min, 14000g). 
100µL of deproteinized supernatant was dried under vacuum (40°C). Dried residues were 
resolved with 40µL of coupling reagent: 
methanol/triethylamine/H2O/phenylisothiocyanate (PITC) (7/1/1/1) and allowed to react 
for 20 minutes at room temperature. The samples were dried again and resolved in 100µL 
of sodium acetate buffer (10mM, pH 6.4). The same method was applied to the combined 
standard solutions of carnosine (Flamma) and anserine (Sigma). The derivatized samples 
(20 μL) were chromatographed on a Waters HPLC system with ODS2 guard column (80Å, 
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5 µm, 4.6 mm X 10 mm), a Spherisorb C18/ODS2 column (4.6 x 150 mm, 5 µm), and UV 
detector (wavelength: 210 nm). The columns were equilibrated with buffer A (10 mM 
sodium acetate adjusted to pH 6.4 with 6% acetic acid) and buffer B (60% acetonitrile-40% 
buffer A) at a flow rate of 0.8 ml/min at 25°C. The limit of quantification of muscle 
homogenates was 7 µM (~0,7 mmol/kg DW muscle). Total HCDs are the sum of muscle 
carnosine and anserine. 
Statistics 
Rodent study. To compare body weight, AUCglucose, AUCinsulin, muscle carnosine, anserine 
and HCDs between the HF/CAF groups (HF 45%, HF 60%, CAF or HF 70%) and their own 
control group, data were analyzed by an independent t-test. Z-scores were calculated for 
every rat/mouse of the high-fat/cafeteria group to compare muscle carnosine levels of 
these obese rats between the 4 intervention studies. Z-scores were calculated using mean 
and standard deviation of the specific control groups. To compare the z-scores of muscle 
carnosine, anserine and HCDs between the four HF/CAF groups, This statistical analysis 
was also used to compare muscle carnosine, anserine and HCD between the 3 groups 
(CON, HF 70% and HF 70%+ex) in the HF 70% study.  
Human study. To compare muscle carnosine between the 4 groups (lean, obese, preT2D 
and T2D), a one-way ANOVA was performed. When a significant group effect was shown, 
a post hoc LSD test was done. All analyses (human and rodent) were done with SPSS 
statistical software (SPSS 20, Chicago, IL) and statistical significance was set at p < 0.05. 
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RESULTS 
Body weight and glucose tolerance (table 2) 
Rodent study: In the HF 45% study, end body weight tended (p=0.08) to be higher in HF 
compared to CON, but glucose tolerance (AUCglucose and AUCinsulin) was not significantly 
altered. In the 60% HF study, end body weight and AUCinsulin was higher in HF (+ 12% and 
+ 71% respectively, p<0.05) compared to CON, and AUCglucose tended to be higher (+ 22%, 
p=0.054). In the CAF study, body weight, AUCglucose and AUCinsulin were all higher in HF 
compared to CON (+ 12%, 25% and 139% respectively, p<0.05). In the HF 70% study, both 
body weight and AUCglucose were higher in HF compared to CON (+ 14% and + 81% 
respectively, p<0.05). In high-fat diet mice subjected to an endurance exercise program 
(HF 70%+ex), body weight was normalized back to levels of CON mice, however, AUCglucose 
could not be decreased by exercise. Plasma insulin at time points -30 min and +15 min 
from the OGTT was not different between the three groups.  
Study Obesity Glucose tolerance test 
Delta body 
weight (g) 
End body 
weight (g) 
Total AUC for glucose  Total AUC for insulin 
mmol.l-1.min % 
increase 
ng.ml-1.min % 
increase 
Rat studies 
HF 45% CON (n=8)  
HF (n=7) 
323 ± 32 
  377 ± 61 * 
430 ± 34 
  480 ± 69 $ 
999 ± 138 
1038 ± 127 
 
4 
463 ± 134 
533 ± 246 
 
15 
HF 60% CON (n=9) 
HF (n=9) 
334 ± 48 
  390 ± 44 * 
486 ± 57 
  545 ± 47 * 
1144 ± 186 
  1397 ± 305  $ 
 
22 
171 ± 74 
   293 ± 139 * 
 
71 
CAFa CON (n=11) 
CAF (n=11) 
255 ± 14 
305 ± 10* 
490 ±  47 
548 ± 55 * 
579 ± 29 
   721 ± 44 * 
 
25 
185 ± 28 
   443 ± 39 * 
 
139 
Mouse study 
HF 70%a  CON (n=8) 
HF (n=8) 
HF + ex (n=6) 
3.9 ± 1.0 
6.1 ± 1.1 * 
4.7 ± 1.3 ** 
21.6 ± 1.9 
23.1 ± 1.5 
20.7 ± 1.4** 
168 ± 68 
304 ± 127 * 
280 ± 71 * 
 
81 
67 
 
not available 
 
 
Table 2: Rodent study: Degree of obesity and glucose tolerance in the 4 interventions. Values are expressed as mean ± 
SD. * p<0.05 versus CON, ** p<0.05 HF+ex versus HF and $ p<0.1 versus CON. Underlined % increase (compared to CON) 
are significant with p<0.05. aData from the CAF and HF 70% study are obtained from respectively Vaisy et al. (2011) and 
Deldicque et al. (2013). 
Human study. Body weight and BMI of the lean subjects was significantly lower compared 
to the other three groups (body weight: lean: 78±10, obese: 99±21, preT2D: 103±8, T2D: 
97±12 kg; BMI: lean: 25±1, obese: 29±3, preT2D: 32±2, T2D: 31±3 kg/m2).  
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Muscle carnosine, anserine and HCDs (table 3) 
Rodent study: In the HF 45% and HF 60% study, neither muscle carnosine, nor anserine, 
nor the sum (total HCDs) was altered by high-fat feeding (for both muscle types GR and 
GW). In the CAF study, muscle anserine and total HCDs tended to increase in GW by 14% 
(p=0.085) and 12% (p=0.076), respectively. No changes were reported for muscle 
carnosine and GR. In the HF 70% study, muscle carnosine significantly increased with 30% 
(p<0.05) and muscle HCDs tended to increase (+21%) in HF compared to CON (p= 0.095). 
Muscle anserine followed a similar pattern, but no significant results were obtained. Daily 
exercise training (HF 70%+ex) seemed to counteract the high-fat diet-induced increase in 
muscle anserine and total HCDs (p=0.082) compared to HF.  
 Carnosine 
mmol/kg DW 
Anserine 
mmol/kg DW 
HCD 
mmol/kg DW 
Study Group GW GR GW GR GW GR 
Rat studies 
HF 45% CON (n=8) 
HF (n=7) 
19.1 ± 4.1 
18.2 ± 4.0 
9.2 ± 2.1 
8.3 ± 1.4 
34.6 ± 2.4 
35.7 ± 6.5 
29.2 ± 7.6 
29.4 ± 5.4 
53.7 ± 3.6 
53.9 ± 9.3 
38.5 ± 7.8 
37.7 ± 6.0 
HF 60% CON (n=9) 
HF (n=9) 
13.7 ± 3.6 
12.8 ± 2.0 
5.9 ± 2.0 
4.9 ± 2.0 
38.3 ± 4.3 
37.7 ± 4.5 
25.4 ± 7.0 
21.8 ± 4.4 
52.0 ± 4.9 
50.5 ± 4.7 
31.3 ± 7.3 
26.7 ± 4.1 
CAF CON (n=11) 
CAF (n=11) 
9.7 ± 1.8 
10.5 ± 2.3 
7.1 ± 0.9 
7.9 ± 1.3 
30.4 ± 5.1 
  34.6 ± 5.7 $ 
24.0 ± 4.0 
23.3 ± 3.1 
40.1 ± 6.4 
  45.1 ± 6.2 $ 
31.1 ± 4.9 
31.2 ± 3.9 
Mouse study 
 
HF 70% 
 
CON (n=8) 
HF (n=8) 
HF+ex (n=6) 
GAS 
5.4 ± 1.3 
    7.0 ± 1.7  * 
5.7 ± 1.1 
GAS 
11.1 ± 2.4 
12.9 ± 2.5   
   10.7 ± 1.7 $$ 
GAS 
16.4 ± 3.6 
   19.9 ± 4.1 $ 
    16.4 ± 2.6  $$ 
 
Table 3: Rodent study: Muscle carnosine, anserine and total HCD for the animals of the rat (HF 45%, HF 60% and CAF) 
and mouse studies (HF 70%). Values are expressed as mean ± SD. * p< 0.05 HF versus CON, $ p< 0.1 HF vs CON and 
$$ p<0.1 HF+ex vs HF. GW, GR and GAS represent the white, the red and the gastrocnemius as a whole, respectively. 
If the z-scores for muscle HCDs are compared between the 4 intervention diets, we 
observe higher z-scores in the groups with marked glucose intolerance (CAF and HF 70%) 
compared to the groups with no or limited glucose intolerance (HF 45% and HF 60%) 
(figure 1). This pattern is similar for muscle carnosine (HF 45%: -0.42 ± 0.97, HF 60%: -0.32 
± 0.80, CAF: 0.87 ± 1.25, HF 70%: 1.24 ± 1.30) and muscle anserine (HF 45%: 0.14 ± 0.53, 
HF 60%: -0.49 ± 0.87, CAF: 0.52 ± 0.62, HF 70%: 0.78 ± 1.06) separately. 
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Figure 1: Rodent study: Z-scores of total muscle HCDs for the groups HF 45%, HF 60%, CAF and HF 70% compared to 
their own control group (zero-line). Diamonds and stripes represent individual and group values, respectively. * p< 0.05 
vs HF 60%, ** p< 0.05 vs HF 45%.  
Human study. Muscle carnosine gradually increased with increasing glucose intolerance. 
Muscle carnosine of the obese, preT2D and T2D is higher [+21% (p>0.1), +30% (p<0.05) 
and +39% (p<0.05), respectively], compared to the lean (figure 2). 
 
 
Figure 2: Human study: Muscle carnosine content in lean, obese, prediabetic patients (preT2D) and diabetic type 2 
patients (T2D). Subjects are age-matched across the groups. Values are expressed as mean ± SD. * p<0.05 versus control. 
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DISCUSSION 
According to the ‘scavenging theory’, it is currently believed that carnosine levels in 
diabetic tissues are decreased. Briefly, carnosine sacrifices itself to scavenge reactive 
carbonyls species such as HNE and acrolein in vivo (Aldini 2011; Baba 2013), species 
which are abundantly present in diabetic tissues (Samjoo 2013). Indeed, a decrease in 
carnosine content has been reported in organs such as retina, kidney and liver (Pfister 
2011; Riedl 2011; Mong 2011), however, literature about carnosine levels in diabetic 
muscles are contradictive. In collaboration with a Brazilian research group, we previously 
reported a decrease in muscle carnosine (Gualano 2012), whereas others found an 
increase (Srikanthan 2012). Therefore, we have examined the effect of different degrees 
of glucose intolerance on muscle carnosine and anserine in both rodents (diet-
intervention study) and humans (cross-sectional study with lean, obese, preT2D patients 
and T2D patients). This paper shows that muscle HCDs increase with progressive glucose 
intolerance.  
In the search for explaining this increase, we first looked at the known determinants of 
muscle carnosine and whether or not glucose intolerance could play an interfering role. 
Muscle fiber type is one of the most important determinants of muscle carnosine content 
(next to age and sex)(Parkhouse 1985; Harris 1998; Everaert 2011; Baguet 2012). Muscles 
with a high portion of fast glycolytic type II fibers possess more (almost a double) 
carnosine and anserine compared to muscles with a higher portion of oxidative type I 
fibers (Harris 1998; Hill 2007; Baguet 2011; Everaert 2013b). Obesity and diabetes have 
several times been associated with alterations in muscle fiber type distribution, yet with 
opposing findings. On the one hand, insulin resistance and diabetes are associated with 
an elevated portion of fast glycolytic type II muscle fibers (Oberbach 2006; Stuart 2013). 
On the other hand, several studies have demonstrated that treatment of lean animals 
with a high-fat diet is followed by muscle fiber alterations in favor of oxidative 
metabolism including increased proportions of type I fibers in skeletal muscle. This, in an 
attempt to remove the overload of fat delivery (Abou 1992; Shortreed 2009). These 
apparently opposing findings may be the sequential outcome of a complex mechanism 
that regulates excess of fat availability, being different for the initial phase compared to 
the long-term phase. In line with this, Yasuda et al. (2002) demonstrated a higher % of 
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type I fibers (and a lower % of type IIA fibers) in soleus muscle of 5- and 9 week-old Goto-
Kakizaki rats (non-obese diabetic rats). On the other hand, an increased % of type IIB 
fibers was observed in plantaris muscle of 9- and 20-week-old Goto-Kakizaki rats (Yasuda 
2002). Interestingly, this study (HF 70% study) could demonstrate that an endurance 
exercise program (in glucose-intolerant mice possessing elevated muscle HCDs) tended to 
normalize muscle HCDs. As endurance exercise training is known to stimulate or preserve 
slow type I fibers, it is likely that muscle fiber type is accounted for this normalization. 
Our paper does not exclude the ‘self-sacrificial theory’ in other tissues and probably it is 
also present in skeletal muscle, we only suggest that it is of minor importance in skeletal 
muscle. Carnosine concentrations are, as already mentioned, a 1000-fold higher in 
skeletal muscle compared to other tissues such as kidney and liver, and the highly active 
enzyme carnosine synthase, which is more expressed in the fast glycolytic type II fibers, 
will probably easily restore HCD levels if necessary. Moreover, it is possible that a 
compensation mechanism is activated by initially decreased muscle carnosine levels, 
ultimately leading to net increased carnosine levels. 
However, the ‘self-sacrificial theory’ itself can be questioned as no evidence is provided 
for a possible degradation pathway of the subsequently formed carnosine-adducts. As a 
result, net carnosine levels would remain equal. But why did Gualano et al. (2012) found a 
decrease in muscle carnosine in Brazilian diabetes type 2 patients? Two possible factors 
can be put forward. First, low testosterone levels are common in men with obesity and 
type 2 diabetes and may be associated with insulin resistance (Grossmann 2008; 
Grossmann 2013). In addition, muscle carnosine levels have been shown to be negatively 
modified by orchidectomy in male mice (Penafiel 2004; Everaert 2013a). Second, we have 
recently shown that meal and beta-alanine co-ingestion enhances muscle carnosine 
loading in healthy subjects, suggesting that insulin plays a role (Stegen 2013). Meal-
induced elevations in serum insulin are capable of stimulating the sodium-dependent 
beta-alanine transporter TauT, secondary to its action of increasing sacrolemmal Na+/K+-
ATPase pump activity (Clausen 2003), resulting in increased beta-alanine flux into the 
muscle. Extrapolating these data, it can be suggested that insulin resistance, a common 
hallmark of obesity and diabetes (Kahn 2003; DeFronzo 2009; Bergman 2012), has a 
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lowering effect on intramuscular beta-alanine availability and therefore muscle carnosine 
levels.  
So, several factors explaining both an increase or decrease in muscle carnosine (or 
anserine) can be put forward to explain the existing and conflicting literature (cfr supra). 
However, this paper demonstrates both in rodents (interventional) and in humans (cross-
sectional) that muscle HCDs increase with progressive glucose intolerance. These data 
implicate that caution is warranted to treat diabetic patients with beta-alanine as a deficit 
in muscle HCDs in this population is not assured. Moreover, we underscore the 
importance of future studies aiming to better understand the metabolic pathways and 
the (patho)physiological significance of HCD in muscle in particular and in the body in 
general. 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
We greatly acknowledge the work of Monique Ramaekers and Bram Stegen for their 
assistance during the glucose tolerance tests (rodent study). 
  
PART II: Study 4 
 
148 
REFERENCE LIST 
Abou MJ, Yakubu F, Lin D, Peters JC, Atkinson JB and Hill JO. Skeletal muscle composition 
in dietary obesity-susceptible and dietary obesity-resistant rats. Am J Physiol 262: R684-
R688, 1992. 
Aldini G, Orioli M, Rossoni G, Savi F, Braidotti P, Vistoli G, Yeum KJ, Negrisoli G and Carini 
M. The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in 
Zucker obese rats. J Cell Mol Med 15: 1339-1354, 2011. 
Baba SP, Hoetker JD, Merchant M, Klein JB, Cai J, Barski OA, Conklin DJ and Bhatnagar A. 
Role of aldose reductase in the metabolism and detoxification of carnosine-acrolein 
conjugates. J Biol Chem 288: 28163-28179, 2013. 
Baguet A, Everaert I, Hespel P, Petrovic M, Achten E and Derave W. A new method for 
non-invasive estimation of human muscle fiber type composition. PLoS One 6: e21956, 
2011. 
Baguet A, Everaert I, Achten E, Thomis M and Derave W. The influence of sex, age and 
heritability on human skeletal muscle carnosine content. Amino Acids 43: 13-20, 2012. 
Bergman BC, Howard D, Schauer IE, Maahs DM, Snell-Bergeon JK, Eckel RH, Perreault L 
and Rewers M. Features of hepatic and skeletal muscle insulin resistance unique to type 1 
diabetes. J Clin Endocrinol Metab 97: 1663-1672, 2012. 
Boldyrev AA and Severin SE. The histidine-containing dipeptides, carnosine and anserine: 
distribution, properties and biological significance. Adv Enzyme Regul 30: 175-194, 1990. 
Boldyrev AA. Carnosine and Oxidative Stress in Cells and Tissues. New York: Nova Science 
Publishers, 2006. 
Boldyrev AA. Carnosine: new concept for the function of an old molecule. Biochemistry 
(Mosc ) 77: 313-326, 2012. 
Boldyrev AA, Aldini G and Derave W. Physiology and pathophysiology of carnosine. 
Physiol Rev 93: 1803-1845, 2013. 
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 
414: 813-820, 2001. 
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 
54: 1615-1625, 2005. 
Buse MG, Weigand DA, Peeler D and Hedden MP. The effect of diabetes and the redox 
potential on amino acid content and release by isolated rat hemidiaphragms. Metabolism 
29: 605-616, 1980. 
Carini M, Aldini G, Beretta G, Arlandini E and Facino RM. Acrolein-sequestering ability of 
endogenous dipeptides: characterization of carnosine and homocarnosine/acrolein 
adducts by electrospray ionization tandem mass spectrometry. J Mass Spectrom 38: 996-
1006, 2003. 
  MUSCLE HCD AND GLUCOSE INTOLERANCE   
 
 
149 
Clausen T. Na+-K+ pump regulation and skeletal muscle contractility. Physiol Rev 83: 
1269-1324, 2003. 
Crush KG. Carnosine and related substances in animal tissues. Comp Biochem Physiol 34: 
3-30, 1970. 
Davey CL. The significance of carnosine and anserine in striated skeletal muscle. Arch 
Biochem Biophys 89: 303-308, 1960. 
Decker EA, Livisay SA and Zhou S. A re-evaluation of the antioxidant activity of purified 
carnosine. Biochemistry (Mosc ) 65: 766-770, 2000. 
DeFronzo RA and Tripathy D. Skeletal muscle insulin resistance is the primary defect in 
type 2 diabetes. Diabetes Care 32 Suppl 2: S157-S163, 2009. 
Del Favero S, Roschel H, Solis MY, Hayashi AP, Artioli GG, Otaduy MC, Benatti FB, Harris 
RC, Wise JA, Leite CC, Pereira RM, de Sa-Pinto AL, Lancha-Junior AH and Gualano B. Beta-
alanine (Carnosyn) supplementation in elderly subjects (60-80 years): effects on muscle 
carnosine content and physical capacity. Amino Acids 43: 49-56, 2012. 
Deldicque L, Cani PD, Delzenne NM, Baar K and Francaux M. Endurance training in mice 
increases the unfolded protein response induced by a high-fat diet. J Physiol Biochem 69: 
215-225, 2013. 
Delp MD and Duan C. Composition and size of type I, IIA, IID/X, and IIB fibers and citrate 
synthase activity of rat muscle. J Appl Physiol 80: 261-270, 1996. 
Dobbie H and Kermack WO. Complex-formation between polypeptides and metals. 2. The 
reaction between cupric ions and some dipeptides. Biochem J 59: 246-257, 1955. 
Egorov SY, Kurella EG, Boldyrev AA and Krasnovsky AA, Jr. Quenching of singlet molecular 
oxygen by carnosine and related antioxidants. Monitoring 1270-nm phosphorescence in 
aqueous media. Biochem Mol Biol Int 41: 687-694, 1997. 
Everaert I, Mooyaart A, Baguet A, Zutinic A, Baelde H, Achten E, Taes Y, de Heer E and 
Derave W. Vegetarianism, female gender and increasing age, but not CNDP1 genotype, 
are associated with reduced muscle carnosine levels in humans. Amino Acids 40: 1221-
1229, 2011. 
Everaert I, De Naeyer H, Taes Y and Derave W. Gene expression of carnosine-related 
enzymes and transporters in skeletal muscle. Eur J Appl Physiol 113: 1169-1179, 2013a. 
Everaert I, Stegen S, Vanheel B, Taes Y and Derave W. Effect of Beta-Alanine and 
Carnosine Supplementation on Muscle Contractility in Mice. Med Sci Sports Exerc 45: 43-
51, 2013b. 
Fontana M, Pinnen F, Lucente G and Pecci L. Prevention of peroxynitrite-dependent 
damage by carnosine and related sulphonamido pseudodipeptides. Cell Mol Life Sci 59: 
546-551, 2002. 
PART II: Study 4 
 
150 
Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD 
and Jerums G. Low testosterone levels are common and associated with insulin resistance 
in men with diabetes. J Clin Endocrinol Metab 93: 1834-1840, 2008. 
Grossmann M. Testosterone and glucose metabolism in men: current concepts and 
controversies. J Endocrinol 220: R37-R55, 2013. 
Gualano B, Everaert I, Stegen S, Artioli GG, Taes Y, Roschel H, Achten E, Otaduy MC, 
Lancha-Junior AH, Harris R and Derave W. Reduced muscle carnosine content in type 2, 
but not in type 1 diabetic patients. Amino Acids 43: 21-24, 2012. 
Harris RC, Tallon MJ, Dunnett M, Boobis L, Coakley J, Kim HJ, Fallowfield JL, Hill CA, Sale C 
and Wise JA. The absorption of orally supplied beta-alanine and its effect on muscle 
carnosine synthesis in human vastus lateralis. Amino Acids 30: 279-289, 2006. 
Harris R, Dunnett M and Greenhaff PL. Carnosine and taurine contents in individual fibres 
of human vastus lateralis muscle. J Sports Sci 16: 639-643, 1998. 
Hill CA, Harris RC, Kim HJ, Harris BD, Sale C, Boobis LH, Kim CK and Wise JA. Influence of 
beta-alanine supplementation on skeletal muscle carnosine concentrations and high 
intensity cycling capacity. Amino Acids 32: 225-233, 2007. 
Hipkiss AR, Brownson C, Bertani MF, Ruiz E and Ferro A. Reaction of carnosine with aged 
proteins: another protective process? Ann N Y Acad Sci 959: 285-294, 2002. 
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the 
pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19, 2003. 
Kamal MA, Jiang H, Hu Y, Keep RF and Smith DE. Influence of genetic knockout of Pept2 
on the in vivo disposition of endogenous and exogenous carnosine in wild-type and Pept2 
null mice. Am J Physiol Regul Integr Comp Physiol 296: R986-R991, 2009. 
Kiens B. Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev 86: 
205-243, 2006. 
Kohen R, Yamamoto Y, Cundy KC and Ames BN. Antioxidant activity of carnosine, 
homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci U S A 85: 
3175-3179, 1988. 
Mineo P, Vitalini D, La Mendola D, Rizzarelli E, Scamporrino E and Vecchio G. Electrospray 
mass spectrometric studies of L-carnosine (beta-alanyl-L-histidine) complexes with 
copper(II) or zinc ions in aqueous solution. Rapid Commun Mass Spectrom 16: 722-729, 
2002. 
Mong MC, Chao CY and Yin MC. Histidine and carnosine alleviated hepatic steatosis in 
mice consumed high saturated fat diet. Eur J Pharmacol 653: 82-88, 2011. 
Nagai K, Niijima A, Yamano T, Otani H, Okumra N, Tsuruoka N, Nakai M and Kiso Y. 
Possible role of L-carnosine in the regulation of blood glucose through controlling 
autonomic nerves. Exp Biol Med (Maywood ) 228: 1138-1145, 2003. 
  MUSCLE HCD AND GLUCOSE INTOLERANCE   
 
 
151 
Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R, Schon MR, Bluher M 
and Punkt K. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme 
activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 29: 895-900, 
2006. 
Orioli M, Aldini G, Beretta G, Facino RM and Carini M. LC-ESI-MS/MS determination of 4-
hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides 
as early markers of oxidative stress in excitable tissues. J Chromatogr B Analyt Technol 
Biomed Life Sci 827: 109-118, 2005. 
Parkhouse WS, McKenzie DC, Hochachka PW and Ovalle WK. Buffering capacity of 
deproteinized human vastus lateralis muscle. J Appl Physiol 58: 14-17, 1985. 
Pedersen BK and Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a 
secretory organ. Nat Rev Endocrinol 8: 457-465, 2012. 
Penafiel R, Ruzafa C, Monserrat F and Cremades A. Gender-related differences in 
carnosine, anserine and lysine content of murine skeletal muscle. Amino Acids 26: 53-58, 
2004. 
Peters V, Schmitt CP, Zschocke J, Gross ML, Brismar K and Forsberg E. Carnosine 
treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. 
Amino Acids 42: 2411-2416, 2011. 
Pfister F, Riedl E, Wang Q, vom HF, Deinzer M, Harmsen MC, Molema G, Yard B, Feng Y 
and Hammes HP. Oral carnosine supplementation prevents vascular damage in 
experimental diabetic retinopathy. Cell Physiol Biochem 28: 125-136, 2011. 
Riedl E, Pfister F, Braunagel M, Brinkkotter P, Sternik P, Deinzer M, Bakker SJ, Henning RH, 
van den Born J, Kramer BK, Navis G, Hammes HP, Yard B and Koeppel H. Carnosine 
prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. Cell Physiol 
Biochem 28: 279-288, 2011. 
Sale C, Artioli GG, Gualano B, Saunders B, Hobson RM and Harris RC. Carnosine: from 
exercise performance to health. Amino Acids 44: 1477-1491, 2013. 
Samjoo IA, Safdar A, Hamadeh MJ, Raha S and Tarnopolsky MA. The effect of endurance 
exercise on both skeletal muscle and systemic oxidative stress in previously sedentary 
obese men. Nutr Diabetes 3: e88, 2013. 
Sauerhofer S, Yuan G, Braun GS, Deinzer M, Neumaier M, Gretz N, Floege J, Kriz W, van 
der Woude F and Moeller MJ. L-carnosine, a substrate of carnosinase-1, influences 
glucose metabolism. Diabetes 56: 2425-2432, 2007. 
Shortreed KE, Krause MP, Huang JH, Dhanani D, Moradi J, Ceddia RB and Hawke TJ. 
Muscle-specific adaptations, impaired oxidative capacity and maintenance of contractile 
function characterize diet-induced obese mouse skeletal muscle. PLoS One 4: e7293, 2009. 
Soliman K, Mohamed A and Metwally N. Attenuation of some metabolic deteriorations 
induced by diabetes mellitus using carnosine. Journal of Applied Sciences 7: 2252-2260, 
2007. 
PART II: Study 4 
 
152 
Srikanthan P, Singhal A, Lee CC, Nagarajan R, Wilson N, Roberts CK, Hahn TJ and Thomas 
MA. Characterization of Intra-myocellular Lipids using 2D Localized Correlated 
Spectroscopy and Abdominal Fat using MRI in Type 2 Diabetes. Magn Reson Insights 5: 
29-36, 2012. 
Stegen S, Blancquaert L, Everaert I, Bex T, Taes Y, Calders P, Achten E and Derave W. Meal 
and Beta-alanine coingestion enhances muscle carnosine loading. Med Sci Sports Exerc 45: 
1478-1485, 2013. 
Stuart CA, McCurry MP, Marino A, South MA, Howell ME, Layne AS, Ramsey MW and 
Stone MH. Slow-twitch fiber proportion in skeletal muscle correlates with insulin 
responsiveness. J Clin Endocrinol Metab 98: 2027-2036, 2013. 
Szwergold BS. Carnosine and anserine act as effective transglycating agents in 
decomposition of aldose-derived Schiff bases. Biochem Biophys Res Commun 336: 36-41, 
2005. 
Tamaki N, Tsunemori F, Wakabayashi M and Hama T. Effect of histidine-free and -excess 
diets on anserine and carnosine contents in rat gastrocnemius muscle. J Nutr Sci 
Vitaminol (Tokyo) 23: 331-340, 1977. 
Vaisy M, Szlufcik K, De Bock K, Eijnde BO, Van Proeyen K, Verbeke K, Van Veldhoven P and 
Hespel P. Exercise-induced, but not creatine-induced, decrease in intramyocellular lipid 
content improves insulin sensitivity in rats. J Nutr Biochem 22: 1178-1185, 2011. 
Yamano T, Niijima A, Iimori S, Tsuruoka N, Kiso Y and Nagai K. Effect of L-carnosine on the 
hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats. Neurosci Lett 
313: 78-82, 2001. 
Yasuda K, Nishikawa W, Iwanaka N, Nakamura E, Seino Y, Tsuda K and Ishihara A. 
Abnormality in fibre type distribution of soleus and plantaris muscles in non-obese 
diabetic Goto-Kakizaki rats. Clin Exp Pharmacol Physiol 29: 1001-1008, 2002. 
Zapp J and Wilson D. Quantitative studies of carnosine and anserine in mammalian 
muscle. J Biol Chem 19-27, 1938. 
     
 
 
Study  5. Serum carnosinase content and activity in type 2 diabetic patients 
 
 
 
Study 5 
 
 
SERUM CARNOSINASE CONTENT AND ACTIVITY 
 IN TYPE 2 DIABETIC PATIENTS. 
 
Stegen S, Sigal R, Kenny G, Khandwala F, De Heer E, Yard B, Calders P, Peersman W, Derave W 
Manuscript in progress  
  
 
SERUM CARNOSINASE IN DIABETES TYPE 2 
 
155 
ABSTRACT 
Introduction. A polymorphism in the serum carnosinase gene (CNDP1), encoding for low 
serum carnosinase (CN1) activity, is associated with reduced risk of diabetic nephropathy. 
The substrates of CN1, carnosine and anserine, have been associated on their turn with a 
later and milder evolution of diabetes in type 1 and type 2 diabetic rodent models, when 
given as a supplement. These two findings have created the hypothesis that low CN1 
activity levels are protective in the development of diabetes or diabetes-related diseases 
as it would increase the bioavailability of its substrates in the circulation. On the other 
hand, it is suggested that hyperglycemia increases CN1 activity, pointing towards the 
importance of good glycemic control in type 2 diabetic patients (T2D). 
Aims. This study has two main aims: 1) to investigate whether T2D patients are indeed 
characterized by higher CN1 levels (content and activity) and whether exercise training or 
a better glycemic control could suppress CN1. 2) to explore the relationship between CN1 
activity and lipid profile and blood pressure in T2D patients.  
Methods. Plasma samples were taken from a large cohort T2D patients (153 men, 90 
women, age:54.3±7.1 yrs) before and after a 6-month exercise training program (4 groups: 
remaining sedentary, aerobic exercise, resistance exercise and combined exercise 
training)(part of DARE clinical trial). Plasma CN1 content and activity, HbA1c, lipid profile 
and blood pressure were measured. In healthy subjects (90 men, 66 women, age: 
24.4±7.5 yrs), CN1 content and activity was also determined.   
Results and conclusions: We provided evidence that hyperglycemia does not elevate CN1 
content and activity levels as 1) no correlation between CN1 and HbA1c is present in T2D 
patients and 2) there is no difference in CN1 content between healthy subjects and T2D 
patients, moreover CN1 activity was significantly higher in the healthy subjects. In 
addition, CN1 content and activity are stable over a 6-month period and not influenced by 
chronic exercise training. Finally, CN1 was associated with lipid profile, but findings were 
inconsistent between CN1 content and activity.  
Keywords:  CNDP1, carnosine, histidine-containing dipeptides, carnosinase specific 
activity  
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INTRODUCTION 
Human serum carnosinase or CN1 belongs to the family of the M20 metalloproteinases 
and is secreted by the liver or brain into the circulation, where it is highly active in the 
adult human (Jackson 1991; Teufel 2003). It hydrolyses the histidine-containing 
dipeptides carnosine (β-alanyl-L-histidine), homocarnosine (γ-aminobutyryl-histidine) and 
anserine (β-alanyl-N-π-methylhistidine) back into its constituent amino acids, with the 
highest specificity for carnosine (Peters 2010; Peters 2011b). In the past decade, two 
different research approaches have associated this carnosine/carnosinase system with 
diabetes or diabetic complications.  
First, carnosine supplementation has recently been associated with a later and milder 
evolution of diabetes in type 1 and 2 diabetic rodent models (Sauerhofer 2007; Soliman 
2007; Pfister 2011; Riedl 2011; Peters 2011a). The mechanism has been attributed to 
carnosine’s physiological and biochemical properties (Boldyrev 2013). Carnosine can 
interact with oxidative and glycative species (Hipkiss 1995; Decker 2000), but also with its 
deleterious derivatives in vivo, such as reactive carbonyl species (Aldini 2011; Baba 2013) 
and protein carbonyls (Baba 2013). As consequence, the formation of advanced glycation 
and lipoxidation end-products (AGEs and ALEs), which are abundantly present (and 
detrimental) in diabetes or diabetes-related diseases (Metz 2003), will be suppressed 
(Aldini 2011). From a physiological point of view, it has been demonstrated that carnosine 
increases insulin secretion in rodent diabetic models (Nagai 2003a; Sauerhofer 2007). 
Moreover, Lee et al. (2005) reported reduced triglyceride and cholesterol levels in heart 
and liver after carnosine supplementation in diabetic Balb/cA mice. Later animal studies 
could confirm beneficial effects of carnosine supplementation on dyslipidemia in both 
plasma and tissues (Mong 2011; Aldini 2011), together with an anti-atherogenic (Menini 
2012) and anti-hypertensive effect (Aldini 2011).  
Second, several genome-wide linkage scans for diabetic nephropathy and subsequently 
fine-mapping have demonstrated that some polymorphisms in the gene for CN1 (CNDP1) 
are closely associated with diabetic nephropathy susceptibility (Janssen 2005; Freedman 
2007; Mooyaart 2010; Zhu 2013). More specifically, Caucasian diabetic patients 
homozygous for the 5 leucine allele were less susceptible to diabetic nephropathy 
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(especially women). In addition, homozygosity for the five-leucine allele of CNDP1 (the 
least CTG repeats) was associated with the lowest CN1 actvitiy and vice versa, the more 
CTG repeats in CNDP1 (the 6, 7 or 8 leucine allele), the higher the CN1 activity (Janssen 
2005), but this was only demonstrated in healthy individuals. A later study on Cos-7 
transfected cells (Riedl 2007) confirmed that the 5 leucine allele impairs the efficiency of 
secretion of serum carnosinase, resulting in lower CN1 activity.  
Interestingly, both research approaches share the same working hypothesis, i.e. higher 
bioavailability of carnosine in the circulation, due to carnosine ingestion (by diet or 
supplementation) or lower CN1 activity, will provide more disease-protecting effects 
according to its biochemical properties. This brings us to our first hypothesis. We expect 
that diabetic patients having lower CN1 content and activity display a healthier lipid 
profile and blood pressure compared to patients having high CN1 content and activity.  
Despite the relevance of this carnosine/carnosinase system in diabetes or diabetes 
related complications, little is known about the determinants of CN1 content and activity 
in  type 2 diabetes. Therefore, this study will better characterize those determinants in 
this population. First, we expect that CN1 content and activity will be higher in women 
then in men, as demonstrated in healthy individuals (Bando 1984; Peters 2010; Everaert 
2011). Second, we hypothesize that hemoglobin A1C (HbA1c) is positively correlated with 
CN1 content and activity. CN1 is a heavily glycosylated protein with three putative N-
glycosylation sites (Teufel 2003), as consequence, Riedl et al. (2010) stepwise deleted of 
its putative N-glycosylation sites in Cos-7 cells and found that CN1 secretion and activity 
was decreased. In a next step Riedl et al. (2010) suggested that hyperglycemia would 
increase CN1 secretion/activity because of increased N-glycosylation. Hyperglycemia 
triggers the hexosamine pathway, leading to elevated UDP-N-acetylglucosamine (GlcNAc) 
concentrations (Brownlee 2001), which is a critical factor in the N-glycosylation (Sasai 
2002). Indeed, they demonstrated that (CGT)5 homozygous diabetic (type 1 and 2) 
patients had increased CN1 activity levels compared to (CGT)5 homozygous healthy 
controls. In this light, it can be hypothesized that exercise training in diabetic patients, 
aiming for ameliorating insulin sensitivity and thereby lowering hyperglycemia and HbA1c, 
decreases CN1 content and activity (third assumption). Moreover, our lab has recently 
reported lower CN1 levels (both content and activity) in elite athletes, involved in high 
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intensity exercise, compared to untrained controls (Baguet 2014). However, the effect of 
exercise on CN1 has not yet been investigated.  
For these purposes, we investigated CN1 content and activity in a large cohort diabetic 
type 2 patients (153 men and 90 women), before and after a 6-month intervention of 
exercise training (aerobic exercise, resistance exercise, combined aerobic and resistance 
exercise) or remaining sedentary (control). In addition, CN1 content and activity levels of 
diabetic type 2 patients will also be compared with healthy subjects (90 men and 66 
women). 
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METHODS 
Blood samples from patients with diabetes type 2 (153 men, 90 women) were taken from 
the DARE (Diabetes Aerobic and Resistance Exercise) clinical trial to measure CN1 content 
and activity before and after a 6-month exercise training program and compared with 
healthy subjects. The DARE clinical trial was originally designed to determine the effect of 
aerobic and resistance training alone (6 months) versus a sedentary control group, and 
the incremental effects of doing both types of exercise (combined exercise training) 
versus aerobic or resistance training alone, on glycemic control and other risk factors for 
cardiovascular disease (Sigal 2007). Design, participant characteristics and intervention 
are briefly described below and the reader is referred to the full manuscript of Sigal R.J. et 
al. (2007) for further details. 
Design 
Diabetes type 2 patients. A 26-week, single-center, randomized, control trial with parallel-
group design was performed. Previously inactive persons with type 2 diabetes were 
randomly assigned to 1 of 4 groups: aerobic training, resistance training, combined 
aerobic and resistance training, or a control group that reverted to prestudy activity levels. 
Before and after the 6-month intervention period, heparin plasma blood samples were 
taken in fasted state and participants were instructed not to exercise 48 hours before 
each visit. The study was approved by the Ottawa Hospital Research Ethics Board, and all 
participants gave informed consent. 
Healthy subjects. Heparin blood samples were collected to quantify plasma carnosinase 
protein content and activity (not in fasted state).  
Participants 
Diabetes type 2 patients. Baseline characteristics are presented in table 1. Inclusion 
criteria included type 2 diabetes (as defined by the American Diabetes Association (1997)) 
for more than 6 months and a baseline hemoglobin A1c value of 6.6% to 9.9% (normal 
range, 4.0% to 6.0%). Exclusion criteria were current insulin therapy; participation in 
exercise during the previous 6 months; changes during the previous 2 months in oral 
hypoglycemic, antihypertensive, or lipid-lowering agents or body weight (≥5%); serum 
creatinine level of 200 µmol/L or greater (≥2.26 mg/dL); proteinuria greater than 1 g/d; 
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blood pressure greater than 160/95 mm Hg; restrictions in physical activity because of 
disease; or presence of other medical conditions that made participation inadvisable. The 
exercise intervention took place at 8 community-based exercise facilities in the Ottawa–
Gatineau region, Canada. Exercise was supervised by personal trainers. 
Baseline Characteristics Control group Aerobic 
training group 
Resistance 
training  
group 
Combined 
exercise 
training group 
Men/women, n/n 38/23 39/20 39/24 37/23 
Mean age (SD), y 54,6 (7,1) 54,0 (6,6) 54,8 (7,6) 53,6 (7,2) 
Mean hemoglobin A1c value (SD), % 7,66 (0,88) 7,69 (0,86) 7,72 (0,86) 7,66 (0,92) 
 
Table 1. Baseline characteristics of diabetic type 2 patients 
Healthy subjects. 156 healthy Belgian (Caucasian) subjects (90 men and 66 women) with a 
mean age of 24.4 yrs (SD ± 7.5) (age range: 18 – 69 yrs). All subjects were physically active 
(but not engaged in competitive sports or specifically trained) and nobody used 
medication. The control subjects were collected from two different studies from our lab 
(Everaert 2011, Baguet 2014). 
Intervention 
Diabetes type 2 patients. Exercise group participants exercised 3 times weekly, and 
training progressed gradually in duration and intensity. The aerobic training group 
exercised on treadmills or bicycle ergometers. Participants progressed from 15 to 20 
minutes per session at 60% of the maximum heart rate to 45 minutes per session at 75% 
of the maximum heart rate, as determined by using a maximal treadmill exercise test. The 
resistance training group performed 7 different exercises on weight machines each 
session, progressing to 2 to 3 sets of each exercise at the maximum weight that could be 
lifted 7 to 9 times. The combined exercise training group did the full aerobic training 
program plus the full resistance training program to ensure an adequate dose of each 
type of exercise. Control participants were asked to revert to prestudy activity levels, had 
the same dietary intervention and spent the same time with the research coordinator and 
dietitian as did the participants from the exercise groups. 
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Plasma analyses 
Glycemic control, lipid profile and blood pressure. Hemoglobin A1c was measured by using 
turbidimetric immunoinhibition, and total cholesterol, high-density lipoprotein (HDL) 
cholesterol, and triglyceride levels were measured by using enzymatic methods on a 
Beckman-Coulter LX20 analyzer (Beckman Instruments, Brea, California). Low-density 
lipoprotein (LDL) cholesterol levels were calculated by using the Friedewald equation 
(Friedewald 1972). Blood pressure was measured after 10 minutes at rest; the mean of 2 
readings obtained 2 minutes apart was used in statistical analysis. 
CN1 content, activity and specific activity. CN1 concentrations (content) were determined 
by a sandwich ELISA (enzyme-linked immunosorbent assay). In brief, a human CN1 ELISA 
was developed by coating high absorbant microtitre plates (Greiner BioChemia, Flacht, 
Germany) overnight with 100 µl of goat polyclonal anti-human CN1 (1 µg/ml) (R&D, 
Wiesbaden Germany). The plates were extensively washed and incubated with 5 % w/v of 
dry milk powder to avoid unspecific binding. For each sample and standard, serial dilution 
was carried out. The plates were placed on a shaker for 1 hr and subsequently extensively 
washed with PBS/Tween. Hereafter, anti-human carnosinase monoclonal antibody (clone 
ATLAS, Abcam) was added for 1 hr followed by extensively washing. HRP conjugated goat 
anti-mouse IgG was added for 1 hr and the plates were washed. After addition of 
peroxidase substrate (deep-Blue POD) (Roche diagnostics, Mannheim, Germany) the 
reaction was stopped after 15 minutes by adding 50 µl of 1 M H2SO4 and read in an ELISA 
reader at 450 nm. CN1 protein concentrations were assessed in the linear part of the 
dilution curve. Sensitivity of the ELISA was approximately 20 ng/ml. 
CN1 activity was determined according to a method described by Teufel et al. (2003). 
Briefly, the reaction was initiated by addition of substrate (L-carnosine) to a heparin 
plasma sample and stopped after 10 min of incubation at 37 °C by adding 1 % SSA. 
Liberated histidine was derivatized with o-phtaldialdehyde (OPA) and the maximum 
increase was used for determining the maximum activity. Fluorescence was measured by 
excitation at 360 nm and emission at 460 nm.  
CN1 specific activity is calculated by dividing CN1 activity by its content (the activity of an 
enzyme per milligram of total protein) and expressed as μmol/min/mg.  
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Statistical analysis.  
At baseline, the pearson correlation coefficient was calculated to study 1) the relationship 
between CN1 content and CN1activity within subjects and 2) the effect of age on CN1 
content and CN1 activity, separately for men and women. To investigate the intra-
individual  variation of CN1 content and activity over a 6-month period, the intraclass 
coefficient (single measures) was calculated for control subjects only. A two-sided 
independent-samples T-test was performed to compare CN1 content and activity 
between men and women at baseline. A linear regression analysis was performed to 
study the relationship between CN1 content/activity (independent variable) and  glycemic 
control (HbA1c), the lipid profile (triglycerides, total cholesterol, HDL, LDL and the ratio 
total cholesterol/HDL) and blood pressure (SBP and DBP) (dependent variables). In this 
model, age and sex were taken as covariates and the natural logarithm of CN1content 
and activity was used because 1) the independent variables (CN1 content and activity) 
were skewly distributed and 2) the curve estimation between the independent and 
dependent variables showed a logarithmic function, rather than a linear function. The 
beta-coefficients are reported. Finally, the effect of a 6-month aerobic, resistance or 
combined exercise training on CN1 content and activity was investigated by a linear 
mixed model design, adjusted by gender, age and BMI. All analyses, except for the linear 
mixed model design, were done with SPSS statistical software (SPSS 20, Chicago, IL) and 
statistical significance was set at p<0.05.  
 
  
 RESULTS
CN1 in healthy versus T2D subjects 
CN1 content
levels (~28%) than 
pattern between populations. In healthy subjects, 
men, but this difference disappears in type 2 diabetic patients. Moreover, CN1 activity 
levels are significantly lower in type 2 diabetic patients ver
more pronounced in the women (
consequence, 
healthy subjects and more pronounced in diabetic women (
13%). Moreover, CN1 specific activity is equal between sexes in healthy subjects, but is 
lower in women than in men for the diabetic patients (figure 1C). 
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Both populations demonstrate a low, but highly significant, correlation between CN1 
content and activity at baseline (healthy subjects: r=0.464, p<0.001; T2D patients: r=0.222, 
p=0.001) (figure 2). When analyzing the data according to sex, this correlation is similar in 
healthy and diabetic women (healthy women: r=0.305, p=0.020; T2D women: r=0.345, 
p=0.001) and healthy men (r=0.469, p<0.001), but the correlation disappears in diabetic 
men (r=0.149, p=0.067).  
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Figure 2. 2A represents the correlation between CN1 content and CN1 activity at baseline for all type 2 diabetic patients 
(trendline is given), 2B and 2C show the intra-individual variation for respectively CN1 content and CN1 activity over a 6-
month period for control subjects only (line of identity is given). Significance level was set at p<0.05. 
Influence of age, glycemic control and exercise training on CN1 in T2D patients. 
Figure 3 represents CN1 content and activity according to age. Here, only correlations are 
made for the diabetic population as the healthy subjects are all from the same age. In 
diabetic patients, CN1 protein content is negatively correlated with age in women (r=-210; 
p=0.049) (figure 3B), but not in men (r=-0.122, p=0.132) (figure 3A). CN1 activity is 
negatively correlated with age, for both men (r=-0.186; p=0.022) and women separately 
(r=0.273; p=0.011) (figure 3C and 3D). There is no correlation between HbA1c and CN1 
protein content or activity in patients with diabetes type 2 (table 2).  
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Figure 3. CN1 content (3A and 3B) and activity (3C and 3D) are presented in relation to the age of the subjects, which 
are shown separately for men (3A and 3C) vs women (3B and 3D) and healthy vs type 2 diabetes (T2D). Significant 
correlations are given with trendline. Significance level was set at p< 0.05. 
 
  CN1 content CN1 activity 
Beta-
coefficient 
p- 
value 
Beta-
coefficient 
p- 
value 
Glycemic control   
HbA1c 0,036 0,596 -0,007 0,920 
Lipid profile   
Triglycerides 0,131 0,055 0,046 0,485 
Total cholesterol 0,056 0,412 0,097 0,145 
HDL -0,153 0,020 0,131 0,038 
LDL 0,027 0,706 0,278 0,782 
Total cholesterol/HDL 0,182 0,007 -0,039 0,555 
Blood pressure   
BPS -0,039 0,563 0,085 0,190 
BPD -0,097 0,146 0,005 0,937 
  
Table 2. Correlations between CN1 content and activity (taken as natural logarithm) and glycemic control, lipid profile 
and blood pressure, adjusted for age and sex (baseline measurements). Beta-coefficients and p-values are given. 
Significance level was set at p<0.05. 
The effect of a 6-month exercise intervention on CN1 could be investigated. Table 3 
provides the changes in CN1 protein content and activity, by time and exercise training 
for 6 months, and adjusted by age, gender and BMI. Neither CN1 protein content, nor 
CN1 activity was influenced by a 6-month exercise program, irrespectively the type of 
exercise (neither aerobic or resistance exercise alone, nor the combination of both types).  
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Baseline 6 Month 6 Months - Baseline 
N Mean SE N Mean SE Adjusted Mean Lower CI Upper CI P-value 
Mixed models for CN1 content (expressed as µg/ml) 
Control 61 69.07 3.80 59 71.45 4.02 2.32 -1.15 5.79 0.19 
Aerobic 59 67.74 3.83 49 69.14 4.04 1.41 -2.44 5.25 0.47 
Resistance 62 70.31 3.79 55 72.73 4.05 2.32 -1.33 5.97 0.21 
Combined 59 66.95 3.65 57 66.78 3.72 -0.17 -3.88 3.53 0.93 
6 Months - Baseline:       Difference Lower CI Upper CI P-value 
Aerobic vs Control       -0.91 -6.08 4.25 0.73 
Resistance vs Control       0.00 -5.04 5.03 1.00 
Combined vs Control       -2.50 -7.57 2.57 0.33 
Mixed models for CN1 activty (expressed as µmol/ml/h) 
Control 61 4.25 0.15 58 4.40 0.17 0.15 -0.15 0.46 0.32 
Aerobic 57 4.26 0.15 48 4.44 0.19 0.19 -0.15 0.52 0.27 
Resistance 62 4.54 0.15 54 4.62 0.18 0.07 -0.24 0.39 0.64 
Combined 59 4.38 0.15 56 4.27 0.17 -0.11 -0.42 0.21 0.50 
6 Months - Baseline:       Difference Lower CI Upper CI P-value 
Aerobic vs Control       0.03 -0.42 0.48 0.88 
Resistance vs Control       -0.08 -0.51 0.36 0.73 
Combined vs Control       -0.26 -0.70 0.18 0.24 
 
Table 3. Changes in CN1 protein content and activity, by time and exercise training for 6 months. Results are estimated 
means from linear mixed-effects models, adjusted for age, gender and BMI. Significance level was set at p<0.05. 
The pre-post samples of the non-exercise control group demonstrate a good test-retest 
for CN1 (figure 2B and 2C). The intraclass correlation coefficient (ICC) for CN1 content and 
activity over a 6-month period in the sedentary diabetic-control group was 0.914 
(p=0.000) and 0.625 (p=0.000), respectively, demonstrating an excellent stability for CN1 
content, but only a moderate stability for CN1 activity. 
CN1, lipid profile and blood pressure in T2D patients (table 2) 
Concerning the lipid profile, the ratio of total cholesterol/HDL was positively correlated 
with CN1 content (p<0.01). Although the relationship was significant in a linear regression 
as well (r=0.167, p=0.012), a logarithmic function better met the model (r=0.182, 
p=0.007). CN1 activity on the other hand, was not associated with the ratio total 
cholesterol/HDL. In addition, HDL alone was negatively correlated with CN1 protein 
content (r=-0.153, p=0.020), but positively with CN1 activity (r=0.131, p=0.038). 
Interestingly, these effects appear to be sex-specific as the correlations are 
predominantly present for men (CN1 content: total cholesterol/HDL: r=0.239, p=0.002; 
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HDL: r=-0.168, p=0.039) (CN1 activity: HDL: r=0.271, p=0.001), but not for women. Finally, 
blood pressure and CN1 protein content or activity were not correlated with each other.  
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DISCUSSION 
CN1 in healthy versus T2D subjects 
It was hypothesized that T2D patients have higher CN1 levels (both content and activity) 
compared to healthy subjects. This assumption was based on the study of Riedl et al. 
(2010), who demonstrated that N-glycosylation increases CN1 content and activity in Cos-
7 cells. Moreover, they hypothesized that hyperglycemia increases N-glycosylation and 
thus increases CN1 activity as well, which was confirmed in a small sample of type 1 and 2 
diabetic patients compared to healthy subjects.  
This study provides evidence that T2D patients are not characterized by elevated CN1 
levels.  First, no correlation is present between HbA1c and CN1 (content and activity) in 
diabetic type 2 patients. Second, CN1 content is similar between populations, and CN1 
activity is even significantly lower in T2D patients compared to healthy subjects. 
Moreover, this effect is more pronounced in diabetic women than in men, resulting in a 
disappearance of the sex difference in CN1 activity which is usually present in healthy 
subjects. As consequence, CN1 specific activity is lower for T2D patients, and here as well 
more pronounced in diabetic women (-32%) than in men (-13%). The ‘specific’ activity is 
the activity of an enzyme per milligram of total protein (expressed in μmol/min/mg) and 
is a measure of enzyme quality. Alteration of normal enzyme function is indeed one of the 
side-effects of chronic hyperglycemia (Brownlee 2005). As mentioned in the introduction, 
N-glycosylation was hypothesized to increase CN1 activity, however it is also known that 
glycation (non-enzymatic glycosylation) has detrimental effects on proteins (and thus also 
enzyme activity) by disrupting molecular conformation, possibly partly explaining the 
observed decrease in specific activity (Aronson 2008). The observed decrease in CN1 
activity in a diabetic population compared to healthy controls could be interpreted as 
protective because of higher bioavailability of CN1 substrates, carnosine and anserine. 
Indeed, we have demonstrated in the introduction that a polymorphism in the serum 
carnosinase gene (CNDP1), encoding for low CN1 activity, is associated with reduced risk 
of diabetic nephropathy (Janssen 2005; Zhu 2013).  
We suggest that this observation is specific for a diabetic population, but caution is 
warranted as the age range was different between the two populations. However, to our 
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opinion this age difference does not explain a decrease in CN1 as no (or a slight) increase 
was reported previously in literature from the age of 20 years until the age of 50 years 
(Lenney 1982; Peters 2010). Moreover, the observed decrease in CN1 activity with age in 
T2D patients (age range: 39 – 70 yrs) is perhaps an epiphenomenon of increased duration 
of diabetes (data lacking).  
It was previously reported that CN1 activity is greatly determined by its content in healthy 
adult individuals as demonstrated by Adelman et al. (r=0.79) and Everaert et al. (r=0.58). 
However, this study demonstrates lower correlations in both populations. Healthy and 
diabetic women and healthy men display similar correlations (respectively r=0.305 with 
p=0.020, r=0.345 with p=0.001 and r=0.469 with p<0.001), whereas a dissociation 
between content and activity is present in diabetic men (r=0.149, p=0.067). Clearly, the 
correlation between CN1 activity and CN1 content is not so strong as it was previously 
presented, especially in the diabetic men. Therefore, it is necessary to further search for 
factors that specifically influence CN1 activity (without a change in CN1 content). For the 
moment, only two possibilities have been suggested; allosteric conformations of CN1 in 
children and adults (Peters 2010) and competitive inhibition by homocarnosine and 
anserine (Peters 2011b). 
Effect exercise training on CN1 in T2D patients 
We hypothesized that exercise training (aerobic, resistance or combined exercise) would 
suppress CN1 content and activity, but this could not be confirmed. The hypothesis was 
based on 2 observations. First, Baguet et al. (2014) reported lower CN1 levels (both 
content and activity) in elite athletes, involved in high-intensity exercise, compared to 
untrained controls (data own lab). Second, Riedl et al. (2010) showed elevated CN1 
activity levels in diabetic patients, suggesting that exercise training, aiming for 
ameliorating insulin sensitivity and thereby lowering hyperglycemia, decreases CN1 
activity levels. Concerning the latter, we have now demonstrated that T2D patients are 
not characterized by higher CN1 activity levels and therefore it is a rather logical 
consequence that lowering hyperglycemia (through exercise) has no effect. Nevertheless, 
we can exclude that exercise training (according to either one of the two theories) lowers 
CN1 activity.  
SERUM CARNOSINASE IN DIABETES TYPE 2 
 
171 
Low CN1 content/activity associated with lipid profile and blood pressure?  
Several studies have recently brought the attention to the protective effect of carnosine 
administration on dyslipidemia (lipid profile in plasma (Aldini 2011; Mong 2011), 
cholesterol levels in heart and liver (Lee 2005; Mong 2011), atherosclerosis (Menini 2012)) 
and blood pressure (Aldini 2011) in rodents. Our hypothesis that diabetic patients with 
the lowest CN1 levels, should have the highest circulating carnosine levels upon dietary 
ingestion and therefore should have the most healthy lipid profile, could not be 
convincingly accepted. Low CN1 content is associated with high HDL levels (p=0.020) and 
a low ratio total cholesterol/HDL (p=0.007), which indeed confirms our hypothesis, since 
both associations represent a beneficial lipid profile. When both sexes are analyzed 
separately, this pattern remains present in the men (HDL: B=-0.168, p=0.039; total 
cholesterol/HDL: B= 0.239, p=0.002), but not significantly in women (HDL: B=-0.119, 
p=0.265; total cholesterol/HDL: B=0.092, p=0.402). Yet, when looking at CN1 activity, our 
hypothesis must be rejected. Only HDL is significantly correlated with CN1 activity, 
although in the opposite way (B=0.131, p=0.038) and only in the men (B=0.271, p=0.001). 
As already mentioned above, there appears to be a dissociation between CN1 activity and 
CN1 content in diabetic type 2 patients, predominantly in the men. 
Mong et al. (2011) is the first in providing an explanation for this possible lipid lowering 
effect. His group demonstrated that carnosine supplementation markedly lowered lipid 
accumulation in circulation, liver and adipose tissue in high fat diet mice via diminishing 
the mRNA expression of sterol regulatory element binding proteins (SREBPs). SREBPs are 
important transcription factors responsible for fatty acid and cholesterol metabolism 
(Shimano 1999), in which SREBP-1c is more effective in modulating the expression of 
genes involved in fatty acid synthesis, whereas SREBP-2 is more predominant in 
mediating genes associated with cholesterol synthesis (Shimomura 1997; Horton 1998). 
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Conclusion 
To summarize, we provided evidence that diabetic patients are not characterized by 
elevated CN1 levels. While CN1 content was equal between healthy subjects and T2D 
patients, CN1 activity was even lowered in T2D patients. Moreover, there was no 
relationship between CN1 (content and activity) and HbA1c in diabetic patients, as 
consequence a 6-month exercise program, aiming to lower HbA1c, could not suppress 
CN1. Finally, CN1 content and activity have contrasting associations with markers of 
dyslipidemia.  
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1. CARNOSINE-CARNOSINASE SYSTEM IN A DIABETIC STATE 
From literature it was suggested that both muscle carnosine content and serum 
carnosinase (CN1) are possibly altered in a diabetic state. In this first chapter we will 
provide an answer based on studies 1, 3, 4 and 5.  
1.1. Diabetes associated changes in muscle carnosine content 
In part I, it was suggested that carnosine levels in tissues are possibly decreased in a 
diabetic state. Some rodent studies demonstrate a decrease in diabetic liver, retina and 
kidneys, however these findings are not confirmed by others (they demonstrated a 
decrease, although not significantly) (Riedl 2011; Pfister 2011; Mong 2011). Concerning 
carnosine content in skeletal muscle, only two studies exist and they are contradictive 
(Gualano et al. reporting a decrease and Skrikanthan et al. reporting a increase). The 
working hypothesis behind this ‘possible’ decrease is the fact that carnosine can quench 
RCS (Aldini 2011), possibly followed by a clearance from the muscle as hypothesized by 
Hipkiss and coworkers (Hipkiss 2000a).  
In study 4 we provided evidence that muscle HCDs increase with progressive glucose 
tolerance, which was demonstrated by both an interventional study (in rodents) and a 
cross-sectional study (in humans). In the rodent study, muscle carnosine increased with 
~30% in the most drastic overfed, glucose-intolerant rodent model (high-fat diet 
compared to control diet) (p<0.05). Anserine was not significantly increased (+16%), but 
the total amount of HCD tended to increase (+21%, p<0.1). In the human study, muscle 
carnosine of prediabetic and diabetic type 2 patients increased with 30% (p<0.05) and 39% 
(p<0.05), respectively, compared to the healthy lean subjects.   
However, we cannot deny the data of Gualano et al. (2012) (a joint project) reporting a 45% 
decrease in gastrocnemius muscle of type 2 diabetic patients compared to healthy 
controls. Therefore, we here provide a working model with diabetes-related factors 
possibly influencing baseline muscle carnosine content, as presented in figure 1. Chapter 
1.1.1. will focus on diabetes-related factors explaining a possible decrease in muscle 
carnosine content, whereas chapter 1.1.2. will focus on the factors explaining a possible 
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Interestingly, Baba et al. (2013) confirmed very recently the presence of these Carn-HNE 
adducts in skeletal muscle of C57BL/6 mice. Moreover, they showed for the first time that 
these adducts, a.k.a. carnosine propanals, have still some reactive activities but that these 
propanals are in a next step reduced (detoxified) by aldose reductase, forming carnosine 
propanols. These species carry no reactive properties any longer.  
However, a crucial link is still missing. How are these adducts actually cleared from the 
skeletal muscle? Up to now, there is still no evidence for a regulated degradation 
mechanism, except for the theory of Hipkiss et al. (2000), which hypothesizes proteolysis 
of carnosine-protein-carbonyl adducts (carnosinylated proteins) (figure 10, part I), 
however there is no clear evidence provided to support such a mechanism. 
In this work, we could confirm the ability of carnosine to quench RCS such as HNE in 
urine and plasma of high-fat diet rats. In addition, these adducts are recently confirmed 
in skeletal muscle. However, up to now, no evidence exists for a possible degradation 
pathway of these adducts.  
1.1.1.2. Insulin resistance  
Skeletal muscle insulin resistance is a typical characteristic for diabetes type 2 (DeFronzo 
1991; Kruszynska 1996; Kahn 2003; DeFronzo 2009), but it plays also a role in type 1 
diabetes disease more than is commonly recognized (DeFronzo 1982; Bergman 2012; 
Donga 2013). 
In study 1 we demonstrated that meal and beta-alanine co-ingestion stimulates muscle 
carnosine loading, suggesting that insulin plays a role. Although this study was more 
designed to study the ‘loading’ aspect, this mechanism can probably also affect baseline 
levels. First, we will discuss our results from the loading study (study 1), to extrapolate 
these data thereafter to baseline carnosine levels in a diabetic state.  
The way how insulin increases muscle carnosine loading can be explained by two possible 
mechanisms. First, it has been shown that insulin stimulates the Na+/K+ pump in skeletal 
muscle, which increases extracellular Na+ availability in circulation (Clausen 2003). In turn, 
increased extracellular Na+ availability stimulates the sodium dependent beta-alanine 
transporter TauT. So, it is likely that stimulating TauT (by meal) at the moment of beta-
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2001; Clausen 2003; Galuska 2009), which is unfavorable for the sodium-dependent beta-
alanine transporter TauT and thus beta-alanine uptake can be declined. Second, insulin 
resistant patients are characterized by lower muscle capillary density (Lillioja 1987; Marin 
1994; Rattigan 2007), which decreases beta-alanine availability for the muscle, again 
possibly blunting beta-alanine uptake. Off course, it can be questioned whether these 
factors play a role in situations where no beta-alanine is exogenously obtained (as in our 
rodent models, study 4). 
Conclusion: We demonstrated in study 1 that meal and beta-alanine co-ingestion 
enhances muscle carnosine loading, suggesting that insulin plays a role. Extrapolating 
these data to non-loading conditions, insulin resistance could have a lowering effect on 
baseline levels.  
1.1.1.3. Decreased physical activity  
Diabetic patients are often (not always) characterized by a sedentary lifestyle (Myers 
2003; Hu 2003). The way how decreased physical activity can possibly lower muscle 
carnosine content is actually closely related to the previous factor (insulin resistance), as 
these factors share similar mechanisms. Na+/K+ pump activity and muscle blood flow are 
influenced by both insulin and contraction (Benziane 2008), like it is also the case for the 
glucose transporter GLUT4. Contraction (acute) and chronic exercise can respectively 
acutely and chronically increase muscle blood flow. In addition, contraction stimulates 
the Na+/K+ ATPase activity in skeletal muscle, independently from insulin stimulation 
(Benziane 2008). 
In line with this, our own lab recently demonstrated that carnosine loading is more 
pronounced in trained versus untrained muscles of athletes (Bex 2013). Muscle carnosine 
loading was compared between the arms and the legs of kayakers (predominantly using 
their arms) and cyclists (predominantly using their legs). Muscle carnosine loading was 80% 
higher in the arms of the kayakers than in the legs, and the other way around, loading 
was higher in the legs than in the arms of the cyclers.  
Similar as above, we can question whether this factor can contribute in a situation where 
no exogenous beta-alanine is taken (as in study 4).  
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Nevertheless, we can conclude that fiber type can explain an increase in muscle carnosine 
in obese and diabetic individuals, but it is questionable whether this was responsible for 
an increase in our high-fat rodent models (study 4).  
1.1.2.2. Mitochondrial dysfunction  
It became clear from study 1 that during beta-alanine supplementation, the major part (> 
90%) is oxidized/metabolized in the body. There are some indications that the 
mitochondrial enzymes ‘malonic semialdehyde dehydrogenase, MSAD’ and ‘beta-alanine 
transaminase, ABAT’ are taking part in the oxidation of beta-alanine (Pollitt 1985; 
Everaert 2013). In addition, Lefort et al. (2010) has shown that single mitochondria, 
isolated from skeletal muscle in obese patients, have lower amino acid-metabolizing 
enzymes such as MSAD (Lefort 2010). Moreover, Pollitt et al. reported that a deficiency in 
MSAD results in excessive excretion of beta-alanine (Pollitt 1985). If this would be similar 
with beta-alanine in skeletal muscle, more beta-alanine would be available in skeletal 
muscle to be converted to carnosine/anserine.  
1.1.2.3. Sacrificial dipeptide  
Strangely enough, investigating the ‘sacrificial theory’ from another perspective can lead 
to an increase of tissue carnosine rather than a decrease. As mentioned above Baba et al. 
(2013) published very recently a crucial paper, by demonstrating that carnosine-
propanals (these are adducts of carnosine with reactive carbonyl species such as HNE and 
acrolein) are reduced/detoxified by the enzyme aldose reductase (AR) to carnosine-
propanols (Baba 2013). In addition, AR-null mice (mice lacking the enzyme AR) had higher 
levels of carnosine-propanals in skeletal muscle because these conjugates were not 
reduced. Interestingly, in hyperglycemic conditions, the enzyme aldose reductase is 
predominantly used to eliminate the excess of glucose, resulting in less availability of AR 
for reducing the carnosine-propanals, and thus an accumulation of these conjugates.  
On the other hand, it can be also argued that the sacrificial theory has no effect at all, 
because 1) no degradation pathway for these carnosine conjugates is established, 2) the 
total amount of carnosine, carnosine-propanals and carnosine-propanols probably does 
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not change and 3) the methods measuring carnosine (HPLC and 1H-MRS) probably detect 
all forms.  
1.1.2.4. Increased plasma beta-alanine availability  
Very recently Zhou et al. (2013) evaluated plasma amino acid differences between 
healthy individuals (lean and obese) and diabetic type 2 individuals (lean and obese)(Zhou 
2013). In general, fasting plasma beta-alanine was 18% higher in diabetic group (25 µM/l) 
compared to the control group (21.1µM). Interestingly, the biggest difference was found 
between the lean healthy (16.9 µM/l) and the lean diabetic (24.8 µM) subjects, whereas 
the difference was less pronounced between the healthy obese (22.2 µM/l) and diabetic 
obese (25.1 µM/l) subjects, suggesting that diabetes rather than obesity is responsible for 
this increase.  
Comparing these results to our own data from study 1 in which plasma beta-alanine was 
followed throughout the day in 4 subjects, it is remarkable that Zhou and colleagues 
found relatively high fasting plasma beta-alanine levels in all subjects, whereas we could 
often not detect beta-alanine in fasted state (detection limit: 7 µM).  
1.1.2.5. Endogenous compensation 
In general, the body is equipped with several endogenous protective systems, activated 
once homeostasis in the normal healthy body is disturbed (principle of pursuing 
homeostasis). For example, in response to the supplementary production of ROS during 
exercise, the antioxidant system will be activated, resulting in an improved antioxidant 
status of the individual (Liu 2000; Finaud 2006).  
Related to this work, it could be possible that a kind of compensation mechanism is 
activated by factors responsible for a decrease in muscle carnosine (decreased Na+/K+ 
pump activity, decreased muscle blood flow, the quenching of increased ROS,…). A 
compensation mechanism regarding muscle carnosine synthase has been demonstrated 
by our own lab (Everaert 2013). Muscle carnosine decreased (-47%) after orchidectomy in 
mice, whereby a compensatory increase in carnosine synthase mRNA levels (a 2-fold) 
occurred. 
  
188 
PART III: GENERAL DISCUSSION
 
1.1.3.
In study 4
sectional), that muscle HCDs increase with progress
cannot deny the data of Gualano et al. 
gastrocnemius muscle of type 2 diabetic patients compared to healthy controls. 
different 
be expla
slightly insulin resistant and 
only. On the other hand,
hypoglycemic medication, which is 
subjects. 
muscle carnosine
minor importance. Perhaps, 
determining muscle carnosine content in a diabetic state) 
Therefore, we provided a work
balance between diabetes
responsible for a decrease
muscle carnosine will be 
 
 
 Conclusion: the balance between decreasing and increasing factors 
 we could demonstrate, both in rodents (interventional) and in humans (cross
conclusions
ined by a di
Thus, it is possible that
) 
 
 between our data and 
fference in diabetes
our
 the
was not yet
-related 
. D
increased, decreased or remain equal.
 
(2012) 
 T2D patients
 T2D patients
a pha
 insulin resistance 
 very prominent in our 
insulin resistanc
ing model that muscle carnosine in a diabetic state is a 
factors responsible for an increase and factors 
epending on the factors dominating in a specific situation, 
(a joint project) reporting a 45% decrease in 
the data of Gualano et al. (2012)
-stage. The animals tested in study 4 were only 
 were mild diabetic as they were diet
 of Gualano et al. 
se further in diabetes disease compared to 
e can become a more dominant factor
ive glucose intolerance. 
(a factor responsible for 
T2D patients
in more severe diabetes.
(2012
 and thus a factor of 
 
 
However
 can possibly 
-treated 
) were on oral 
decreas
 
-
, we 
The 
our 
ing 
 (in 
  PART III: GENERAL DISCUSSION 
 
189 
1.2. Serum carnosinase in a diabetic population  
In the introduction (part I) it was suggested that CN1 may play a role in the development 
of diabetes or diabetes-related complications (Janssen 2005; Sauerhofer 2007; Riedl 
2010). Briefly, low CN1 is assumed to be protective because the bioavailability of its 
substrates carnosine and anserine in circulation would be higher, as they would be less 
rapidly hydrolyzed by CN1. Thus, more protection against ROS, RCS, AGEs and ALEs can be 
provided by carnosine and anserine, resulting in a decreased risk of diabetic related 
complications.  
In relation to diabetes, it is speculated that hyperglycemia increases CN1 content and 
activity. Riedl et al. (2010) demonstrated in transfected cells that N-glycosylation is an 
important determinant for CN1 content and activity. The authors further extrapolated 
this observation to the assumption that hyperglycemia would increase CN1 activity, by 
inducing N-glycosylation (see working mechanism in part I). Indeed, their hypothesis was 
confirmed as they demonstrated that 11 diabetic patients with the 5-5 genotype had ~25% 
higher CN1 activity levels compared to 15 homozygous healthy controls. From the data 
above, we expected to see a positive correlation between HbA1c (a marker of 
hyperglycemia over the past 2-3 months) and CN1 content/activity in a large cohort of 
diabetic type 2 patients (study 5), but this expectation was not fulfilled (figure 6).  
 
Figure 6. The correlation between HbA1c and CN1 content (A) and CN1 activity (B). No significant correlations are 
reported.  
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Moreover, a comparison was also made with a healthy control group. CN1 content was 
similar between populations and CN1 activity was even significantly lower in type 2 
diabetic patients compared to healthy subjects. As consequence, CN1 specific activity is 
lower for diabetic type 2 patients. Therefore, we suggested in study 5 that CN1 activity in 
a diabetic state is probably not only influenced by N-glycosylation (stimulating CN1 
activity) (Riedl 2010), but also by glycation (decreasing CN1 activity by molecular 
disruption). Glycation of enzymes, leading to decreased activity, has already been 
reported previously (Beranek 2001; Bousova 2005a; Bousova 2005b; Aronson 2008).   
Caution remains warranted as the control group is not matched for CTG genotype, age 
and BMI. To our opinion the age difference can not be responsible for a difference 
between populations as no (or a slight) increase was reported previously in healthy 
subjects from the age of 20 years until the age of 50 years. The observed decrease in CN1 
activity with age in diabetic type 2 patients (age range: 39 – 70 years) is perhaps an 
epiphenomenon of increased duration of diabetes (data lacking). Nevertheless, a 
comparison with a correct healthy control group is necessary.  
In a next step, we explored whether CN1 is stable over time (6-months) and whether 
exercise training (endurance, resistance or the combination), aiming for decreasing HbA1c, 
influences CN1. When looking at the intraclass correlation coefficients for CN1 content 
and activity over a 6-month period in the diabetic control group (non-exercise), these 
were respectively 0.914 (p<0.001) and 0.625 (p<0.001), demonstrating an excellent 
stability for CN1 content, but a rather moderate stability for CN1 activity. In addition, 
irrespectively the kind of exercise program followed, CN1 activity and content did not 
significantly change, although the HbA1c significantly decreased with 0.90%, 0.43%, 0.30% 
in the respectively exercise groups: combined, aerobic or resistance exercise training. 
However, the absence of an exercise effect is not surprising as we demonstrated that 
diabetic patients do not have elevated CN1 levels.  
Finally, we hypothesized that diabetic patients with low CN1 levels, should have the most 
healthy lipid profile. This hypothesis was based on the theory that individuals with low 
CN1 levels should have the highest circulating carnosine levels upon dietary ingestion, 
and thus more carnosine would be available in plasma to exert its lipid-lowering effects 
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(part I). However, our hypothesis could not be accepted. Only in the men, CN1 content 
was negatively correlated with HDL (p=0.039) and positively with the ratio total 
cholesterol/HDL (p=0.002), which indeed confirmed our hypothesis. However, 
correlations were the other way around for CN1 activity. Nevertheless, future research 
must incorporate lipid-lowering medication (if taken) into the analysis, as this can be a 
disturbing factor.  
To summarize, we hypothesized that exercise training or a better glycemic control could 
suppress elevated CN1 levels possibly present in diabetic patients. However, we 
provided evidence that diabetic patients are not characterized by elevated CN1 levels. 
While CN1 content was equal between healthy subjects and T2D patients, CN1 activity 
was even lower in T2D patients. Moreover, there was no relationship between CN1 
(content and activity) and HbA1c in T2D patients. In addition, CN1 content and activity 
are stable over a 6-month period and not influenced by chronic exercise training. And 
finally, CN1 content and activity have contrasting associations with markers of 
dyslipidemia. 
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2. NET MUSCLE CARNOSINE TURNOVER FROM A BROADER PERSPECTIVE.  
In this chapter, net muscle carnosine turnover is observed from a broader perspective 
and discussed for four different phases: muscle carnosine at baseline, during loading, 
washout and maintenance. 
2.1. Net muscle carnosine turnover at baseline 
As discussed in study 2 (part II), net muscle carnosine turnover is a balance between 
carnosine synthesis and degradation. At baseline, muscle carnosine synthesis and 
degradation are in a steady equilibrium and predominantly determined by fiber type, age 
and sex. The role of dietary beta-alanine intake (by meat and fish intake) is up to now not 
really clear. As we demonstrated in this work, a diabetic state can change this steady 
equilibrium (chapter I, part III).  
2.2. Net muscle carnosine turnover during loading 
During beta-alanine supplementation (loading), carnosine synthesis will be elevated 
because of increased precursor availability and thus net turnover will be strongly positive. 
There is a large inter-individual variability concerning this loading efficiency, which is 
demonstrated in study 1. The highest increase (3.27 mM) was 8 times higher than the 
lowest increase (0.40 mM) after a supplementation period of 3.2 gr beta-alanine per day 
for 6-7 weeks.  
Study 1 and 2 searched for determinants of muscle carnosine loading. Only 1 significant 
determinant was found, i.e. meal timing. Taking beta-alanine at the start of the meal 
results in a higher absolute (0.58 mM) and relative (23%) increase compared to taking 
beta-alanine in between the meals in soleus muscle. On the other hand, muscle fiber type, 
gender, supplementation form, body weight, fat-free mass and baseline carnosine 
content did not influence the absolute increase. It remains however to be determined 
whether the higher relative increases in women and lighter individuals, which are actually 
a consequence of the fact that these individuals start with lower baseline levels, are 
relevant from a practical point of view. As discussed in paper 2, it has already been 
reported that there is a correlation between the relative change in carnosine and 
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performance enhancement, but perhaps this observation is secondary to or a result of an 
absolute increase in muscle carnosine.  
Very recently, our own lab found that carnosine loading is more pronounced in trained 
versus untrained muscles (Bex 2013), which appears to be the most dominant 
determinant. For example, arm muscles (m. deltoideus) from kayakers had a 80% higher 
absolute increase than the leg muscles (m. soleus + m. gastrocnemius) after a 
supplementation period of 6.4g beta-alanine per day for 3 weeks, whereas the opposite 
pattern was observed in the cyclists. As said, this difference can be attributed to an 
acute/chronic increase in blood flow, acute/chronic adaptation of transporters and 
enzymes involved in carnosine synthesis and acute/chronic increase in Na+/K+ pump 
activity. In line with this, it can be assumed that muscle carnosine loading would be less 
efficient in sedentary and unfit diabetic individuals, exhibiting decreased muscle blood 
flow and Na+/K+ pump activity (cfr supra).  
Although the different loading protocols (discussed in study 1 and 2) have proven their 
ergogenic relevance, caution must remain present as the majority (> 90%) of the ingested 
beta-alanine has an unknown metabolic fate. We have demonstrated in study 1 that only 
~3% of chronically ingested beta-alanine is incorporated into muscle carnosine and only a 
similar amount is lost through urinary excretion. When comparing this efficiency to the 
efficiently of creatine supplementation, another popular nutritional supplement, this is 
very low (figure 7). Figure 7 compares the efficiency of beta-alanine and creatine 
supplementation, each with and without coingestion of macronutrients (MN). 
Notwithstanding the fact that the accumulation efficiency is higher when beta-alanine is 
ingested with a meal (~20% higher) compared to ingestion in between the meals and the 
fact that trained muscle are more efficient than untrained muscles (~80% higher), the % 
ingested beta-alanine accumulated in skeletal muscle remains remarkably low (figure 7). 
Therefore, the question raises ‘where does all the beta-alanine go?’ Two possibilities can 
be put forward.  
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Figure 7. Comparison of the destination of chronic beta-alanine supplementation (with ‘+MN’ or without ‘- MN’ 
macronutrients) with the destination of chronic creatine supplementation (- MN and + MN). * p<0.05, a significance 
increase in muscle accumulation +MN vs –MN. (Steenge 2000) 
First, beta-alanine can be converted into carnosine in other (non-muscle) tissues. 
However, as the presence of carnosine and carnosine synthase in non-muscle tissues is 
much lower than in muscle, this pathway has probably little quantitative significance. 
Therefore, a major part of the ingested beta-alanine is likely metabolized somewhere else 
(second possibility). ABAT (beta-alanine transaminase, also known as 4-aminobutyrate 
aminotransferase) is an important enzyme in the oxidation of beta-alanine. It can convert 
beta-alanine into malonate semi-aldehyde, which be decarboxylated to acetaldehyde and 
further converted to acetyl-CoA, to finally enter the citric acid cycle. De Biase et al. (1995) 
demonstrated that the expression of ABAT is predominantly present in liver, but high 
amounts are also present in pancreas, brain and kidney in human tissues (De Biase 1995). 
Our lab recently focused on this enzyme in skeletal muscle and demonstrated its mRNA 
expression in rodent skeletal muscle and showed an upregulation upon beta-alanine 
supplementation (Everaert 2013). It remains to be determined to what extend ABAT can 
contribute to the ‘unknown metabolic fate’, and whether or not other enzymes are 
involved.  
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2.3. Net muscle carnosine turnover during wash-out and maintenance 
When daily beta-alanine intake over a prolonged period (loading) is terminated, a slow 
degradation process takes place, reaching pre-supplementation levels in 6-20 weeks 
(Baguet 2009; Stellingwerff 2012). This wash-out can be attributed to an increased 
elimination rate, induced by increased muscle carnosine levels through prolonged 
supplementation (calculated from Hill 2007b, discussion study 2). 
Therefore, to keep muscle carnosine at a constant elevated level a maintenance dose is 
recommended to counteract the increased elimination rate. Study 2 is the first study in 
establishing a suitable maintenance dose of ~1.2g beta-alanine/day to keep muscle 
carnosine content elevated at 30-50% above baseline. Taking together the current 
knowledge, athletes must be advised to phase their beta-alanine intake towards the 
competition as represented in figure 8.  
 
 
Figure 8. Current advice of beta-alanine supplementation prior to peak performance or competition period.  
Although it can be argued why athletes would not continue to take a loading dose on the 
off-chance that carnosine levels continue to increase, we would currently disadvise non-
stop supplementation because of the following arguments: 1) physiological effects of 
long-term supplementation (> 12 w) with high doses are unknown, 2) we must keep in 
mind that 90% of ingested beta-alanine is unaccounted for and 3) no data exists about 
the acute effects of high doses of beta-alanine on performance (negative or positive).  
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// //
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3. EFFECTS OF CARNOSINE SUPPLEMENTATION  
3.1. Site of action: systemic effect or tissue effect 
As said in the introduction, the role of carnosine must be explored from two approaches. 
The first one, investigating the endogenous carnosine-carnosinase system in a diabetic 
setting, is discussed in chapter 1 from the general discussion. The second one, 
investigating the effect of artificially increasing plasma or tissue carnosine, will be handled 
in this chapter.  
In study 3, the role of carnosine was investigated by raising plasma and muscle carnosine 
(through carnosine supplementation) or by raising muscle carnosine alone (through beta-
alanine supplementation) in a very mild high-fat diet rat model. Our design was 
innovative as it allowed us to assess carnosine’s site of action (plasma or tissue/muscle). 
In addition, using a more real-life model (high-fat diet), in contrast to the severe animal 
models used in the previous studies, made it possible to look at the effects of carnosine in 
the initial stage of metabolic disturbance. We could conclude that plasma carnosine, and 
not muscle carnosine, is involved in preventing early-stage metabolic stress in circulation 
and muscle. More specifically, carnosine supplementation (increasing both plasma and 
muscle carnosine) could reduce elevated plasma and urine CML (induced by high-fat diet) 
with ~50% and muscle iNOS mRNA with 47%, whereas beta-alanine supplementation 
(only increasing muscle carnosine) had no effects. The fact that only carnosine 
supplementation, and not beta-alanine, protected skeletal muscle from increased 
inflammatory signaling (although both groups equally increased muscle carnosine above 
normal levels), likely points to a systemic effect with skeletal muscle as a target organ.  
In figure 9, several possible pathways are represented by which systemic disturbances 
(diet-induced) can provoke metabolic changes in skeletal muscle. Study 3 demonstrated 
that elevated plasma carnosine attenuates inflammatory signaling in skeletal muscle, 
possibly through the AGE-RAGE pathway (marked by bold lines in figure 9). Plasma CML is 
one of the most important ligands for RAGE and this RAGE-AGE interaction triggers 
intracellular events increasing nuclear transcription factors such as nuclear factor- kappa 
B (NF-ĸB) (Kislinger 1999). The latter can increase the transcription of inflammatory 
products such as TNFα and iNOS (Kislinger 1999; Adams 2002), which is known to inhibit
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the insulin signaling pathway and thus insulin-induced glucose uptake in skeletal muscle 
(Uysal 1997; Perreault 2001; Yasukawa 2005; Plomgaard 2005; Carvalho-Filho 2006; 
Ropelle 2013). Hofmann et al. (2002) showed that reduced AGE intake leads to lower 
levels of circulating AGEs and to improved insulin sensitivity in db/db mice (Hofmann 
2002). The other way around, Cassese et al. (2008) demonstrated reduced insulin-induced 
glucose uptake and protein kinase B phosphorylation in skeletal muscle of C57/BL6 mice 
receiving a high AGEs diet (Cassese 2008).  
However, as presented in figure 9, this AGE-RAGE pathway is only a part of a more 
complex entity concerning skeletal muscle insulin resistance (Wei 2008; Abdul-Ghani 
2010; Kewalramani 2010). Indeed, chronic elevated circulating fatty acids can directly 
negatively affect metabolic pathways in skeletal muscle (figure 9). Fatty acids can enter 
the muscle fiber and create (in pathological circumstances) an overproduction of 
diacylglycerol (DAG) or ceramides. These metabolites are known to inhibit the insulin 
pathway. In addition, saturated fatty acids from the circulation can activate the toll-like 
receptor (TLR), which can activate inflammatory pathways (Tsukumo 2007; Martins 2012).  
Unfortunately, the 60% high-fat diet (study 3) was not drastic enough to significantly alter 
glucose tolerance (IVGTT) and glucose transport in skeletal muscle, therefore lacking a 
true end point of our observations. However, we observed that fasting plasma insulin was 
reduced by ~45% in the carnosine supplemented high-fat group compared to the high-fat 
group without supplementation, suggesting a better basal whole body insulin sensitivity.  
Does it mean that carnosine in skeletal muscle has no protective function? Probably, 
carnosine exerts its functions in muscle as well. It is possible that increasing muscle 
carnosine by beta-alanine supplementation has some protective effects on insulin 
signaling by quenching HNE, decreasing intramyocellular CML, increasing anti-oxidant 
capacity,… but we assume that additionally increasing plasma carnosine provides extra 
benefits by acting on two sites (systemic and local effects). 
Conclusion: Plasma carnosine and not muscle carnosine is involved in preventing early-
stage lipid-oxidation in circulation and inflammatory signaling in skeletal muscle.  
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3.2. Properties of the hydrolysis products of carnosine 
From the literature above, it can be concluded that the molecule carnosine carries many 
biochemical and physiological properties. However, carnosine is almost immediately 
hydrolyzed by CN1 into its two constituent amino acids beta-alanine and histidine, at least 
in humans. Therefore, it can be questioned whether the hydrolysis products of carnosine 
(beta-alanine and histidine) are accounted for some of the observed properties. Although 
rats (and mice) do not have CN1, Aldini et al. (2011) have demonstrated that carnosine is 
cleared from the blood 2 hours after carnosine supplementation (100 mg/kg body weight). 
In those species, the catalytical activity of carnosine mainly takes place in the kidney 
because of the presence of tissue carnosinase.  
Table 1 provides an overview of the biochemical properties of carnosine and the 
hydrolysis products beta-alanine and histidine. From this table, it can be deducted that 
most of the functions of carnosine are related to histidine or its imidazole moiety, except 
for the buffering capacity and the quenching of reactive aldehydes, these properties are 
much better accomplished by the dipeptide. Caution is warranted however, as the 
references from table 1 contain  in vitro or animal experiments.  
Property Carnosine Beta-
alanine 
Histidine References 
Anti-oxidant  (scavenging effect) 
Peroxyl radicals 
Hydroxyl radicals 
 
** 
** 
 
/ 
/ 
 
** 
** 
 
(Kohen 1988; Decker 2000) 
(Boldyrev 1992; Tamba 1999) 
Metal ion chelating 
Cu2+ chelation 
 
** 
 
ND 
 
*** 
 
(Velez 2008) 
Buffering activity (pKa) ** ND * (Abe 2000) 
Scavenging of reactive carbonyl 
species 
 
** 
 
/ 
 
* 
 
(Aldini 2002b) 
Anti-inflammatory effect ** ND ** (Lee 2005; Liu 2008) 
Lipid lowering effect ** ND ** (Mong 2011) 
 
Table 1. Comparison of the biochemical and physiological properties of carnosine with its hydrolysis products beta-
alanine and histidine (based on Boldyrev 2013). ** represent equal activity as carnosine, *  lower activity, *** higher 
activity, / no activity, ND not determined.  
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A side note must be made for beta-alanine. We know that the majority of ingested beta-
alanine (> 90%) is metabolized in the body (meaning: not accumulated in tissue carnosine 
or excreted in urine). The initial step of beta-alanine catabolism is thought to be the 
transamination to form malonic acid semialdehyde, which can then be converted into 
acetyl CoA (Griffith 1986). The later has a pivotal role in the citric acid cycle, which is a 
series of chemical reactions to generate energy through the oxidation of acetyl CoA 
derived from carbohydrates, fats and proteins into carbon dioxide and chemical energy in 
the form of adenosine triphosphate (ATP). It can be questioned whether the contribution 
of acetyl CoA derived from beta-alanine is substantial enough to influence glucose and 
fatty acid oxidation.   
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4. FUTURE DIRECTIONS 
Four years of swimming in carnosine’s literature and performing animal and human 
experiments has contributed to new insights into the carnosine-carnosinase system in 
diabetic circumstances (cfr supra). Although the most important research questions are 
adequately addressed, some observations must be further clarified:  
 The finding that carnosine has a systemic effect, rather than a local effect, creates 
an obstacle in translating the animal findings to diabetic patients and in 
developing a carnosine-related treatment for diabetic patients, as the highly active 
CN1 (not present in rodents) almost immediately hydrolyses carnosine in plasma. 
This has opened two research directions:  
First, it becomes interesting to compare diabetic individuals with low versus high 
CN1 levels for markers of metabolic stress (as we did in this work). We cautiously 
proposed that CN1 is associated with markers of dyslipidemia. Further research 
must however clarify this relationship by taking into account hypoglycemic and 
lipid-lowering medication.  
Second, these data have drawn the attention towards the development of 
carnosine derivatives being resistant to CN1 (Vistoli 2012) or towards naturally 
occurring carnosine related compounds with similar characteristics as carnosine 
(and ‘more’ resistant towards CN1). The fact that T2D patients display lower CN1 
activity levels, compared to healthy control subjects, makes them an even more 
interesting population for possible carnosine-related treatments.  
 Although this work disadvises treatment of diabetic patients with beta-alanine, 
two points of interest are necessary to make: 1) it must be determined whether 
severe diabetic patients display increased levels of muscle carnosine as well; 2) we 
cannot deny recent reports of decreased renal and retinal carnosine levels in 
animals with respectively diabetic retino- and nephropathy. Therefore, future 
research can focus on the potential of beta-alanine supplementation to increase 
carnosine levels in kidney and retina and whether these increased carnosine levels 
can protect the tissues from damaging species.  
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 We concluded in study 1 that more than 90% of ingested beta-alanine has an 
unknown metabolic fate. In this work we already discussed the possible role of 
beta-alanine transaminase (ABAT) and malonic deminaldehyde dehydrogenase 
(MSAD) in the degradation of beta-alanine in tissues. Understanding the unknown 
metabolic fate of ingested beta-alanine could lead to much more efficient muscle 
carnosine loading strategies. 
 Last but not least, it must be clarified whether or not carnosine adducts with 
reactive aldehydes are detected by 1H-MRS and by HPLC, in order to correctly 
interpret carnosine concentrations in tissues.  
We can conclude that the journey does not end here and that this work has opened new 
perspectives towards the future.  
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5. CONCLUSIONS 
As the main result, this work delivered new insights into 1) the endogenous carnosine-
carnosinase system in a diabetic state and 2) the protective role of elevated plasma 
and/or tissue carnosine levels. As a by-product, some interesting elements for the sports 
field are provided as well. The main conclusions are presented below: 
1. The endogenous carnosine-carnosinase system is altered by a diabetic state. 
 We demonstrated that muscle carnosine is increased in obese/diabetic 
circumstances, both in rodents and humans (study 4). However, caution is 
warranted as not all our high-fat diet rat models showed elevated muscle 
carnosine levels and as Gualano et al. (2010) demonstrated a decrease in 
diabetic type 2 patients. Therefore, we have put forward the hypothesis that 
muscle carnosine in a diabetic state is a balance between diabetes-related 
upregulating and downregulating factors, and depending on the factors 
dominating in a specific situation, muscle carnosine will be increased, decreased 
or remain equal. 
 We provided evidence that diabetic patients are not characterized by elevated 
CN1 levels. While CN1 content was equal between healthy subjects and type 2 
diabetic patients, CN1 activity was even lower in the patients. Moreover, there 
was no relationship between CN1 (content and activity) and HbA1c (average 
level of blood glucose over the previous 3 months) in diabetic patients. In 
addition, CN1 levels are remarkably stable over a 6-month period and not 
influenced by chronic exercise training in a diabetic population.  
2. Increasing plasma carnosine levels by carnosine supplementation attenuates early-
stage lipid-oxidation in circulation and inflammatory signaling in skeletal muscle. 
In study 3, plasma and muscle carnosine were independently increased by 
respectively carnosine and beta-alanine supplementation to elucidate its effect on 
high-fat diet induced metabolic stress in circulation and tissue (muscle) in a high-fat 
diet rodent model. Elevated plasma carnosine levels, and not elevated muscle 
carnosine levels, demonstrated protective effects in both circulation and skeletal 
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muscle tissue, pointing towards a systemic effect with skeletal muscle as a target 
organ. 
Taking together point 1 and 2, we can disadvise beta-alanine supplementation in 
diabetic patients (as suggested from literature), because 1) diabetic patients have no 
depleted muscle carnosine levels and 2) artificially increasing muscle carnosine levels 
does not attenuate metabolic stress in both circulation and skeletal muscle.   
3. This work provided an explanatory model for muscle carnosine turnover in four 
different phases: muscle carnosine at baseline, during loading, washout and 
maintenance.  
 At baseline, muscle carnosine synthesis and degradation are in a steady 
equilibrium and predominantly determined by skeletal muscle fiber type, age and 
sex. As demonstrated above, a diabetic state can alter this steady equilibrium. 
 During beta-alanine supplementation (loading), carnosine synthesis will be 
elevated because of increased precursor availability and thus net turnover will be 
strongly positive. Studies 1 and 2 searched for determinants of muscle carnosine 
loading. Only one significant determinant was found, i.e. meal-timing. Taking beta-
alanine at the start of the meal results in a higher absolute (0.58 mM) and relative 
(23%) increase in soleus muscle compared to taking beta-alanine in between the 
meals, suggesting that insulin plays a role during loading. On the other hand, 
muscle fiber type, gender, supplementation form (slow-release vs powder beta-
alanine), body weight, fat-free mass and baseline carnosine content did not 
influence the absolute increase in muscle carnosine during loading.  
From study 1, we could calculate that of the total amount of chronically ingested 
beta-alanine only a small portion is incorporated into muscle carnosine (2.8%) and 
only very little is excreted in urine (1.6%), raising a new research question: Where 
does all the beta-alanine go?  
 Upon discontinuation of chronic beta-alanine intake, a net negative balance of 
carnosine turnover is present, demonstrated by a slow wash-out of 6-20 weeks. 
Therefore, study 2 established a suitable maintenance dose of ~1.2g beta-
  PART III: GENERAL DISCUSSION  
 
205 
alanine/day to maintain moderately elevated carnosine stores. This has useful 
implications for athletes and resulted in the advise to phase their beta-alanine 
intake towards the competition.  
To summarize, this thesis provided evidence that the endogenous carnosine-
carnosinase system is influenced by obesity or diabetes type 2. In contrast to what is 
currently believed, we demonstrated that muscle carnosine is higher and CN1 activity is 
lower in diabetic patients compared to healthy control subjects. Thus, alterations in the 
endogenous carnosine-carnosinase system in a diabetic state are rather protective and 
not contributing to a negative viscious circle. In addition, chronic carnosine 
supplementation can attenuate metabolic stress in circulation and skeletal muscle in 
rats. 
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SUMMARY OF THE THESIS 
Background 
It is suggested that the molecule carnosine (beta-alanyl-L-histidine) is a potential 
candidate to counteract the development of diabetes or diabetes-related diseases 
because of its protective biochemical properties. Carnosine is a naturally occurring 
dipeptide that is predominantly and abundantly synthesized (and stored) in skeletal 
muscle by carnosine synthase from its two constituent amino acids beta-alanine and L-
histidine, whereas its breakdown occurs predominantly in the circulation by the highly 
active serum carnosinase (CN1). As carnosine is present in skeletal muscles of many 
vertebrates, it is consumed through the intake of (white) meat and fish.  
This carnosine-carnosinase system has been associated with diabetes or diabetes-related 
diseases by two different research approaches. First, several genome-wide linkage scans 
for diabetic nephropathy have demonstrated that a polymorphism of the serum 
carnosinase gene (CNDP1), leading to low CN1 activity, is associated with reduced risk of 
diabetic nephropathy. Second, the substrates of CN1, carnosine and anserine (methylated 
form of carnosine), have several biochemical properties that appear to be relevant in 
diabetes or related diseases. In vitro studies have demonstrated that carnosine and 
anserine have the ability to act as an anti-oxidant, anti-glycator, metal-ion chelator and 
quencher of reactive carbonyls species and protein carbonyls. This would lead to 
suppressed formation of advanced glycation end-products (AGEs) and advanced 
lipoxidation end-products (ALEs), which are predominantly present in diabetes. Moreover, 
this quenching/scavenging of deleterious species has created the theory that carnosine 
sacrifices itself and becomes depleted in diabetic tissues.  
However, despite the apparent relevance of this carnosine-carnosinase system in 
diabetes or diabetes-related diseases, little is known about the endogenous carnosine 
and carnosinase concentrations in obesity and diabetes and the protective effect of 
carnosine supplementation.  
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Aims of this thesis 
The two main aims of this work are to provide insight into the endogenous carnosine-
carnosinase system in a diabetic state (study 4 and 5) and to investigate whether or not 
elevating plasma and/or tissue carnosine levels have beneficial outcomes (study 3).  
In the build-up to our main aims, this work also conducted two interventional studies in 
healthy subjects and investigated the determinants of muscle carnosine loading under 
normal physiological conditions (study 1 and 2), with the focus on insulin (key hormone in 
diabetes). 
Research and conclusions 
The figure below presents schematically the five studies in this thesis.  
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Conclusion 1: Muscle carnosine content and serum carnosinase are altered in diabetic 
circumstances.  
Research: Study 4 investigated the effect of various degrees of high-fat diets in 
rodents (rats and mice), provoking various degrees of obesity and glucose intolerance, 
on muscle carnosine concentrations. We demonstrated that muscle carnosine 
increases with progressive glucose intolerance. Additional human data (general 
discussion) could confirm this finding. However, as this is in contrast to what is 
currently believed, we have put forward a working model that muscle carnosine in a 
diabetic state is a balance between diabetes-related factors possibly increasing or 
decreasing baseline muscle carnosine.  
Study 5 investigated CN1 content and activity in 243 diabetic type 2 patients (men 
and women) before and after a 6-month exercise program. Two independent 
observations suggest that CN1 is not increased in diabetic individuals. First, there is 
no correlation between HbA1c (average level of blood glucose over the previous 3 
months) and CN1 content and activity in this cohort of type 2 diabetic patients. 
Second, while CN1 content is equal between healthy subjects and T2D patients, CN1 
activity is even lower in T2D patients. Concomitantly, we found that CN1 levels are 
remarkably stable over a 6-month period and not influenced by chronic exercise 
training in a diabetic population.  
Conclusion 2: Increased plasma carnosine levels, but not muscle carnosine levels, 
attenuates early-stage metabolic stress in circulation and skeletal muscle. 
Research: In study 3, plasma and muscle carnosine were independently increased by 
respectively carnosine and beta-alanine supplementation to elucidate its effect on 
metabolic stress in circulation and tissue (muscle) in a high-fat diet rodent model. 
Elevated plasma carnosine levels, and not elevated muscle carnosine levels, resulted 
in protective effects in both circulation and skeletal muscle tissue, pointing towards a 
systemic effect with skeletal muscle as a target organ. 
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Conclusion 3: This work provided an explanatory model for muscle carnosine turnover in 
four different phases: muscle carnosine at baseline, during loading, washout and 
maintenance.  
At baseline, muscle carnosine synthesis and degradation are in a steady equilibrium 
and are predominantly determined by skeletal muscle fiber type, age and sex. As 
demonstrated above, a diabetic state can alter this steady equilibrium. 
During beta-alanine supplementation (loading), carnosine synthesis will be elevated 
because of increased precursor availability and thus net turnover will be strongly 
positive. Studies 1 and 2 searched for determinants of muscle carnosine loading. 
Only 1 significant determinant was found, i.e. meal-timing. Taking beta-alanine at the 
start of the meal results in a higher absolute (+0.58 mM) and relative (+23%) increase 
compared to taking beta-alanine in between the meals in soleus muscle, suggesting 
that insulin plays a role during loading. On the other hand, muscle fiber type, gender, 
supplementation form (slow-release vs powder beta-alanine), body weight, fat-free 
mass and baseline carnosine content did not (or very little) influenced the absolute 
increase in muscle carnosine during loading.  
From study 1, we could calculate that of the total amount of chronically ingested 
beta-alanine only a small portion is incorporated into muscle carnosine (~3%) and 
only very little is excreted in urine (~1.6%), raising a new research question: Where 
does all the beta-alanine go?  
Upon discontinuation of beta-alanine supplementation, a net negative balance of 
carnosine turnover is present, demonstrated by a slow wash-out of 6-20 weeks. 
Therefore, study 2 established a suitable maintenance dose of ~1.2g beta-
alanine/day to maintain moderately elevated carnosine stores. This has useful 
implications for athletes and resulted in the advice to phase their beta-alanine intake 
towards the competition.  
To summarize, this thesis provides evidence that the endogenous carnosine-carnosinase 
system is partly influenced by obesity or diabetes type 2. In contrast to what is currently 
believed, we demonstrated that muscle carnosine increases with progressive glucose 
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intolerance, both in rodents and humans. In addition, CN1 content is equal between 
healthy subjects and type 2 diabetes patients, but CN1 activity is lower in the patients 
(humans). Notwithstanding the fact that the endogenous system is actually functioning 
rather good, elevating plasma carnosine (and not muscle carnosine) can attenuate 
metabolic stress in circulation and skeletal muscle (high-fat diet rat model). The finding 
that carnosine has a systemic effect, rather than a local effect, creates an obstacle in the 
road to developing a carnosine-related treatment for diabetic patients, as the highly 
active enzyme serum carnosinase almost immediately hydrolyses carnosine in plasma. 
This opens new research perspectives towards the search for carnosine related 
compounds being resistant for serum carnosinase.   
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SAMENVATTING VAN DE THESIS 
Achtergrond 
De molecule carnosine (beta-alanyl-L-histidine) heeft het potentieel om de ontwikkeling 
van diabetes of diabetes gerelateerde ziekten tegen te gaan omwille van zijn 
beschermende biochemische eigenschappen. Carnosine is een dipeptide en wordt 
voornamelijk in grote hoeveelheden gesynthetiseerd in de skeletspier door het enzyme 
carnosine synthase, vertrekkende vanuit zijn twee bouwstenen (aminozuren) beta-
alanine en L-histidine. Omgekeerd vindt de afbraak tot zijn twee bouwstenen 
voornamelijk plaats in de circulatie door het enzym serum carnosinase (CN1). Consumptie 
van carnosine gebeurt door het eten van (wit) vlees en vis, aangezien carnosine talrijk 
aanwezig is in skeletspieren van gewervelden.  
Het carnosine-carnosinase systeem is recent door twee onafhankelijke 
onderzoeksbenaderingen geassocieerd met diabetes of diabetes gerelateerde ziekten. 
Ten eerste, genoomstudies voor diabetische nefropathie hebben aangetoond dat een 
polymorfisme van het serum carnosinase gen (CNDP1), dat leidt tot een lagere activiteit 
van CN1, geassocieerd is met een lager risico op diabetische nefropathie. Ten tweede, de 
substraten van CN1, met name carnosine en anserine (de gemethyleerde vorm van 
carnosine), hebben verschillende biochemische eigenschappen die beschermend zouden 
zijn bij suikerziekte. Carnosine heeft bijvoorbeeld anti-oxiderende en anti-glycerende 
eigenschappen en kan reactieve carbonyl groepen of eiwit-carbonyls vangen (en dus 
onschadelijk maken). Deze eigenschappen zouden aan de basis liggen van verminderde 
productie van schadelijke eindproducten van het suiker- en vetmetabolisme (AGEs en 
ALEs genaamd), die talrijk aanwezig zijn bij suikerziekte (diabetes mellitus). Daarenboven 
heeft dit ‘vangen’ van schadelijke moleculen de theorie doen ontstaan dat carnosine 
waarschijnlijk is gedaald in weefsels die onder stress staan, zoals bij diabetes. 
Vanuit de literatuur wordt er dus gesuggereerd dat dit carnosine-carnosinase systeem 
een belangrijke rol speelt in diabetes of diabetes gerelateerde ziekten. Echter, het is niet 
gekend of de endogene productie van carnosine of carnosinase beïnvloed wordt door 
obesitas of diabetes. Daarenboven zijn er weinig in vivo studies beschikbaar over de 
effecten van carnosine suppletie bij deze pathologie. 
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Doelstellingen 
De twee voornaamste doelstellingen van dit werk zijn: 1) inzicht verschaffen over het 
endogene carnosine-carnosinase systeem bij obesitas en diabetes en 2) de effecten 
onderzoeken van het artificieel verhogen van plasma- en spier carnosine op de 
ontwikkeling van obesitas-geïnduceerde metabole stress.  
Naar de aanloop van onze hoofddoelstellingen, zal deze thesis ook twee 
interventiestudies uitvoeren bij gezonde proefpersonen om de determinanten te 
onderzoeken van spier carnosine oplading onder normale fysiologische omstandigheden. 
Hierbij zal voornamelijk aandacht besteed worden aan de rol van insuline (sleutel 
hormoon in diabetes).  
Onderzoek en conclusies 
Onderstaande figuur geeft schematisch de vijf studies weer uit deze thesis.  
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Conclusie 1: Spier carnosine en serum carnosinase concentraties worden beïnvloed door 
glucose intolerantie en diabetes.  
Onderzoek: Studie 4 heeft het effect onderzocht van verschillende vet diëten, die 
tot doel hadden om verschillende gradaties in obesitas en glucose-intolerantie te 
veroorzaken, op spier carnosine concentraties bij knaagdieren (ratten en muizen). 
Spier carnosine concentraties bleken te stijgen naargelang de glucose intolerantie 
toenam. Daarenboven kon additionele humane data deze bevinding bevestigen. 
Echter, dit is in tegenstelling met de theorie dat spier carnosine zichzelf opoffert 
om bijvoorbeeld reactieve carbonyl groepen onschadelijk te maken, waardoor 
verondersteld werd dat carnosine concentraties zouden dalen. Daarom heeft deze 
thesis een werkmodel naar voor gebracht met verschillende diabetes-gerelateerde 
factoren die spier carnosine concentraties zouden kunnen doen stijgen of dalen.  
Studie 5 heeft CN1 concentratie en activiteit onderzocht in 243 patiënten met 
diabetes type 2 (mannen en vrouwen) voor en na een 6-maand durend 
bewegingsprogramma. Twee onafhankelijke observaties tonen aan dat CN1 niet 
gestegen is bij diabeten. Ten eerste, er is geen correlatie tussen HbA1c 
(bloedsuiker over de voorbije 3 maanden) en CN1 concentratie en activiteit in de 
type 2 diabetes patiënten. Ten tweede, CN1 content is gelijk tussen diabeten en 
gezonden en CN1 activiteit was zelfs significant lager in de patiënten populatie. 
Daarnaast hebben we kunnen aantonen dat CN1 zeer stabiel is over de tijd (6 
maanden) en dat het niet beïnvloedbaar is door een bewegingsprogramma.  
Conclusie 2: Het verhogen van plasma carnosine, en niet het verhogen van spier carnosine, 
onderdrukt vroegtijdige metabole stress in de circulatie en in de skeletspier bij 
knaagdieren. 
Onderzoek: In studie 3 werd het effect onderzocht van verhoogde plasma- en spier 
carnosine concentraties, door respectievelijk carnosine en beta-alanine 
supplementatie, op metabole stress in de circulatie en weefsels in hoog-vet dieet-
gevoede ratten. De studie kon aantonen dat enkel het verhogen van plasma 
carnosine bescherming bood in de circulatie en de weefsels, wat duidde op een 
systemisch effect met de spier als doelorgaan.  
  SUMMARY - SAMENVATTING  
 
217 
Conclusie 3: Dit werk heeft een verklarend model aangeboden voor spier carnosine 
turnover (netto verandering) in vier verschillende fases: spier carnosine op basis niveau, 
tijdens oplading, tijdens het uitwassen naar basis niveau en tijdens het onderhouden van 
verhoogde concentraties.  
Op basis niveau zijn spier carnosine synthese en afbraak in evenwicht met elkaar 
en wordt het voornamelijk bepaald door spiervezeltypering, leeftijd en geslacht. 
Hierbij hebben we aangetoond dat diabetes dit evenwicht kan verstoren.  
Tijdens beta-alanine suplementatie (oplading), zal carnosine synthese verhogen 
door gestegen precursor beschikbaarheid waardoor de turnover sterk positief zal 
zijn. Studie 1 en 2 zochten naar determinanten van spier carnosine oplading. 
Slechts 1 determinant werd gevonden, namelijk het gelijktijdig innemen van beta-
alanine met de maaltijden. Wanneer beta-alanine aan de start van de maaltijd 
werd genomen, zag men een hogere absolute (+0.58 mM) en relatieve (+23%) 
toename in de soleus spier, waardoor gesuggereerd werd dat insuline een rol 
speelt tijdens oplading. De andere onderzochte determinanten (spiervezeltype, 
geslacht, supplementatie vorm ‘snel versus traag werkende’, lichaamsgewicht, 
vet-vrije massa en spier carnosine bij aanvang) hadden geen (of zeer weinig) 
invloed op de absolute stijging in spier carnosine. Ten slotte hebben we 
aangetoond dat slechts ~3% van de ingenomen beta-alanine wordt opgenomen in 
de spier en ook zeer weinig (~1.6%) wordt uitgescheiden in de urine, waardoor 
een nieuwe onderzoeksvraag is ontstaan: ‘Waar gaat het merendeel van de 
ingenomen beta-alanine naar toe in ons lichaam?’ 
Nadat dagelijkse beta-alanine inname wordt stopgezet, wordt de balans van 
carnosine turnover negatief, dat is aangetoond door het zeer traag uitwassen van 
de spier (6-20 weken). Daarom heeft studie 2 een geschikte onderhoudsdosis 
voorgesteld van ~1.2g beta-alanine/dag om verhoogde spier carnosine niveaus te 
verzekeren. Deze bevinding is van belang voor atleten waardoor we nu het advies 
uitschrijven om de beta-alanine supplementatie op te delen in fases met een piek 
naar de competitie periodes.  
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We kunnen dus samenvatten dat deze thesis bewijs levert dat het endogeen carnosine-
carnosinase systeem in beperkte mate wordt beïnvloed door obesitas en diabetes type 2. 
In tegenstelling tot wat momenteel wordt verondersteld, hebben we aangetoond dat 
spier carnosine stijgt met toenemende mate van glucose intolerantie (zowel 
dierexperimenteel als humaan). Daarnaast blijkt CN1 content niet te veranderen door 
diabetes en CN1 activiteit was in onze studie zelfs lager bij de diabeten dan bij de 
gezonden. Niettegenstaande dat het endogene systeem vrij goed functioneert, helpt het 
verhogen van plasma carnosine (en niet het verhogen van spier carnosine) tegen 
metabole stress in de circulatie en het spierweefsel (bij ratten die een vet-dieet hebben 
gevolgd). De bevinding dat carnosine een systemisch effect heeft, en geen lokaal effect, 
vormt een probleem om deze toepassing te vertalen naar mensen, aangezien zij het zeer 
actieve serum carnosinase enzym bezitten. Dit opent de zoektocht naar carnosine-achtige 
stoffen die resistent zijn aan het enzym en we kunnen stellen dat er zich reeds 
interessante kandidaten hebben aangeboden.  
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